

Reporting and Analysis Plan

Study ID: 202018

Official Title of Study: Reporting and Analysis Plan for A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors

IND: 121958

EudraCT: 2019-000868-18

Approval Date of Document: 04-Feb-2022

Division	: Worldwide Development
Information Type	: Reporting and Analysis Plan (RAP)

Title	: Reporting and Analysis Plan for A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.
Compound Name	: Otilimab
Compound Number	: GSK3196165
Effective Date	: Refer to Document Date

Description:	
<ul style="list-style-type: none"> • The purpose of this RAP is to describe the planned analyses and output to be included in the Clinical Study Report for Protocol 2018N385816_02. • This RAP is intended to describe the final analyses required for the study. • This RAP will be provided to the study team members to convey the content of the Statistical Analysis Complete (SAC) deliverable. 	

RAP Author(s):

Approver	Date
PPD Statistics Leader (Biostatistics)	Refer to Document Date

Copyright 2022 the GlaxoSmithKline group of companies. All rights reserved.
 Unauthorised copying or use of this information is prohibited

Biostatistics Line Approvals:

Approver	Date	Approval Method
PPD [REDACTED] PPD [REDACTED] (Biostatistics)	Refer to Document Date	eSignature
PPD [REDACTED] Programming Leader (Biostatistics)	Refer to Document Date	eSignature

TABLE OF CONTENTS

	PAGE
1. INTRODUCTION.....	7
2. SUMMARY OF KEY PROTOCOL INFORMATION	7
2.1. Changes to the Protocol Defined Statistical Analysis Plan	7
2.2. Study Objective(s) and Endpoint(s).....	9
2.3. Study Design	11
2.4. Statistical Hypotheses / Statistical Analyses	12
3. PLANNED ANALYSES	13
3.1. Interim Analyses	13
3.2. Final Analyses	13
4. ANALYSIS POPULATIONS	14
4.1. Protocol Deviations.....	15
5. CONSIDERATIONS FOR DATA ANALYSES AND DATA HANDLING CONVENTIONS.....	16
5.1. Study Treatment & Sub-group Display Descriptors	16
5.1.1. Study Treatment & Sub-group Display Descriptors for Study Population Displays	16
5.1.2. Study Treatment & Sub-group Display Descriptors for Efficacy Displays.....	17
5.1.3. Study Treatment & Sub-group Display Descriptors for Safety Displays - Adverse Events (AEs) and Laboratory Assessments	17
5.1.4. Study Treatment descriptors used for Figures	20
5.2. Baseline Definitions	20
5.2.1. Baseline definition in Period 1 and Period 1+2.....	20
5.2.2. Baseline definition in Period 2.....	21
5.3. Multicentre Studies	21
5.4. Examination of Covariates, Other Strata and Subgroups	22
5.4.1. Covariates and Other Strata	22
5.4.2. Examination of Subgroups.....	22
5.5. Multiple Comparisons and Multiplicity	23
5.6. Other Considerations for Data Analyses and Data Handling Conventions.....	27
6. STUDY POPULATION ANALYSES	28
6.1. Overview of Planned Study Population Analyses.....	28
7. EFFICACY ANALYSES.....	29
7.1. Primary Efficacy Analyses	29
7.1.1. Primary Estimand Strategy	29
7.1.1.1. Population	29
7.1.1.2. Treatment.....	29
7.1.1.3. Outcome Variable.....	29
7.1.1.4. Summary Measure	29
7.1.1.5. Strategy for Intercurrent (Post-Randomization) Events	30

7.1.1.6.	Handling of missing data	30
7.1.1.7.	Sensitivity Analysis for the handling of missing data	31
7.1.2.	Supplementary Analysis	31
7.1.2.1.	Supplemental Estimand 1	31
7.1.2.2.	Supplemental Estimand 2	31
7.1.2.3.	Per-protocol Analysis	32
7.1.3.	Statistical Analyses / Methods	32
7.1.3.1.	Statistical Methodology Specification	33
7.2.	Secondary Efficacy Analyses	33
7.2.1.	Estimand strategy	33
7.2.1.1.	Population	34
7.2.1.2.	Treatment	34
7.2.1.3.	Outcome Variables	34
7.2.1.4.	Summary Measure	34
7.2.1.5.	Strategy for Intercurrent (Post-Randomization) Events	35
7.2.1.6.	Handling of missing data	35
7.2.1.7.	Sensitivity Analysis for the handling of missing data	35
7.2.2.	Supplementary Analysis	35
7.2.3.	Statistical Analyses / Methods	36
7.2.3.1.	Statistical Methodology Specification	37



8.	SAFETY ANALYSES	43
8.1.	Adverse Events Analyses	43
8.1.1.	Adverse Events of Special Interest and Other Important AEs Analyses	44
8.2.	Clinical Laboratory Analyses	44
8.3.	Other Safety Analyses	45
8.3.1.	Immunogenicity Analyses	45
9.	PHARMACOKINETIC ANALYSES	47
9.1.	Primary Pharmacokinetic Analyses	47
9.1.1.	Endpoint / Variables	47
9.1.1.1.	Drug Concentration Measures	47
9.1.2.	Summary Measure	47
9.1.3.	Population of Interest	47
9.1.5.	Statistical Analyses / Methods	47
10.	POPULATION PHARMACOKINETIC (POPPK) ANALYSES	48
11.	PHARMACODYNAMIC AND BIOMARKER ANALYSES	49
11.1.	Exploratory Pharmacodynamic and Biomarker Analyses	49
11.1.1.	Endpoint / Variables	49

- 11.1.2. Summary Measure 49
- 11.1.3. Population of Interest 49
- 11.1.5. Statistical Analyses / Methods 50
- 12. PHARMACOKINETIC / PHARMACODYNAMIC ANALYSES 51
- 13. REFERENCES 52
- 14. APPENDICES 53
 - 14.1. Appendix 1: Protocol Deviation Management and Definitions for Per Protocol Population 53
 - 14.1.1. Exclusions from Per Protocol Population 53
 - 14.2. Appendix 2: Schedule of Activities 54
 - 14.2.1. Protocol Defined Schedule of Events 54
 - 14.3. Appendix 3: Assessment Windows 57
 - 14.3.1. Definitions of Assessment Windows for Analyses 57
 - 14.4. Appendix 4: Study Phases and Treatment Emergent Adverse Events 58
 - 14.4.1. Study Phases 58
 - 14.4.1.1. Study Phases for Concomitant Medication 59
 - 14.4.2. Treatment Emergent Flag for Adverse Events 59
 - 14.5. Appendix 5: Data Display Standards & Handling Conventions 60
 - 14.5.1. Reporting Process 60
 - 14.5.2. Reporting Standards 60
 - 14.5.3. Reporting Standards for Pharmacokinetic Concentration Data 61
 - 14.5.4. Reporting Standards for Log-transformed Parameters 61
 - 14.6. Appendix 6: Derived and Transformed Data 62
 - 14.6.1. General 62
 - 14.6.2. Study Population 63
 - 14.6.3. Efficacy 68
 - 14.6.3.1. ACR20/50/70 68
 - 14.6.3.2. Tender/Painful and Swollen Joint Counts 69
 - 14.6.3.3. Pain VAS 69
 - 14.6.3.4. Patient's/Physician's Global Assessment of Arthritis Disease Activity 69
 - CCI
 - 14.6.3.6. CDAI 71
 - 14.6.3.7. DAS28-CRP and DAS28-ESR 71
 - 14.6.3.8. EULAR Response 73
 - 14.6.3.9. ACR/EULAR Remission 73
 - 14.6.3.10. SF-36 74
 - CCI
 - CCI
 - 14.7. Appendix 7: Reporting Standards for Missing Data 83
 - 14.7.1. Premature Withdrawals 83
 - 14.7.2. Handling of Missing Data 83
 - 14.7.2.1. Handling of Missing and Partial Dates 84
 - 14.7.2.2. Handling of Missing Efficacy Data 84

- 14.8. Appendix 8: Laboratory Parameters of Interest..... 85
 - 14.8.1. Laboratory Value Gradings 85
 - 14.8.2. Laboratory Values of Potential Clinical Importance 85
 - 14.8.3. ECG Values of Potential Clinical Importance 88
 - 14.8.4. Vital Signs Values of Potential Clinical Importance 88
- 14.9. Appendix 9: List of Preferred Terms..... 89
 - 14.9.1. Herpes Zoster..... 89
 - 14.9.2. Mycobacterium Tuberculosis 89
- 14.10. Appendix 10: Missing Data Imputation Strategies 90
 - 14.10.1. Primary Estimand Strategy 90
 - 14.10.1.1. Multiple Imputation using off-treatment data within treatment arm 90
 - 14.10.1.2. Multiple Imputation using off-treatment data across all treatment arms 90
 - 14.10.1.3. Multiple imputation under MAR assumption..... 90
 - 14.10.2. Supplemental Estimand 1 Strategy 91
 - 14.10.3. Supplemental Estimand 2 Strategy 91
 - 14.10.4. Intermittent Missing Data Multiple Imputation..... 91
- 14.11. Appendix 11: Abbreviations and Trademarks..... 92
 - 14.11.1. Abbreviations..... 92
 - 14.11.2. Trademarks 94
- 14.12. Appendix 12: List of Data Displays..... 95
 - 14.12.1. Data Display Numbering 95
 - 14.12.2. Mock Example Shell Referencing 95
 - 14.12.3. Deliverables..... 95
- 14.13. Appendix 13: Example Mock Shells for Data Displays 163

1. INTRODUCTION

The purpose of this reporting and analysis plan (RAP) is to describe the analyses to be included in the Clinical Study Report for Protocol:

Revision Chronology:		
2018N385816_00	06-MAR-2019	Original
2018N385816_01	22-MAY-2019	Correction of contraceptive requirements for Women of Childbearing Potential (WOCBP) and additional clarifications.
2018N385816_02	21-JAN-2020	(1) To introduce new medical device safety reporting wording, required in advance of roll out of pre-filled syringes to this study. (2) Other minor corrections and clarifications.

2. SUMMARY OF KEY PROTOCOL INFORMATION

2.1. Changes to the Protocol Defined Statistical Analysis Plan

Changes from the originally planned statistical analysis specified in the protocol amendment 2 (Dated: 21/Jan/2020) and protocol addendum Appendix 10_JPN_03 (Dated:16/JUL/2020) are outlined in [Table 1](#).

Table 1 Changes to Protocol Defined Analysis Plan

Protocol	Reporting & Analysis Plan	
Statistical Analysis Plan	Statistical Analysis Plan	Rationale for Changes
<ul style="list-style-type: none"> In order to preserve type 1 error, each of the primary and key secondary endpoints (ACR20, HAQ-DI, CDAI and Pain VAS) will be assessed sequentially using a step-down approach. 	<ul style="list-style-type: none"> The step-down approach detailed in the protocol is extended to make use of a graphical multiple testing procedure and the principle of alpha-propagation. Additional comparisons for superiority versus placebo and versus sarilumab on the FACIT-Fatigue score are added into the multiplicity control. 	<ul style="list-style-type: none"> To ensure that comparisons of interest are controlled for multiplicity per the regulatory agency's feedback
<ul style="list-style-type: none"> Major Secondary Efficacy Endpoints are HAQ-DI, CDAI total score and Arthritis Pain VAS 	<ul style="list-style-type: none"> FACIT Fatigue is added as a Major Secondary Efficacy Endpoint 	<ul style="list-style-type: none"> Major Secondary Efficacy Endpoints are aligned with the updated hierarchy (described on row above)
<ul style="list-style-type: none"> ACR20 will be analysed using GEE 	<ul style="list-style-type: none"> ACR20 will be analysed using Logistic Regression 	<ul style="list-style-type: none"> Missing data handling strategies will implement multiple imputation to generate full analysis datasets. GEE analysis

Protocol	Reporting & Analysis Plan	
Statistical Analysis Plan	Statistical Analysis Plan	Rationale for Changes
		provides no additional benefit over logistic regression when working with full datasets
<ul style="list-style-type: none"> CDAI total score, HAQ-DI and pain VAS will be analysed using MMRM 	<ul style="list-style-type: none"> CDAI total score, HAQ-DI and pain VAS will be analysed using ANCOVA 	<ul style="list-style-type: none"> Missing data handling strategies will implement multiple imputation to generate full analysis datasets. MMRM analysis provides no additional benefit over ANCOVA when working with full datasets
<ul style="list-style-type: none"> Intercurrent Event specified as discontinuation of study intervention 	<ul style="list-style-type: none"> Additional intercurrent events specified: <ul style="list-style-type: none"> Discontinuation of study intervention for any reason. Use of prohibited medication Change in stable dose of background medication. 	<ul style="list-style-type: none"> Following regulatory feedback.
<ul style="list-style-type: none"> For the Japan submission, only the analysis of the primary endpoint will determine the success of the study and this will be assessed sequentially across doses to control for multiplicity, as contained in the first two steps of the step-down procedure. 	<ul style="list-style-type: none"> Japan submission will use the same multiple testing procedure as the global submission. 	<ul style="list-style-type: none"> Following regulatory feedback.

2.2. Study Objective(s) and Endpoint(s)

Objectives	Endpoints
Primary Objectives	Primary Endpoints
<ul style="list-style-type: none"> To compare the efficacy of GSK3196165 at doses of 90 mg and 150 mg weekly versus placebo for the treatment of participants with moderately to severely active RA who are on a stable background of csDMARD(s) and who have had an inadequate response to biological DMARDs and/or JAK inhibitors. 	<ul style="list-style-type: none"> Proportion of participants achieving ACR20 at Week 12.
Secondary Objectives	Secondary Endpoints
<p>To Compare:</p> <ul style="list-style-type: none"> Efficacy of GSK3196165 at doses of 90 mg and 150 mg weekly versus sarilumab, for the treatment of participants with moderately to severely active RA who are on a stable background of csDMARD(s) and who have had an inadequate response to biological DMARDs and/or JAK inhibitors. 	<p>Major Secondary Efficacy Endpoints</p> <p>Change from baseline at Week 12 (versus placebo) in:</p> <ul style="list-style-type: none"> HAQ-DI FACIT-Fatigue <p>Change from baseline at Week 24 (versus sarilumab) in:</p> <ul style="list-style-type: none"> CDAI total score Arthritis pain VAS FACIT-Fatigue <p>Other Secondary Efficacy Endpoints</p> <p>Proportion of participants at Week 12 (vs. placebo and vs. sarilumab) and Week 24 (vs. sarilumab) achieving:</p> <ul style="list-style-type: none"> CDAI total score ≤ 10 (CDAI LDA) CDAI total score ≤ 2.8 (CDAI Remission) ACR20/50/70 DAS28-CRP ≤ 3.2 and DAS28(ESR) ≤ 3.2 (DAS28 LDA) DAS28(CRP) < 2.6 and DAS28(ESR) < 2.6 (DAS28 Remission). A good/moderate EULAR response ACR/EULAR Remission <p>Change from baseline at Week 12 (vs. placebo and vs. sarilumab) and Week 24 (vs. sarilumab) in:</p> <ul style="list-style-type: none"> CDAI total score DAS28(CRP)/DAS28(ESR)
<ul style="list-style-type: none"> The effect of GSK3196165 on Patient Reported Outcomes (PROs) versus placebo and the active comparator sarilumab. 	<ul style="list-style-type: none"> Change from baseline at Week 12 (vs. placebo and vs. sarilumab) and Week 24 (vs. sarilumab) in: HAQ-DI Arthritis pain VAS SF-36 physical and mental component scores, and domain scores
<ul style="list-style-type: none"> Safety and tolerability of GSK3196165 versus placebo and the active comparator sarilumab 	<ul style="list-style-type: none"> Incidence of AEs, SAEs, AESIs Change from baseline in key lab parameters Proportion of participants with NCICTCAE \geq Grade 3 haematology/clinical chemistry abnormalities

Objectives	Endpoints
<ul style="list-style-type: none"> To determine the immunogenic potential of GSK3196165 	Safety Biomarker Endpoints <ul style="list-style-type: none"> GM-CSF autoantibody concentrations Immunogenicity
Exploratory	Exploratory Endpoints
<div style="background-color: black; height: 180px; width: 100%;"></div>	<div style="background-color: black; height: 180px; width: 100%;"></div>
<ul style="list-style-type: none"> Pharmacokinetics (PK) Exposure-response Pharmacodynamic (PD) biomarkers 	PK/PD Endpoints <ul style="list-style-type: none"> GSK3196165 apparent clearance (CL/F) and other PK parameters as appropriate. Exposure-response relationship for key efficacy and safety endpoints. Biomarkers of target engagement, downstream signalling of GM-CSF and ECM degradation. CCI
<div style="background-color: black; height: 50px; width: 100%;"></div>	<div style="background-color: black; height: 50px; width: 100%;"></div>

2.3. Study Design

Overview of Study Design and Key Features	
<p>The diagram illustrates the study design timeline from W-6 to W24. A 'Screening' phase occurs between W-6 and W0. At W0, participants are randomized into six arms: three placebo arms and three active treatment arms. The active treatment arms are GSK3196165 150mg weekly + csDMARD, GSK3196165 90mg weekly + csDMARD, and Sarilumab 200mg every other week (EoW) + csDMARD. At W12, participants in the three placebo arms switch to their respective active treatment arms. At W24, there is an option to transition to LTE study 209564 or exit after safety follow-up at Week 34.</p>	
Design Features	<ul style="list-style-type: none"> Phase 3, randomized, double-blind, parallel group, multicentre, placebo and active comparator (sarilumab)-controlled study of the efficacy and safety of GSK3196165 in participants with moderately to severely active RA, who have had an inadequate response to treatment with bDMARDs and/or JAK inhibitors.
Dosing	<ul style="list-style-type: none"> GSK3196165 and placebo will be administered by weekly subcutaneous (SC) injection; participants randomized to sarilumab will receive SC injections of sarilumab every other week, plus a placebo injection in the intervening weeks to maintain the blind. In parallel to receiving study intervention, all participants will receive a stable dose of background csDMARD(s) (refer to Section 6.5 of the protocol). Any participant whose background DMARD is MTX must also receive ≥ 5 mg/week folic (or folinic) acid orally (dosing regimen at the discretion of the investigator). Dose modifications to background DMARDs are discussed in Section 6.6.2 of the protocol.
Time & Events	<ul style="list-style-type: none"> Refer to Appendix 2: Schedule of Activities
Treatment Assignment	<ul style="list-style-type: none"> Upon successful screening, participants will be randomised to one of six intervention arms, in a ratio of 6:6:6:1:1:1 to GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, sarilumab 200 mg SC every other week or placebo (three arms) respectively, all in combination with background csDMARD(s). At Week 12, participants in the three placebo arms will switch from placebo to active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or sarilumab 200 mg SC every other week). Randomisation will be stratified by previously failed medication (1 bDMARD, >1 bDMARD or ≥ 1 JAK inhibitor [regardless of whether bDMARD received in past]). For the purpose of all analyses up to week 12, the placebo-sequence arms will be pooled into a single placebo arm.
Interim Analysis	<ul style="list-style-type: none"> The primary analysis will be conducted when the planned target of 525 randomised participants has been reached. No interim analysis with respect to this population is planned. However, if at the time of the primary analysis a sufficient number of participants that are required for the key Asian subgroup is not reached, then recruitment in these countries may continue.

Overview of Study Design and Key Features	
	<ul style="list-style-type: none"> • Participants who have already been enrolled from the key Asian country subgroup at the time of reaching the 525 target will be included in the primary analysis. Double-blinding will be maintained for any subjects continuing in the study at the time of the primary analysis. The primary analysis will be the basis of all inferences. • If enrolment continues beyond the planned target of 525 randomised participants, secondary analyses will be conducted upon completion of enrolment/follow-up for the entire study population, based on all randomised subjects.

2.4. Statistical Hypotheses / Statistical Analyses

The primary objective of the study is to determine whether GSK3196165 is superior to placebo in the treatment of participants with moderately to severely active RA despite treatment with biological DMARDs and/or Janus Kinase inhibitors (i.e. bDMARD-IR and/or JAK-IR), as assessed by the proportion of participants achieving ACR20 at Week 12.

The study will test the null hypothesis that there is no difference between 150 mg dose of GSK3196165 and placebo in the proportion of participants achieving ACR20 response at Week 12 versus the alternative hypothesis that the 150 mg dose of GSK3196165 differs from placebo in the proportion of participants with ACR20 response at Week 12.

3. PLANNED ANALYSES

3.1. Interim Analyses

The primary analysis will be conducted when the planned target of 525 randomised participants has been reached. No interim analysis with respect to this population is planned. However, if at the time of reaching approximately 525 randomised participants a sufficient number of participants that are required for the Key Asian subgroup is not reached, then recruitment in these countries may continue. Participants who have already been enrolled from the key Asian country subgroup at the time of reaching the 525 target will be included in the primary analysis. Double-blinding will be maintained for any subjects continuing in the study at the time of the primary analysis. The primary analysis will be the basis of all inferences. If enrolment continues beyond the planned target of 525 randomised participants, secondary analyses will be conducted upon completion of enrolment/follow-up for the entire study population, based on all randomised subjects.

An Independent Data Monitoring Committee (IDMC) will be utilised in this study to ensure ongoing objective medical and/or statistical review of safety data in order to protect the welfare of participants in the study and the scientific validity of the study. Full details of the data to be reviewed, the frequency of review and members of the committee are included in the IDMC Charter [Version 1.0 09 May 2019]. Full details of the analyses are included in a separate IDMC RAP [Version 1.0 30 Apr 2020]. Monthly Safety Review Team (SRT) reviews will be performed using blinded SDTM datasets and will be reviewed using Spotfire software.

3.2. Final Analyses

The final planned analyses on the primary analysis cohort (i.e. the first approximately 525 participants) will be performed after the completion of the following sequential steps:

1. All participants to be included in the primary analyses have completed the study as defined in the protocol.
2. All required database cleaning activities have been completed and final database release (DBR) and database freeze (DBF) has been declared by Data Management.
3. All criteria for unblinding the randomization codes have been met.
4. Prior to unblinding, all protocol deviations that will result in an exclusion from the per-protocol population have been assigned in the analysis dataset.
5. Randomization codes have been distributed according to Cenduit Interactive Response Technology (C.I.R.T) system procedures.

If required, the final planned analyses on the overarching set will be performed after the completion of the following sequential steps:

1. All additional participants from the key Asian country cohort who are not included in the primary analysis have completed the study as defined in the protocol.

2. All required database cleaning activities have been completed and final database release (DBR) and database freeze (DBF) has been declared by Data Management.
3. All criteria for unblinding the randomization codes have been met.
4. Prior to unblinding, all protocol deviations that will result in an exclusion from the per-protocol population have been assigned in the analysis dataset.
5. Randomization codes have been distributed according to Cenduit Interactive Response Technology (C.I.R.T) system procedures.

4. ANALYSIS POPULATIONS

Population	Definition / Criteria	Analyses Evaluated
Screened	<ul style="list-style-type: none"> • All participants who were screened for eligibility 	<ul style="list-style-type: none"> • Study Population
Randomized	<ul style="list-style-type: none"> • All participants who were randomly assigned to treatment in the study. • This population will be based on the treatment the participant was randomized to. • Any participant who receives a treatment randomization number will be considered to have been randomized. 	<ul style="list-style-type: none"> • Study Population
Enrolled	<ul style="list-style-type: none"> • All participants who passed screening and entered the study. • Note screening failures (who never passed screening even if rescreened) and participants screened but never enrolled into the study (Reserve, Not Used) are excluded from the Enrolled population as they did not enter the study. 	<ul style="list-style-type: none"> • Study Population
Safety	<ul style="list-style-type: none"> • All randomized participants who received at least one dose of study treatment. • This population will be based on the treatment the subject actually received. • Note: Participants who were not randomized but received at least one dose of study treatment should be listed. 	<ul style="list-style-type: none"> • Safety • Biomarker
Safety – Subjects who Entered Period 2	<ul style="list-style-type: none"> • All participants randomized to a placebo switch treatment arm (i.e. Placebo to GSK3196165 90mg, Placebo to GSK3196165 150mg or Placebo to Sarilumab 200mg) who received at least one dose of study treatment in period 2. • This population will be based on the treatment the subject actually received. 	<ul style="list-style-type: none"> • Safety
Intent-To-Treat (ITT)	<ul style="list-style-type: none"> • All randomized participants who received at least one dose of study treatment. • This population will be based on the treatment the subject was randomized to. • Any participant who receives a treatment randomization number will be considered to have been randomized. 	<ul style="list-style-type: none"> • Study Population • Efficacy
Per-Protocol	<ul style="list-style-type: none"> • All participants in the ITT population who comply with the protocol. 	<ul style="list-style-type: none"> • Efficacy

Population	Definition / Criteria	Analyses Evaluated
(PP)	<ul style="list-style-type: none"> Protocol deviations that would exclude participants from the PP population are defined in Appendix 1: Protocol Deviation Management and Definitions for Per Protocol Population). The PP set will not be analysed if this population comprises more than 85% of the ITT population. 	
Pharmacokinetic (PK)	<ul style="list-style-type: none"> All participants in the Safety population who had at least 1 non-missing PK assessment (Non-quantifiable [NQ] values will be considered as non-missing values). 	<ul style="list-style-type: none"> PK

Refer to [Appendix 12: List of Data Displays](#) which details the population used for each display.

4.1. Protocol Deviations

Important protocol deviations (including deviations related to study inclusion/exclusion criteria, conduct of the trial, patient management or patient assessment) will be summarised by IQVIA CTMS category. GSK subcategories will be included in individual subject listings.

Important deviations and other criteria which result in exclusion from the analysis population will also be summarised and listed. (Please refer to [Appendix 1: Protocol Deviation Management and Definitions for Per Protocol Population](#)).

Protocol deviations will be tracked by IQVIA and overseen by the GSK study team throughout the conduct of the study in accordance with the latest version of the Protocol Deviation Management Plan maintained by IQVIA in their TMF system.

- Data will be reviewed prior to unblinding and freezing the database to ensure all important deviations are captured and categorised in the protocol deviations dataset.
- Deviations leading to exclusion from the Per Protocol Population will be identified in the ADDV dataset.

A separate listing of all inclusion/exclusion criteria deviations will also be provided. This summary will be based on data as recorded on the inclusion/exclusion page of the eCRF.

Additional protocol deviations may be identified during the study and will be documented in protocol deviation adjudication meeting minutes prior to database freeze.

All violations will be discussed and adjudicated as important or not important. Only protocol deviations that have the potential to impact the efficacy evaluation (and are important) will lead to exclusion from the per-protocol population.

5. CONSIDERATIONS FOR DATA ANALYSES AND DATA HANDLING CONVENTIONS

5.1. Study Treatment & Sub-group Display Descriptors

5.1.1. Study Treatment & Sub-group Display Descriptors for Study Population Displays

Unless otherwise specified, all study population outputs will display the pooled placebo arm as follows:

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
1	GSK3196165 150mg	OTI 150mg QW	3
2	GSK3196165 90mg	OTI 90mg QW	2
3	Sarilumab 200mg	SARI 200mg Q2W	4
4+5+6	Placebo to GSK3196165 150mg + Placebo to GSK3196165 90mg + Placebo to Sarilumab 200mg	Pooled PBO	1

All study population outputs required to be displayed by randomised treatment arm will display all randomised treatment arms as follows:

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
1	GSK3196165 150mg	OTI 150mg QW	5
2	GSK3196165 90mg	OTI 90mg QW	4
3	Sarilumab 200mg	SARI 200mg Q2W	6
4	Placebo to GSK3196165 150mg	PBO to OTI 150mg QW	2
5	Placebo to GSK3196165 90mg	PBO to OTI 90mg QW	1
6	Placebo to Sarilumab 200mg	PBO to SARI 200mg Q2W	3

5.1.2. Study Treatment & Sub-group Display Descriptors for Efficacy Displays

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
1	GSK3196165 150mg	OTI 150mg QW	3
2	GSK3196165 90mg	OTI 90mg QW	2
3	Sarilumab 200mg	SARI 200mg Q2W	4
4	Placebo to GSK3196165 150mg	PBO to OTI 150mg QW	6
5	Placebo to GSK3196165 90mg	PBO to OTI 90mg QW	5
6	Placebo to Sarilumab 200mg	PBO to SARI 200mg Q2W	7
4+5+6	Placebo to GSK3196165 150mg + Placebo to GSK3196165 90mg + Placebo to Sarilumab 200mg	Pooled PBO	1

For the purpose of analyses up to week 12, the placebo-sequence groups will be pooled into a single placebo arm.

Treatment comparisons will be displayed as follows using the descriptors as specified:

1. Otilimab 90mg vs Pooled Placebo
2. Otilimab 150mg vs Pooled Placebo
3. Sarilumab 200mg vs Pooled Placebo
4. Otilimab 90mg vs Sarilumab 200mg
5. Otilimab 150mg vs Sarilumab 200mg


5.1.3. Study Treatment & Sub-group Display Descriptors for Safety Displays - Adverse Events (AEs) and Laboratory Assessments

Each AE display will be produced for the time periods below (see [Figure 1](#) for graphical representation):

1. Period 1 – up to week 12, to be displayed for all participants.
 - Period 1 is defined as time from randomisation and first dose of treatment up to dosing of Period 2 treatment (Week 12) or date of study withdrawal or date of treatment withdrawal plus safety follow up, whichever is earlier. AEs that occur at week 12 visit i.e. AE start date is at week 12 visit will be assigned to Period 2.
 - The placebo-sequence groups up to week 12 will be pooled into a single placebo arm.
2. Period 2 – post week 12, to be displayed for participants who were originally randomised to receive placebo and switched at week 12 only.
 - Period 2 is defined as time from first dose of treatment of period 2 (week 12) until date of study completion or date of study withdrawal or date of treatment withdrawal plus safety follow up, whichever is earlier.

3. Period 1+2 – from week 0 to week 24, to be displayed for participants who were originally randomised to Otilimab 150mg, Otilimab 90mg or Sarilumab 200mg only.
 - Period 1+2 is defined as time from randomisation until date of study completion or date of study withdrawal or date of treatment withdrawal plus safety follow up, whichever is earlier.

Figure 1 Graphical Representation of Study Design with Periods and Treatment Arms within Each Period



For displays for Period 1 (up to week 12), the following treatment group descriptions will be used:

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
1	GSK3196165 150mg	OTI 150mg QW	3
2	GSK3196165 90mg	OTI 90mg QW	2
3	Sarilumab 200mg	SARI 200mg Q2W	4
4+5+6	Placebo to GSK3196165 150mg + Placebo to GSK3196165 90mg + Placebo to Sarilumab 200mg	Pooled PBO	1

Treatment comparisons will be displayed as follows using the descriptors as specified:

1. Otilimab 150mg vs Pooled Placebo
2. Otilimab 90mg vs Pooled Placebo
3. Sarilumab 200mg vs Pooled Placebo
4. Otilimab 150mg vs Sarilumab 200mg
5. Otilimab 90mg vs Sarilumab 200mg

6. Otilimab 150mg vs Otilimab 90mg

For displays for Period 2 (post week 12), the following treatment group descriptions will be used:

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
4	Placebo to GSK3196165 150mg	PBO to OTI 150mg QW	2
5	Placebo to GSK3196165 90mg	PBO to OTI 90mg QW	1
6	Placebo to Sarilumab 200mg	PBO to SARI 200mg Q2W	3

Treatment comparisons will be displayed as follows using the descriptors as specified:

1. Placebo to Otilimab 150mg vs Placebo to Sarilumab 200mg
2. Placebo to Otilimab 90mg vs Placebo to Sarilumab 200mg
3. Placebo to Otilimab 150mg vs Placebo to Otilimab 90mg

For displays for Period 1+2 (Week 0 to week 24), the following treatment group descriptions will be used:

Treatment Group Descriptions			
Cenduit Interactive Response Technology (CIRT)		Data Displays for Reporting	
Code	Description	Description	Order in TLF
1	GSK3196165 150mg	OTI 150mg QW	2
2	GSK3196165 90mg	OTI 90mg QW	1
3	Sarilumab 200mg	SARI 200mg Q2W	3

Treatment comparisons will be displayed as follows using the descriptors as specified:

1. Otilimab 150mg vs Sarilumab 200mg
2. Otilimab 90mg vs Sarilumab 200mg
3. Otilimab 150mg vs Otilimab 90mg

5.1.4. Study Treatment descriptors used for Figures

Table 2 describes the format required for the reporting of figures.

Table 2 Treatment Descriptors, Colours, Line Style, and Symbols to be used for Figures

Treatment Description	Colour	SAS Colour	Marker Symbol	Line pattern
Pooled PBO	Black	#333333	X	2
PBO to OTI 90mg QW	Orange	#F36633	SquareFilled	2
PBO to OTI 150mg QW	Green	#167716	DiamondFilled	2
PBO to SARI 200mg Q2W	Purple	#BF00BF	TriangleFilled	2
OTI 90mg QW	Orange	#F36633	Square	1
OTI 150mg QW	Green	#167716	Diamond	1
SARI 200mg Q2W	Purple	#BF00BF	Triangle	1

5.2. Baseline Definitions

5.2.1. Baseline definition in Period 1 and Period 1+2

For all endpoints (except as noted in baseline definitions) the baseline value will be the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. If time is not collected, Day 1 assessments are assumed to be taken prior to first dose and used as baseline.

Parameter	Study Assessments Considered as Baseline		Baseline Used in Data Display
	Screening	Day 1 (Pre-Dose)	
Efficacy			
Tender Joint Count 28		X	Day 1 (Pre-Dose)
Tender Joint Count 68		X	Day 1 (Pre-Dose)
Swollen Joint Count 28		X	Day 1 (Pre-Dose)
Swollen Joint Count 66		X	Day 1 (Pre-Dose)
Pain VAS		X	Day 1 (Pre-Dose)
Patient's Global Assessment of Arthritis (PtGA)		X	Day 1 (Pre-Dose)
Physician's Global Assessment of Arthritis (PhGA)		X	Day 1 (Pre-Dose)
Acute-phase reactant (CRP)		X	Day 1 (Pre-Dose)
Acute-phase reactant (ESR)		X	Day 1 (Pre-Dose)
HAQ-DI		X	Day 1 (Pre-Dose)
DAS28-CRP Total Score		X	Day 1 (Pre-Dose)
DAS28-ESR Total Score		X	Day 1 (Pre-Dose)

Parameter	Study Assessments Considered as Baseline		Baseline Used in Data Display
	Screening	Day 1 (Pre-Dose)	
SF-36		X	Day 1 (Pre-Dose)
FACIT-Fatigue		X	Day 1 (Pre-Dose)
Safety			
Vital Signs	X	X	Day 1 (Pre-Dose) [1]
ECG (12-lead)	X	X	Day 1 (Pre-Dose) [1]
Laboratory	X	X	Day 1 (Pre-Dose) [1]
Pulmonary assessments	X	X	Day 1 (Pre-Dose) [1]
Immunogenicity		X	Day 1 (Pre-Dose)
Exploratory			
Blood PD Biomarkers		X	Day 1 (Pre-Dose)

CCI

[1] the baseline value will be the latest pre-dose assessment with a non-missing value

Unless otherwise stated, if baseline data is missing no derivation will be performed and baseline will be set to missing.

5.2.2. Baseline definition in Period 2

For all safety assessments the baseline value will be the latest pre-dose assessment before the first dose in period 2 with a non-missing value, including those from unscheduled visits.

5.3. Multicentre Studies

In this multicentre global study, enrolment will be presented by investigative site, country, and the regions.

Region	Countries
US and Canada	United States and Canada
European Continent	Belgium, Czech Republic, Germany, Hungary, Italy, Lithuania, Poland, Spain, United Kingdom
Latin America and South Africa	Argentina, South Africa
Asia	Japan, South Korea

5.4. Examination of Covariates, Other Strata and Subgroups

5.4.1. Covariates and Other Strata

The list of covariates and other strata may be used in descriptive summaries and statistical analyses, some of which may also be used for subgroup analyses. Additional covariates and other strata of clinical interest may also be considered.

Category	Details
Strata	Randomisation Stratification Factors: <ul style="list-style-type: none"> • Previously failed medication: <ul style="list-style-type: none"> ○ 1 bDMARD ○ > 1 bDMARD ○ \geq 1 JAK inhibitor
Covariates	Relevant baseline score

5.4.2. Examination of Subgroups

The list of subgroups may be used in descriptive summaries and statistical analyses for the primary and/or key secondary endpoints. Additional subgroups of clinical interest may also be considered.

- If the percentage of subjects is small (<1%) within a particular subgroup, then the subgroup categories may be refined prior to unblinding the trial.
- If the category cannot be refined further, then descriptive rather than statistical comparisons may be performed for the particular subgroup.

Subgroup	Categories	Overall Group
Prior Failed Medication	1 bDMARD, >1 bDMARD, \geq 1 JAK inhibitor	Disease Characteristic
Region	US and Canada, European Continent, Latin America and South Africa, Asia	Demographic
Specific Region	Europe, other	Demographic
Specific Region	USA, other	Demographic
Specific Region	Japan (Japan Region and Japanese Heritage Race), other	Demographic
Age	<50 years, 50 to 64 years, \geq 65 years	Demographic
Ethnicity	Hispanic or Latino, Not Hispanic or Latino	Demographic
Race	Black or African American/African Heritage, Asian, White, Other (American Indian or Alaskan Native, Native Hawaiian or Other Pacific Islander, Multiple)	Demographic
Gender	Male, Female	Demographic
Baseline Body Weight	<60kg, 60-100kg, >100kg	Demographic
Baseline both RF Negative and Anti-CCP Negative	Both Negative, At Least One Positive	Disease Characteristic
Baseline DAS28-CRP	<5.1, \geq 5.1	Disease Characteristic
Baseline CDAI	<22, \geq 22	Disease Characteristic

Subgroup	Categories	Overall Group
Duration of RA	≤5 years, >5 to ≤10 years, >10 years	Disease Characteristic
BMI	<25, ≥25 and <30, ≥30	Demographic

5.5. Multiple Comparisons and Multiplicity

The following graphical multiple testing procedure described in [Bretz, 2009] will be used to control the type I error for the primary and key secondary endpoints.

Each hypothesis will be assessed sequentially using a step-down approach where testing of the second hypothesis will commence only if all null hypotheses of the prior steps are rejected. Additionally, as there are two doses of GSK3196165 within each test, this will also be incorporated into the step-down procedure.

A graphical presentation of the multiplicity control is provided in [Figure 2](#).

If any of the hypotheses in the list are not rejected (i.e. the testing sequence fails at this step), the subsequent test(s) will still be performed but the results will be uncontrolled for multiplicity.

The proposed testing sequence of primary and key secondary hypotheses is:

1. ACR20 GSK3196165 vs Placebo for Superiority at week 12
2. HAQ-DI GSK3196165 vs Placebo for Superiority at week 12
3. CDAI total score GSK3196165 vs Sarilumab for Superiority at week 24
4. FACIT-Fatigue GSK3196165 vs. Placebo for Superiority at Week 12
5. Pain VAS GSK3196165 vs Sarilumab for Superiority at week 24
6. FACIT-Fatigue GSK3196165 vs. Sarilumab for Superiority at Week 24


The following steps will be followed to test the aforementioned hypotheses:

Step	Test	Pre-requisite(s)	P-value (2-sided)
1	ACR20 at week 12 for GSK3196165 150mg vs. placebo	None	0.05
2	ACR20 at week 12 for GSK3196165 90mg vs. placebo	Step 1 passed	0.025
3	HAQ-DI at week 12 for GSK3196165 150mg vs. placebo	Both step 1 and 2 passed	0.05
		Step 1 passed and step 2 failed	0.025
4	HAQ-DI at week 12 for GSK3196165 90mg vs. placebo	Step 3 tested at p=0.05 and passed	0.025
		Step 3 tested at p=0.025 and passed	0.0125
5	CDAI total score at week 24 for superiority of GSK3196165 150mg vs. Sarilumab	Step 3 tested at p=0.05 and step 4 passed	0.05
		Step 3 tested at p=0.05 and step 4 failed	0.025
		Step 3 tested at p=0.025 and step 4 passed	0.025
		Step 3 tested at p=0.025 and step 4 failed	0.0125
6	CDAI total score at week 24 for superiority of GSK3196165 90mg vs. Sarilumab	Step 5 tested at p=0.05 and passed	0.05
		Step 5 tested at p=0.025 and passed	0.025
		Step 5 tested at p=0.0125 and passed	0.0125
7	FACIT-Fatigue at week 12 for superiority of GSK3196165 150mg vs. placebo	Step 6 tested at p=0.05 and passed	0.05
		Step 6 tested at p=0.025 and passed	0.025
		Step 6 tested at p=0.0125 and passed	0.0125
8	FACIT-Fatigue at week 12 for superiority of GSK3196165 90mg vs. placebo	Step 7 tested at p=0.05 and passed	0.05
		Step 7 tested at p=0.025 and passed	0.025
		Step 7 tested at p=0.0125 and passed	0.0125
9	Pain VAS at week 24 superiority of GSK3196165 150mg vs. Sarilumab	Step 8 tested at p=0.05 and passed	0.05
		Step 8 tested at p=0.025 and passed	0.025
		Step 8 tested at p=0.0125 and passed	0.0125
10	Pain VAS at week 24 superiority of GSK3196165 90mg vs. Sarilumab	Step 9 tested at p=0.05 and passed	0.05
		Step 9 tested at p=0.025 and passed	0.025
		Step 9 tested at p=0.0125 and passed	0.0125
11	FACIT-Fatigue at week 24 for superiority of	Step 10 tested at p=0.05 and passed	0.05
		Step 10 tested at p=0.025 and passed	0.025
		Step 10 tested at p=0.0125 and passed	0.0125

Step	Test	Pre-requisite(s)	P-value (2-sided)
	GSK3196165 150mg vs. Sarilumab		
12	FACIT-Fatigue at week 24 for superiority of GSK3196165 90mg vs. Sarilumab	Step 11 tested at $p=0.05$ and passed	0.05
		Step 11 tested at $p=0.025$ and passed	0.025
		Step 11 tested at $p=0.0125$ and passed	0.0125

Analyses of other efficacy endpoints will not be subject to any multiplicity adjustment.

Figure 2 Graphical presentation of the Multiple Testing Procedure



Note: The number in the circles refer to the initial weighting of alpha. The number along the arrows refer to the weighting of alpha which is passed along to the next test.

5.6. Other Considerations for Data Analyses and Data Handling Conventions

Other considerations for data analyses and data handling conventions are outlined in the appendices:

Section	Component
14.3	Appendix 3: Assessment Windows
14.4	Appendix 4: Study Phases and Treatment Emergent Adverse Events
14.5	Appendix 5: Data Display Standards & Handling Conventions
14.5	Appendix 6: Derived and Transformed Data
14.7	Appendix 7: Reporting Standards for Missing Data
14.8	Appendix 8: Laboratory Parameters of Interest
14.9	Appendix 9: List of Preferred Terms
14.10	Appendix 10: Missing Data Imputation Strategies

6. STUDY POPULATION ANALYSES

6.1. Overview of Planned Study Population Analyses

The study population analyses will be based on the “Screened”, “Randomised”, “Enrolled” or “ITT” population, unless otherwise specified.

Study population analyses including analyses of subject’s disposition, protocol deviations, demographic and baseline characteristics, prior and concomitant medications, and exposure and treatment compliance will be based on GSK Core Data Standards.

All concomitant medications summaries will use the “while on treatment” approach, i.e. any concomitant medications which are taken post discontinuation of study intervention plus safety follow-up (+84 days), will be excluded.

Additional study population outputs relating to the COVID-19 pandemic will be based on GSK Core Data Standards, including:

- Participant status and disposition by relationship to COVID-19 pandemic
- Treatment status and reasons for discontinuation of study treatment by relationship to COVID-19 pandemic
- Participants by country and site by implementation of pandemic measures
- Protocol deviations related to COVID-19 pandemic
- COVID-19 Visits and Assessments Impacts
- Recruitment relative to COVID-19 pandemic measures

Details of the planned displays are presented in [Appendix 12: List of Data Displays](#).

7. EFFICACY ANALYSES

As discussed in the ICH E9 addendum (R1) [[ICH HARMONISED GUIDELINE](#), 2019] the specification of treatment effects to be estimated (the estimand) should include:

- The population of interest.
- The treatment condition of interest.
- The outcome variable of interest.
- The summary measure (which may be a model-based estimate or comparison).
- The identification and strategy for handling potential intercurrent events.

The following sections provide clarity on each of these components for the efficacy treatment effects to be estimated in this study and details on how missing outcomes will be handled.

7.1. Primary Efficacy Analyses

7.1.1. Primary Estimand Strategy

The primary estimand for this study is derived directly from the primary objective of the study to determine whether GSK3196165 150mg is superior to placebo in the treatment of participants with moderately to severely active RA despite treatment with biological DMARDs and/or Janus Kinase inhibitors (i.e. bDMARD-IR and/or JAKi-IR) This will be assessed by the odds ratio of ACR20 at Week 12 for GSK3196165 versus placebo, regardless of: IP discontinuation for any reason, prohibited medication use or change in stable dose of background therapy. Each component of this estimand is described below.

7.1.1.1. Population

Participants with moderately to severely active RA despite bDMARD or JAKi treatment, which is targeted using the inclusion and exclusion criteria.

7.1.1.2. Treatment

Those who receive at least one dose at either dose of GSK3196165 150mg, compared to those who receive at least one dose of placebo in addition to any other medication taken during the study

7.1.1.3. Outcome Variable

- ACR20 response at week 12.

7.1.1.4. Summary Measure

The odds ratio comparing GSK3196165 150mg with placebo. This measure will be derived from model-based adjusted estimates.

7.1.1.5. Strategy for Intercurrent (Post-Randomization) Events

The intercurrent (post-randomisation) event (IE) anticipated to impact on the interpretation of the treatment effect for the primary objective are:

1. Discontinuation of study intervention for any reason.
2. Use of prohibited medication
3. Change in stable dose of background medication

The handling strategy for all of these IEs will be based on a treatment policy approach; specifically, the effects estimated will be based on initial randomized treatment arm regardless of whether the participant had observed the IE. Data will continue to be collected after the occurrence of the occurrence of the IE, until the participant either completes the study or withdraws from the study before completion.

7.1.1.6. Handling of missing data

Intermittent missing data (i.e. between two non-missing assessments) for the ACR20 response will be imputed under a missing at random (MAR) assumption.

If a participant experiences any of the IEs but efficacy data continues to be collected, their data will be analysed as if they were still on the original randomised intervention.

Study withdrawal before the completion of the study will create missing outcome data. This may occur concurrently or after the IE.

Missing data for the ACR20 response resulting from study withdrawal will be imputed using three possible MI models depending on the availability of off-treatment data (i.e. data that has been collected post discontinuation of study intervention), using principles introduced by [Roger](#), 2019 (Computational details are included in Section 14.10):

1. **MI using off-treatment data within randomised treatment arm:**
If there is sufficient off-treatment data within a randomised treatment arm (i.e. at least 3 participants per arm per visit), then missing data will be imputed conditional on the participant's observed outcomes, using off-treatment data within randomised treatment arm. The use of this MI model assumes that missing outcomes resulting from participants withdrawing from the study would behave in a similar way to other participants who discontinued study intervention, were randomised to the same treatment arm, and continued providing data post-discontinuation of study intervention.
2. **MI using off-treatment data across all treatment arms:**
If there is insufficient off-treatment data within a randomised treatment arm (i.e. failure of the imputation model in option 1) but there is sufficient off-treatment data across all treatment arms combined (i.e. at least 3 participants per visit), then missing data will be imputed conditional on the participant's observed outcomes, using off-treatment data across all treatment arms. The use of this MI model assumes that missing outcomes resulting from participants withdrawing from the study would behave in a similar way to other participants who discontinued study

intervention and continued providing data post-discontinuation of study intervention regardless of randomised treatment arm.

3. MI under MAR assumption:

If there is insufficient off-treatment data (i.e. neither option 1 nor 2 is feasible) then all missing data will be imputed under a MAR assumption. This MI model uses all available data collected on- and off-treatment within randomised treatment arm, and assumes missing outcomes resulting from participants withdrawing from the study would behave in a similar way to participants who were randomised to the same treatment arm and had data collected in the study, with no adjustment for values before or after intercurrent events.

Note: Week 1 data will not be included in any imputation models due to the unavailability of off-treatment data at this visit by design of the study.

7.1.1.7. Sensitivity Analysis for the handling of missing data

An additional tipping point analysis will be performed as sensitivity if the endpoint is statistically significant and it is plausible that the imputation strategy for missing data could alter the conclusions of the analysis. This will be performed at an ACR20 responder level assuming all possible ACR20 response rates from 0 to 100% amongst those with missing ACR20 response in GSK3196165 arm and pooled placebo arm, separately. Full details of this analysis will be included in a separate analysis plan and results included in a separate report.

7.1.2. Supplementary Analysis

Two additional estimands for the primary objective will be considered and are described in this section. Computational details on both of these strategies are included in Section [14.10](#).

7.1.2.1. Supplemental Estimand 1

As an additional estimand for the primary objective, a composite strategy will be considered for the handling of the IE of discontinuation of study intervention for any reason; specifically, a composite response definition will be used. A participant will be considered to be a non-responder if they do not meet the ACR20 response criterion or they discontinue study intervention for any reason. All other IEs will be handled using the same strategies as for the Primary Estimand Strategy (i.e. treatment policy).

7.1.2.2. Supplemental Estimand 2

As a second additional estimand for the primary objective, a hypothetical strategy will be considered for the handling of the IE of discontinuation of study intervention for any reason; specifically, the effects estimated will be under the hypothetical scenario where the IE did not occur.

Any efficacy data collected after the occurrence of this IE will be excluded from the analysis. All data for the treatment response after the occurrence of the IE will be

imputed conditional on the participant's observed outcomes, using on- and off-treatment data within randomised treatment arm. The use of this MI model assumes that missing outcomes would behave in a similar way to other participants who were randomised to the same treatment arm and had data collected in the study, with no adjustment for values before or after intercurrent events.

All other IEs will be handled using the same strategies as for the Primary Estimand Strategy (i.e. treatment policy).

7.1.2.3. Per-protocol Analysis

As a supportive analysis, the primary analyses will be repeated using the "Per-protocol" population (see Section 14.1 for the definition).

7.1.3. Statistical Analyses / Methods

The efficacy analyses will be based in the "Intent-to-Treat" population, unless otherwise specified.

Details of the planned displays are provided in [Appendix 12](#) and will be based on GSK data standards and statistical principles.

Unless otherwise specified, endpoints / variables defined in Section 7.1.1.3 will be summarised using descriptive statistics and graphically presented (where appropriate).

7.1.3.1. Statistical Methodology Specification

Endpoint / Variables
<ul style="list-style-type: none"> Proportion of participants with ACR20 response at week 12.
Model Specification
<ul style="list-style-type: none"> Each estimate will be generated for each imputed data set produced by the multiple imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be combined using Rubin's rules. The proportion of participants with ACR20 response will be statistically analysed using a Logistic Regression model, comparing each randomised treatment arm with control group. The Logistic Regression model will be fitted including fixed effects for treatment arm (GSK3196165 150mg, GSK3196165 90mg, sarilumab 200mg, pooled placebo), baseline swollen joint count 66 and baseline tender joint count 68, and previously failed medication category (1 bDMARD, >1 bDMARD, ≥ 1 JAK inhibitor).
Model Checking & Diagnostics
<ul style="list-style-type: none"> If the logistic model fails to converge due to a small number of responders, the primary endpoint will be analysed using an exact logistic regression. In case of response rates of 0% or 100% in any of the treatment groups, confidence intervals for risk difference and p-values from the t-test for the risk difference comparing to 0 will be provided.
Model Results Presentation
<ul style="list-style-type: none"> Results will be summarised using proportions of subjects (after MI) achieving a response. Differences in the proportions of subjects (after MI) achieving response between each randomized treatment arm and pooled placebo will be summarised. 95% CI for the differences will be constructed using their asymptotic standard errors (asymptotic Wald confidence limits) without continuity correction. Estimates of the Odds Ratio (OR), corresponding 95% confidence intervals and p-values will be constructed using the least squares (LS) means estimates from the logistic regression model. Plots of the proportion of subjects achieving a response and their corresponding asymptotic standard errors will be generated for each treatment group by time.
Subgroup Analyses
<ul style="list-style-type: none"> See Section 5.4 for details on subgroup analyses.
Sensitivity and Supportive Analyses
<ul style="list-style-type: none"> Sensitivity Analysis on the missing data imputation methods may be performed as described in Section 7.1.1.7. Supportive Analysis will be performed as described in Section 7.1.2.

7.2. Secondary Efficacy Analyses

7.2.1. Estimand strategy

The secondary efficacy analysis will use the same estimand as the primary efficacy analysis (see Section 7.1.1 for details).

7.2.1.1. Population

The population of interest for the secondary efficacy analysis is the same as is stated for the primary efficacy analysis (see Section 7.1.1.1).

7.2.1.2. Treatment

The treatment of interest for the secondary efficacy analysis is the same as is stated for the primary efficacy analysis (see Section 7.1.1.2).

7.2.1.3. Outcome Variables

The key secondary outcomes of interest are:

- ACR20 response at week 12 (superiority of GSK3196165 90mg over placebo comparison).
- HAQ-DI at week 12 (superiority over placebo comparison).
- CDAI Total Score at week 24 (superiority over sarilumab).
- FACIT-Fatigue at week 12 (superiority over placebo comparison) and at week 24 (superiority over sarilumab comparison).
- Pain VAS at week 24 (superiority over sarilumab).

The other secondary outcomes of interest (at each visit) are:

- ACR20/50/70 response.
- CDAI LDA (CDAI Total Score \leq 2.8).
- CDAI Remission (CDAI Total Score \leq 2.8).
- DAS28-CRP LDA (DAS28-CRP \leq 3.2).
- DAS28-ESR LDA (DAS28-ESR \leq 3.2).
- DAS28-CRP Remission (DAS28-CRP $<$ 2.6).
- DAS28-ESR Remission (DAS28-ESR $<$ 2.6).
- Good/moderate EULAR response.
- ACR/EULAR Remission.
- TJC28/68 and SJC28/66.
- CRP (mg/L).
- PtGA/PhGA.
- DAS28-(CRP/ESR).
- Arthritis pain VAS.
- SF-36 physical and mental component scores, and individual domain scores.
- FACIT-Fatigue score.

7.2.1.4. Summary Measure

The key secondary summary measures are:

- The odds ratio comparing GSK3196165 90mg arm with placebo in the proportion of participants achieving ACR20 at week 12.
- The difference between GSK3196165 arms and placebo in the change from baseline in HAQ-DI at week 12.
- The difference between GSK3196165 arms and Sarilumab in the change from baseline in CDAI Total Score at week 24.

- The difference between GSK3196165 arms and placebo in the change from baseline in FACIT-Fatigue Score at week 12.
- The difference between GSK3196165 arms and Sarilumab in the change from baseline in arthritis pain VAS at week 24.
- The difference between GSK3196165 arms and Sarilumab in the change from baseline in FACIT-Fatigue Score at week 24.

For all secondary endpoints (including the key secondary endpoints), the following summary measures will be assessed:

- Odds ratio and/or difference from placebo at all assessment visits up to week 12.
- Odds ratio and/or difference from Sarilumab at all assessment visits.

All summary measures will be derived from model-based adjusted estimates for each treatment arm.

7.2.1.5. Strategy for Intercurrent (Post-Randomization) Events

The same strategy as the primary efficacy analysis will be implemented for all secondary efficacy analyses (See Section 7.1.1.5 for full details)

7.2.1.6. Handling of missing data

The same missing data handling strategy as the primary efficacy analysis will be implemented for all secondary efficacy analyses (See Section 7.1.1.6 for full details)

7.2.1.7. Sensitivity Analysis for the handling of missing data

A tipping point analysis will be performed as sensitivity of the key secondary efficacy analyses if the endpoints are statistically significant and it is plausible that the imputation strategy for missing data could alter the conclusions of the analysis. For binary endpoints, the same tipping point strategy as for the primary endpoint will be implemented (see Section 7.1.1.7 for full details). For continuous endpoints, this will be performed by applying a shift parameter to the mean for the participants with missing outcomes in the GSK3196165 arms and the control arm, separately. Full details of this analysis will be included in a separate analysis plan and results included in a separate report.

7.2.2. Supplementary Analysis

The same supplemental strategies as the primary efficacy analysis may be implemented for the key secondary efficacy endpoint analyses as follows:

- Supplemental estimand 1 will be applied to ACR20 (see Section 7.1.2.1 for details).
- Supplemental estimand 2 will be applied to CDAI Total score and Pain VAS (see Section 7.1.2.2 for details).

7.2.3. Statistical Analyses / Methods

The secondary efficacy analyses will be based in the “Intent-to-Treat” population, unless otherwise specified.

Details of the planned displays are provided in [Appendix 12](#), and will be based on GSK data standards and statistical principles.

Unless otherwise specified, endpoints / variables defined in Section [7.2.1.3](#) will be summarised using descriptive statistics and graphically presented (where appropriate).

7.2.3.1. Statistical Methodology Specification

Binary Endpoints

Endpoint / Variables																							
<ul style="list-style-type: none"> Proportion of participants achieving ACR20 response. Proportion of participants achieving CDAI-LDA (CDAI Total Score\leq10). Proportion of participants achieving ACR50/70 response. Proportion of participants achieving CDAI Remission (CDAI Total Score\leq2.8). Proportion of participants achieving DAS28-(CRP/ESR) LDA (DAS28-CRP\leq3.2 or DAS28-ESR\leq3.2). Proportion of participants achieving DAS28-(CRP/ESR) remission (DAS28-CRP$<$2.6 or DAS28-ESR$<$2.6). Proportion of participants achieving Good/moderate EULAR response. 																							
Model Specification																							
<ul style="list-style-type: none"> Each estimate will be generated for each imputed dataset produced by the multiple imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be combined using Rubin's rules. Binary Endpoints will be statistically analysed using the same methods as for the primary endpoint (See Section 7.1.3.1 for full details) however the model will be adjusted for the following baseline values: 																							
<table border="1"> <thead> <tr> <th>Binary Endpoint</th> <th>Baseline adjustment</th> </tr> </thead> <tbody> <tr> <td>ACR20</td> <td>TJC68, SJC66</td> </tr> <tr> <td>ACR50</td> <td>TJC68, SJC66</td> </tr> <tr> <td>ACR70</td> <td>TJC68, SJC66</td> </tr> <tr> <td>CDAI-LDA</td> <td>CDAI Total Score</td> </tr> <tr> <td>CDAI Remission</td> <td>CDAI Total Score</td> </tr> <tr> <td>DAS28-CRP LDA</td> <td>DAS28-CRP</td> </tr> <tr> <td>DAS28-CRP Remission</td> <td>DAS28-CRP</td> </tr> <tr> <td>DAS28-ESR LDA</td> <td>DAS28-ESR</td> </tr> <tr> <td>DAS28-ESR Remission</td> <td>DAS28-ESR</td> </tr> <tr> <td>Good/Moderate EULAR (CRP)</td> <td>DAS28-CRP</td> </tr> </tbody> </table>		Binary Endpoint	Baseline adjustment	ACR20	TJC68, SJC66	ACR50	TJC68, SJC66	ACR70	TJC68, SJC66	CDAI-LDA	CDAI Total Score	CDAI Remission	CDAI Total Score	DAS28-CRP LDA	DAS28-CRP	DAS28-CRP Remission	DAS28-CRP	DAS28-ESR LDA	DAS28-ESR	DAS28-ESR Remission	DAS28-ESR	Good/Moderate EULAR (CRP)	DAS28-CRP
Binary Endpoint	Baseline adjustment																						
ACR20	TJC68, SJC66																						
ACR50	TJC68, SJC66																						
ACR70	TJC68, SJC66																						
CDAI-LDA	CDAI Total Score																						
CDAI Remission	CDAI Total Score																						
DAS28-CRP LDA	DAS28-CRP																						
DAS28-CRP Remission	DAS28-CRP																						
DAS28-ESR LDA	DAS28-ESR																						
DAS28-ESR Remission	DAS28-ESR																						
Good/Moderate EULAR (CRP)	DAS28-CRP																						
<ul style="list-style-type: none"> A separate logistic regression model will be fitted for each assessment time point. For time points up to week 12, all treatment arms will be included in the model (i.e. pooled placebo, GSK3196165 150mg, GSK3196165 90mg, sarilumab 200mg). For time points beyond week 12, only GSK3196165 150mg, GSK3196165 90mg and sarilumab 200mg randomised treatment arms will be included in the model. If at any time point the convergence criterion is not satisfied or maximum likelihood estimates do not exist, then the results of this model will not be reported. 																							
Model Checking & Diagnostics																							
<ul style="list-style-type: none"> The same model checking and diagnostics will be used as for the primary endpoint. See Section 7.1.3.1 for full details. 																							

Model Results Presentation
<ul style="list-style-type: none"> • Binary Endpoints will be presented using the same methods as the primary endpoint. See Section 7.1.3.1 for full details. • The results from each assessment time point model will be presented within the same output. • Non-inferiority over sarilumab on ACR20 will be concluded if the lower limit of the multiplicity corrected 95% CI in the difference in proportions (GSK3196165 minus sarilumab) is greater than -12% (Note: non-inferiority was calculated using the FDA fixed margin approach [FDA, 2016]).
Subgroup Analyses
<ul style="list-style-type: none"> • See Section 5.4 for details on subgroup analyses.
Sensitivity and Supportive Analyses
<ul style="list-style-type: none"> • Sensitivity Analysis on the missing data imputation methods will be performed as described in Section 7.2.1.7. • Supportive Analysis will be performed as described in Section 7.2.2.

Continuous Endpoints

Endpoint / Variables
<ul style="list-style-type: none"> • Change from baseline in HAQ-DI. • Change from baseline in CDAI Total Score. • Change from baseline in FACIT-Fatigue score. • Change from baseline in arthritis pain VAS. • Change from baseline in TJC28/68 and SJC28/66. • Change from baseline in CRP (mg/L) • Change from baseline in PtGA/PhGA. • Change from baseline in DAS28-(CRP/ESR). • Change from baseline in SF-36 physical and mental component scores.
Model Specification
<ul style="list-style-type: none"> • Each estimate will be generated for each imputed dataset produced by the multiple imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be combined using Rubin's rules. • Continuous endpoints will be statistically analysed using an analysis of covariance (ANCOVA) comparing each randomised treatment arm with control groups when controlling for treatment arm, respective baseline value and previously failed medication category (1 bDMARD, >1 bDMARD, ≥ 1 JAK inhibitor). • A separate ANCOVA will be conducted for each assessment time point. For time points up to week 12, all treatment arms will be included in the model (i.e. pooled placebo, GSK3196165 150mg, GSK3196165 90mg, sarilumab 200mg). For time points beyond week 12, only GSK3196165 150mg, GSK3196165 90mg and sarilumab 200mg randomised treatment arms will be included in the model.

Model Checking & Diagnostics
<ul style="list-style-type: none"> If there are any departures from the distributional assumptions, alternative models will be explored using appropriate transformed data.
Model Results Presentation
<ul style="list-style-type: none"> The results from each assessment time point will be presented within the same output. Point estimates and corresponding 95% confidence intervals will be constructed for the treatment differences over placebo and over sarilumab at each visit using the least squares (LS) means estimates. Plots of LS means and corresponding standard error from the model will be generated for each treatment group by visit. Non-inferiority over sarilumab on change from baseline in CDAI Total score will be concluded if the upper limit of the multiplicity corrected 95% CI in the treatment difference (GSK3196165 minus sarilumab) is less than 3.5 (Note: non-inferiority was calculated using the FDA fixed margin approach [FDA, 2016]). Non-inferiority over sarilumab on change from baseline in Pain VAS will be concluded if the upper limit of the multiplicity corrected 95% CI in the treatment difference (GSK3196165 minus sarilumab) is less than 5.3 (Note: non-inferiority was calculated using the FDA fixed margin approach [FDA, 2016]).
Subgroup Analyses
<ul style="list-style-type: none"> See Section 5.4 for details on subgroup analyses.
Sensitivity and Supportive Analyses
<ul style="list-style-type: none"> Sensitivity Analysis on the missing data imputation methods will be performed as described in Section 7.2.1.7. Supportive Analysis will be performed as described in Section 7.2.2. Non-parametric analyses may be conducted if the normality assumption does not hold.

CCI



CCI



CCI



CCI

8. SAFETY ANALYSES

The safety analyses will be based on the “Safety” population, unless otherwise specified.

Safety analysis will be displayed in three different ways (see Section 5.1.3 for details).

All primary safety analysis will use the “while on treatment” approach, i.e. any safety events which occur post discontinuation of study intervention which are not classified as treatment emergent under the definition specified in Section 14.4.2, will be excluded. A sensitivity analysis will be performed on key safety outputs using the “treatment policy” approach, i.e. all safety events reported in the study will be included.

Missing safety data will not be imputed. The details of the planned displays are provided in [Appendix 12](#).

8.1. Adverse Events Analyses

- Adverse events analyses including the analysis of adverse events (AEs), Serious adverse events (SAEs) and other important adverse events will be based on GSK Core Data Standards.

- All AEs will be classified using the current standard GSK Medical Dictionary for Regulatory Activities (i.e. MedDRA version in use at the time of reporting), and grouped by SOC and PT, unless otherwise stated. MedDRA version will be detailed on every table that uses MedDRA.
- Exposure adjusted incidence rates per 100 patient years by treatment group will be presented for all AEs and SAEs.
- Common AEs will be defined as $\geq 5\%$ incidence in any treatment group, unless otherwise specified. Relative risks, based on observed frequencies, for the proportions of subjects with common AEs will be calculated for the comparisons specified in Section 5.1.3.
- AEs with missing intensity will be considered severe.
- Additional safety outputs relating to COVID-19 adverse events including COVID-19 assessments and symptom assessments will be based on GSK Core Data Standards.

8.1.1. Adverse Events of Special Interest and Other Important AEs Analyses

A comprehensive list of MedDRA terms based on clinical review will be used to identify each type of event. Changes to the MedDRA dictionary may occur between the start of the study and the time of reporting and/or emerging data from on-going studies may highlight additional adverse events of special interest, therefore the list of terms to be used for each event of interest and the specific events of interest will be based on the safety review team (SRT) agreements in place at the time of reporting.

The details regarding the derivations of adverse events of special interest (AESI) and other important AEs are provided in Section 14.6.4.

Exposure adjusted incidence rates per 100 patient-years by treatment group will be calculated for each category of AESI and other important AE.

Relative risks, based on observed frequencies, for the proportions of subjects with AESIs will be calculated for the comparisons specified in Section 5.1.3.

8.2. Clinical Laboratory Analyses

Laboratory evaluations including the analyses of Chemistry laboratory tests, Hematology laboratory tests, Urinalysis, fasting lipids, and liver function tests will be based on GSK Core Data Standards.

All laboratory parameters will be summarised, but only laboratory parameters of interest with available CTCAE grades will be used in summary table by grades.

Laboratory parameters of interest are:

- WBCs
- Neutrophils
- Lymphocytes
- Hemoglobin
- Platelets
- ALT
- AST
- ALP
- Bilirubin
- Creatinine
- eGFR
- Total cholesterol
- Low-density lipoprotein (LDL)
- High-density lipoprotein (HDL)
- Triglycerides

Local laboratory parameters will not be included in any summaries and will appear in the listing only.

8.3. Other Safety Analyses

The analyses of non-laboratory safety test results including ECGs and vital signs will be based on GSK Core Data Standards, unless otherwise specified.

8.3.1. Immunogenicity Analyses

An immune response to GSK3196165 can lead to generation of anti-drug antibodies (ADA). For the immunogenicity assessment, two types of antibody assays will be performed, a binding antibody assay and a neutralizing antibody assay.

For the binding antibody assay, there will be three testing steps: screening, confirmation, and titration. The screening assay produces a result of positive or negative relative to a screening cut point. Positive samples continue with the confirmation assay, which also produces a result of positive or negative relative to a confirmation cut point. For samples with a positive confirmation result, a titre value will also be obtained to quantify the degree of binding in a titration assay. Subjects with confirmed positive results, will also be tested in the neutralizing antibody assay, which also reports results as positive or negative.

Subjects will be categorized as positive or negative based on confirmation step and a positive ADA event will further be categorized as transient positive or persistent positive at each visit and for anytime post baseline visit. Transient positive is defined as a single positive immunogenic response where the previous visit is negative, that does not occur at the final study assessment and persistent positive is defined as a positive immunogenic response where the previous visit is positive or the final study assessment is positive. Titers will be summarized by median, minimum, and maximum.

A summary of treatment emergent positive confirmation binding ADA assay results in the subset of subjects who did not have a positive confirmation binding ADA assay result prior to the dosing of study treatment will also be presented.

Neutralizing antibody assay results will be summarised by visit. For anytime post baseline visit, highest result will be used, i.e. according to the following hierarchy: ADA result will be Persistent Positive > Transient Positive > Negative, NAB result will be Positive > Negative and highest titer value.

9. PHARMACOKINETIC ANALYSES

9.1. Primary Pharmacokinetic Analyses

9.1.1. Endpoint / Variables

GSK3196165 serum concentrations.

9.1.1.1. Drug Concentration Measures

Refer to [Appendix 5: Data Display Standards & Handling Conventions \(Section 14.5.3 Reporting Standards for Pharmacokinetic\)](#)

9.1.2. Summary Measure

GSK3196165 serum concentrations at each assessment visit.

9.1.3. Population of Interest

The primary pharmacokinetic analyses will be based on the Pharmacokinetic population, unless otherwise specified.

9.1.4. Strategy for Intercurrent (Post-Randomization) Events

No strategy for the handling of intercurrent events will be implemented.

9.1.5. Statistical Analyses / Methods

Details of the planned displays will be based on GSK Data Standards and statistical principles.

Unless otherwise specified, endpoints / variables defined in Section [9.1.1](#) will be summarised using descriptive statistics and listed.

10. POPULATION PHARMACOKINETIC (POPPK) ANALYSES

The primary goal of this analysis is to characterize the population pharmacokinetics of GSK3196165 administered subcutaneously in participants with Rheumatoid Arthritis. The influence of subject demographics, baseline characteristics, including disease activity, modality of administration, and co-medication on the pharmacokinetics of GSK3196165 in this population will be investigated. The PK data from this study will be combined with PK data from other studies in GSK3196165. Details of the population PK analysis will be provided in a separate technical analysis plan and reported in a standalone report.

11. PHARMACODYNAMIC AND BIOMARKER ANALYSES

11.1. Exploratory Pharmacodynamic and Biomarker Analyses

11.1.1. Endpoint / Variables

- Pharmacodynamic biomarkers:
 - Chemokine (C-C Motif) Ligand 17 (CCL17)
 - MMP Degraded Type 1 Collagen (C1M)
 - Collagen III Neo-peptide C3M (C3M)
 - Soluble Interleukin 2 Receptor (IL2SR)
 - Interleukin 6 (INTLK6)
 - Macrophage-Derived Chemokine (MDC)
 - Osteocalcin (OSTEOC)
 - P4NP 7S Int Epitope 7S Domain T IV Coll (P4NP7S)
 - Citrullinated MMP-Degraded Vimentin (VICM)
- Hepatic CYP3A biomarkers:
 - 4 β -hydroxycholesterol (4B-OHC)
 - Cholesterol
 - Normalised 4 β -hydroxycholesterol (Ratio of 4B-OHC/Cholesterol)
- Safety biomarkers:
 - GM-CSF Autoantibody
- Target Engagement biomarkers:
 - GM-CSF Complex
 - GM-CSF Free Soluble

CCI



11.1.2. Summary Measure

- Change from baseline in pharmacodynamic biomarkers at each assessment visit:
 - Difference from placebo at all assessment visits up to week 12.
 - Difference from Sarilumab at all assessment visits.
- Observed result and ratio to baseline in hepatic CYP3A biomarkers at each assessment visit

11.1.3. Population of Interest

The exploratory pharmacodynamic and biomarker analyses will be based on the Safety population, unless otherwise specified.

11.1.4. Strategy for Intercurrent (Post-Randomization) Events

No strategy for the handling of intercurrent events will be implemented.

11.1.5. Statistical Analyses / Methods

Details of the planned displays will be based on GSK Data Standards and statistical principles.

Unless otherwise specified, endpoints / variables defined in Section 11.1.1 will be summarised using descriptive statistics and graphically presented (where appropriate).

Biomarker levels below the lower limit of quantification (LLOQ) will be replaced by $0.5 \times \text{LLOQ}$ in all analyses.

Endpoint/Variables
<ul style="list-style-type: none"> Change from baseline in pharmacodynamic biomarkers
Model Specification
<ul style="list-style-type: none"> Endpoints will be statistically analysed using Mixed Model Repeated Measures (MMRM) model Two models will be fitted: <ul style="list-style-type: none"> Up to week 12 (placebo comparison): where all treatment arms will be included in the model (i.e. pooled placebo, GSK3196165 150mg, GSK3196165 90mg, sarilumab 200mg). Week 0 to Week 24 (sarilumab comparison): where only GSK3196165 150mg, GSK3196165 90mg and sarilumab 200mg randomised treatment arms will be included in the model. The models will include terms for treatment arm, visit, respective baseline value, previously failed medication category (1 bDMARD, >1 bDMARD, ≥ 1 JAK inhibitor) and treatment arm-by-visit interaction. Models will be fitted using an unstructured covariance matrix. The Kenward and Roger method for approximating the denominator degrees of freedom and correcting for bias in the estimated variance-covariance of the fixed effects will be used.
Model Checking and Diagnostics
<ul style="list-style-type: none"> If there are any departures from the distributional assumptions, alternative models will be explored using appropriate transformed data.
Model Results Presentation
<ul style="list-style-type: none"> Point estimates and corresponding 95% confidence intervals will be constructed for the treatment differences over placebo and over sarilumab at each visit using the least squares (LS) means estimates. Plots of LS means and corresponding standard error from the model will be generated for each treatment group by visit.

12. PHARMACOKINETIC / PHARMACODYNAMIC ANALYSES

The primary goal of this analysis is to characterize the pharmacokinetic / pharmacodynamic relationship of effect of GSK3196165 on efficacy, safety and target engagement including downstream signalling of GM-CSF after SC administration in combination with a csDMARD in participants with moderately to severely active rheumatoid arthritis. The data from this study might be combined with data from other studies in GSK3196165. Details of the PK/PD analysis will be provided in a separate technical analysis plan and reported in a standalone report.

13. REFERENCES

Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. *Stat Med.* 2009;28(4):586-604.

FDA (Food and Drug Administration). Guidance for Industry: Non-Inferiority Clinical Trials to Establish Effectiveness. 2016. <https://www.fda.gov/media/78504/download>

Freyenhagen R, Baron R, Gockel U, Tölle T.R, *CurrMed ResOpin* Vol 22, 2006, 1911-1920 © 2006 Pfizer Pharma GmbH, Pfizerstr.1, 76139 Karlsruhe, Germany.

ICH HARMONISED GUIDELINE. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1). 2019. https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf

NCI. National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 NCI, NIH, DHHS. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf

Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. *Pharmaceutical Statistics.* 2019;18:85–95.

14. APPENDICES

14.1. Appendix 1: Protocol Deviation Management and Definitions for Per Protocol Population

14.1.1. Exclusions from Per Protocol Population

A subject meeting any of the following criteria will be excluded from the Per Protocol population:

Number	Exclusion Description
01	Participant was randomised despite not meeting an eligibility criteria which, in the judgement of the clinical team, constitutes an exclusion from the Per protocol population (Subset of Important Protocol Deviations with GSK category 2)
02	Medication/Vaccine excluded by the protocol was administered, including those restricted prior to the study, during the study and/or during the safety follow-up of the study (Important Protocol Deviations with GSK categories 4A or 4B)
03	Participant substantially did not receive medication as planned per protocol (Important Protocol Deviations with GSK category 7A).
04	Participant received medication while in contraindication (Important Protocol Deviations with GSK category 7B)
05	Participant received wrong study treatment or assignment (Important Protocol Deviations with GSK category 7C)
06	Participant had significant non-compliance or dose modification of background treatment (Important Protocol Deviations with GSK category 7OT)
07	Participant developed withdrawal criteria specified in the protocol but were not withdrawn and continued dosing (Important Protocol Deviations with GSK category 3A, 3B or 3OT)
08	Study blind/unblind procedures: Investigator/site staff/participant/GSK Clinical team did not remain blinded to treatment assignment through Week 24 Exit visit efficacy evaluation, includes emergency unblinding for medical reasons (Important Protocol Deviations with GSK category 8B)
09	Other: a deviation that does not satisfy the above criteria, however, in the judgment of the clinical team, including the medical monitor, constitutes an exclusion from the Per Protocol population.

14.2. Appendix 2: Schedule of Activities

14.2.1. Protocol Defined Schedule of Events

SoA – Screening Period


<p>Participant Screening Task List</p> <p>(after informed consent, all screening assessments must be completed within the 42 days prior to Randomisation)</p> <p>Day -42 to Day -1</p> <p style="text-align: center;">↓</p>		<p>Screening assessment notes</p>	
<p>Informed Consent and optional Genetics consent</p> <p>Inclusion/exclusion criteria</p> <p>Participant Demographics</p> <p>Medical, disease and therapy history</p> <p>Review of asthma/COPD/pulmonary disease history</p> <p>Concomitant Medication Review</p>			
<p>Assessments</p>	<p>Triplicate 12-lead ECG¹</p> <p>Vital signs</p> <p>Full Physical Exam</p> <p>Dyspnoea & Cough assessment, Lung Auscultation, Pulse Oximetry</p> <p>TB evaluation</p> <p>SAE assessment⁶</p> <p>Swollen (66) & Tender (68) joint count²</p> <p>Chest X-ray (posteroanterior)³</p>	<p>1) ECGs should be performed before vital signs and blood draws.</p> <p>2) Joint assessments should be performed by an independent assessor. Where possible the same assessor should perform all joint assessments for an individual participant.</p> <p>3) Unless performed within previous 12 weeks.</p> <p>4) For women of child-bearing potential.</p> <p>5) Fasting is not required, but 6hr fasting status at time of blood draw must be noted on requisition form.</p> <p>6) See Section 8.3.1 for the time period of SAE collection, which varies between countries.</p> <p>See Section 5.4 for screen failures and rescreening.</p>	
	<p>Labs</p>		<p>Haematology, Chemistry, Urinalysis (dip stick)</p> <p>HIV, TB, Hepatitis B & Hepatitis C screen</p> <p>hsCRP</p> <p>Serum pregnancy test⁴</p> <p>Lipid profile⁵</p>

SoA – Treatment Period

		Study intervention GSK3196165 vs sarilumab vs Placebo (W0-W11)										Study intervention GSK3196165 vs sarilumab (W12-W24)										Notes					
Week	Assessment visit Day	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		20	21	22	23	24
	Study activities ¹	Baseline Day 1	Day 8 (±2d)	Day 15 (±2d)	Day 22 (±2d)	Day 29 (±2d)	Day 36 (±2d)	Day 43 (±2d)	Day 50 (±2d)	Day 57 (±2d)	Day 64 (±2d)	Day 71 (±2d)	Day 78 (±2d)	Primary endpoint Day 85 (±3d)	Day 92 (±3d)	Day 99 (±3d)	Day 106 (±3d)	Day 113 (±3d)	Day 120 (±3d)	Day 127 (±3d)	Day 134 (±3d)	Day 141 (±3d)	Day 148 (±3d)	Day 155 (±3d)	Day 162 (±3d)	End of treatment Day 169 (±7d)	
	Randomisation	X																									
PROS ¹	Arthritis pain VAS, PtGA, HAQ-DI	X	X	X		X				X				X	X			X								X	
	PROMIS Pain Interference	X	X	X		X								X				X								X	
	PainDETECT	X																									
	RA Symptom & Impact questionnaire	X	X			X								X				X								X	
	FACIT-Fatigue, SF-36, PROMIS Sleep	X				X								X				X								X	
	Participant Feedback questionnaire													X												X	
Assessments	12-lead ECG ² (S=single, T=triplicate)													S												T	
	Vital signs	X	X	X		X			X					X	X			X								X	
	Brief Physical Exam	X	X	X		X			X					X	X			X								X	
	Dyspnoea & Cough assessment, Lung Auscultation, Pulse Oximetry	X	X	X		X			X					X	X			X								X	
	Pulmonary function tests (FEV ₁ , FVC)	X ¹⁵																									
	Swollen (66) & Tender (68) joint count ³	X	X	X		X			X					X	X			X								X	
	Physician Global Assessment ⁴	X	X	X		X			X					X	X			X								X	
Labs and blood draws	Chest x-ray (posteroanterior)																							X ⁵			
	Haematology, Chemistry, Urinalysis	X	X	X		X			X					X	X			X					X		X		
	Lipid profile ⁶					X												X							X ⁶		
	Urine pregnancy test ⁷	X				X			X					X				X								X	
	hsCRP, ESR ⁸	X	X	X		X			X					X	X			X								X	
	RF, ACPA (anti-CCP)	X																									
	4β-OH cholesterol and cholesterol	X												X												X	
	TB testing																							X			
	Pre-dose PK sample (& GMCSF complex)			X	X				X					X				X								X	
	Immunogenicity blood sampling	X ⁹	X	X										X				X								X	
	Genetic sample ¹⁰	X																									
	Sampling for RNA analysis	X				X								X												X	
	Blood PD & Biomarkers	X	X	X		X								X												X	
Weekly study SC injection ^{11,12,13}	X ^{11,12}	X ¹¹	X ¹²	X	X ¹²	X	X ¹²	X	X ¹²	X	X ¹²	X	X ¹²	X	X ^{11,12}	X ¹¹	X ¹²	X	X ¹²	X	X ¹²	X	X ¹²	X	X ¹²	X	
SAE/AE review ¹⁴	←-----X----->																										
Concomitant medication review ¹⁴	←-----X----->																										

- PROs should be completed before any other assessments, procedures or consultations, to avoid influencing participants' perception.
- ECGs should be performed before vital signs and blood draws.
- Joint assessments should be performed by an independent assessor. Where possible the same assessor should perform all joint assessments for an individual participant.
- Where possible, the same individual should perform all physician global assessments for an individual participant.
- Schedule X-ray between Weeks 22-23.
- Fasting is not required, but 6hr fasting status at time of blood draw must be noted on requisition form.
- For women of child-bearing potential.
- ESR measured locally (using kit provided) by unblind site staff.
- Day 1 sample includes anti-GM-CSF auto-antibody and free GM-CSF analysis.
- Genetics consenting participants only.
- First and second SC injection given **at site** for all participants; monitor participants for 1 hour post dosing at Weeks 0, 1, 12, and 13.
- Dosing must always be performed **by an unblinded administrator on weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, even if PFS are available**. Refer to Section 6.1.
- Dispense weekly for site administration; OR if available, dispense PFS in boxes of 4, every 4 weeks, for home SC dosing.
- Minimum weekly review to Week 12, then every two weeks to Week 24. *A phone call is acceptable if a site visit is not scheduled.*
- May be performed before Day1 if required.

SoA – Safety follow-up visit



Assessments for Early withdrawal from study

Follow Week 24 procedures (with the exception of the 4β-OH cholesterol sample) at the time of withdrawal, or within 1 week, then schedule a safety follow-up visit 12 weeks post last dose of study intervention.

14.3. Appendix 3: Assessment Windows

14.3.1. Definitions of Assessment Windows for Analyses

Data will be analysed as per the planned visit assignment.

Early withdrawal and unscheduled visits will be slotted to the appropriate planned visit. The assigned visit will be based on the interval in which the Study Day for the early withdrawal or unscheduled visit falls according to intervals provided below.

Analysis Set / Domain	Target	Analysis Window		Analysis Timepoint
		Beginning Timepoint	Ending Timepoint	
All	Day-1	Day -42	Day -1	Screening
All	Day 1	Day 1	Day 1	Baseline
All (Efficacy, lung auscultation and pulse oximetry)	Day 8	Day 2	Day 11	Week 1
All (Safety) ^[1]	Day 8	Day 2	Day 22	Week 2
All (Efficacy, lung auscultation and pulse oximetry)	Day 15	Day 12	Day 22	Week 2
All	Day 29	Day 23	Day 43	Week 4
All	Day 57	Day 44	Day 71	Week 8
All	Day 85	Day 72	Day 88	Week 12
All	Day 92	Day 89	Day 95	Week 13
All (Safety)	Day 113	Day 96	Day 135	Week 16
All (Efficacy)	Day 113	Day 96	Day 141	Week 16
All (Safety)	Day 155	Day 136	Day 160	Week 22
All (Efficacy)	Day 169	Day 142	Day 231	Week 24
All (Safety)	Day 169	Day 161	Day 231	Week 24
All (Safety)	Day 239	Day 232	Day 232+	12-week Follow-up (for participants who don't transition into LTE study)
Safety (participants withdrawn early from treatment)	84 days after last treatment	77 days after last treatment	91 days after last treatment	12 Week Follow Up

NOTES:

- If there are two values within a time window, the value closest to the target day for that window will be used . If values are the same distance from the target, then the mean will be taken.
- [1] Excluding lung auscultation and pulse oximetry

14.4. Appendix 4: Study Phases and Treatment Emergent Adverse Events

14.4.1. Study Phases

Assessments and events will be classified according to the time of occurrence relative to study treatment start date.

On-Treatment AEs will be reported as treatment emergent AEs (TEAE). Definition for TEAE can be found in Section 14.4.2.

If an AE happened at week 12 visit, it will be assigned to Period 2.

For Placebo:

Study Phase	Period	Definition
Pre-Treatment		Date ≤ Study Treatment Start Date
On-Treatment	Period 1	Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early Withdrawal (if before Week 12) Visit Date
Off-Treatment Safety Follow-Up ^[1]		Study Treatment Stop Date < Date ≤ Study Treatment Stop Date + 84 days
Off-Treatment		Date ≥ Study Treatment Stop Date + 84 days

[1] The safety follow up definition for Placebo is only valid for participants who withdraw early. The participants that are on placebo who complete Period 1, will continue into Period 2.

For GSK3196165:

Study Phase	Period	Definition
Pre-Treatment		Date ≤ Study Treatment Start Date
On-Treatment	Period 1	Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early Withdrawal (if before week 12) Visit Date + 7 days
	Period 2	Week 12 Visit Date < Date ≤ Study Treatment Stop Date + 7 days or Early Withdrawal (if after week 12) Visit Date + 7 days
Off-Treatment Safety Follow-Up		Study Treatment Stop Date + 7 days < Date ≤ Study Treatment Stop Date + 84 days
Off-Treatment		Date ≥ Study Treatment Stop Date + 84 days

For Sarilumab:

Study Phase	Period	Definition
Pre-Treatment		Date ≤ Study Treatment Start Date
On-Treatment	Period 1	Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early Withdrawal (if before week 12) Visit Date+ 14 days
	Period 2	Week 12 Visit Date < Date ≤ Study Treatment Stop Date + 14 days or Early Withdrawal (if after week 12) Visit Date + 14 days
Off-Treatment Safety Follow-Up		Study Treatment Stop Date + 14 days < Date ≤ Study Treatment Stop Date + 84 days
Off-Treatment		Date ≥ Study Treatment Stop Date + 84 days

14.4.1.1. Study Phases for Concomitant Medication

Study Phase	Definition
Prior	Any medication that started before first dose of study treatment
Concomitant	Any medication that is taken post first dose of study treatment, regardless of whether it was started prior to the first dose of study treatment or not

NOTES:

- Please refer to [Appendix 7: Reporting Standards for Missing Data](#) for handling of missing and partial dates for concomitant medication. Use the rules in this table if concomitant medication date is completely missing.

14.4.2. Treatment Emergent Flag for Adverse Events

Flag	Definition
Treatment Emergent	<ul style="list-style-type: none"> • Study Treatment Start Date ≤ AE Start Date ≤ Study Treatment Stop Date + 84 days.

NOTES:

- If the study treatment stop date is missing, then the AE will be considered to be On-Treatment.
- Time of study treatment dosing and start/stop time of AEs should be considered, if collected.
- If AE happens on the week 12 visit date, it will be assigned to period 2.

14.5. Appendix 5: Data Display Standards & Handling Conventions

14.5.1. Reporting Process

Software	
<ul style="list-style-type: none"> The currently supported versions of SAS software 9.4 will be used. 	
Reporting Area	
HARP Server	: UK1SALX00175
HARP Compound	: GSK3196165/MID202018
Analysis Datasets	
<ul style="list-style-type: none"> Analysis datasets will be created according to CDISC standards (SDTM IG Version 3.2 & ADaM IG Version 1.1). 	
Generation of RTF Files	
<ul style="list-style-type: none"> RTF files will be generated for the final reporting effort for tables and listings. 	

14.5.2. Reporting Standards

General
<ul style="list-style-type: none"> The current GSK Integrated Data Standards Library (IDSL) will be applied for reporting, unless otherwise stated (IDSL Standards Location: https://spope.gsk.com/sites/IDSLLibrary/SitePages/Home.aspx): <ul style="list-style-type: none"> 4.03 to 4.23: General Principles 5.01 to 5.08: Principles Related to Data Listings 6.01 to 6.11: Principles Related to Summary Tables 7.01 to 7.13: Principles Related to Graphics Do not include subject level listings in the main body of the GSK Clinical Study Report. All subject level listings should be located in the modular appendices as ICH or non-ICH listings
Formats
<ul style="list-style-type: none"> GSK IDSL Statistical Principles (5.03 & 6.06.3) for decimal places (DP's) will be adopted for reporting of data based on the raw data collected, unless otherwise stated. Numeric data will be reported at the precision collected on the eCRF. The reported precision from non eCRF sources will follow the IDSL statistical principles but may be adjusted to a clinically interpretable number of DP's.
Planned and Actual Time
<ul style="list-style-type: none"> Reporting for tables, figures, and formal statistical analyses: <ul style="list-style-type: none"> Planned time relative to dosing will be used in figures, summaries, statistical analyses, and calculation of any derived parameters, unless otherwise stated. The impact of any major deviation from the planned assessment times and/or scheduled visit days on the analyses and interpretation of the results will be assessed as appropriate. Reporting for Data Listings: <ul style="list-style-type: none"> Planned and actual time relative to study drug dosing will be shown in listings (Refer to IDSL Statistical Principle 5.05.1). Unscheduled or unplanned readings will be presented within the subject's listings.
Unscheduled Visits
<ul style="list-style-type: none"> Unscheduled visits will be slotted as stated in Section 14.3.1 unless otherwise stated. All unscheduled visits will be included in listings.

Descriptive Summary Statistics	
Continuous Data	Refer to IDSL Statistical Principle 6.06.1
Categorical Data	N, n, frequency, %
Graphical Displays	
<ul style="list-style-type: none"> Refer to IDSL Statistical Principals 7.01 to 7.13. 	

14.5.3. Reporting Standards for Pharmacokinetic Concentration Data

Pharmacokinetic Concentration Data	
Descriptive Summary Statistics, Graphical Displays and Listings	Refer to IDSL PK Display Standards. Refer to IDSL Statistical Principle 6.06.1. Note: Concentration values will be imputed as per GUI_000722, Section 3.5.1 "For the calculation of mean or median pharmacokinetic profiles"

14.5.4. Reporting Standards for Log-transformed Parameters

Reporting of Log-Transformed Parameters	
Descriptive Summary Statistics	N, n, geometric mean, 95% CI of geometric mean, geometric coefficient of variation (CV _b (%)) will be reported. [1] $CV_b (\%) = \sqrt{\exp(SD^2) - 1} * 100$
Figures	Axes will be presented with actual values with an appropriate log-scale (either base 2 or base 10) depending on range of values

14.6. Appendix 6: Derived and Transformed Data

14.6.1. General

<p>Multiple Measurements at One Analysis Time Point</p> <ul style="list-style-type: none"> • Mean of the measurements will be calculated and used in any derivation of summary statistics but if listed, all data will be presented. • Data will be analysed as per the planned visit assignment. • Early withdrawal and unscheduled visits will be slotted to the appropriate planned visit (as per Section 14.3.1). If there are two slotted values within a time window the value closest to the target day for that window will be used except for ECGs. If values are the same distance from the target, then the mean will be taken. • In the instance of both local and central labs being collected at the same timepoint, only the central labs will be used in any analysis. • Triplicate ECG measures will be averaged for each subject and visit prior to generating summary tables. • Participants having both High and Low values for Normal Ranges at any post-baseline visit for safety parameters will be counted in both the High and Low categories of “Any visit post-baseline” row of related summary tables. This will also be applicable to relevant Potential Clinical Importance summary tables.
<p>Study Day</p> <ul style="list-style-type: none"> • Calculated as the number of days from First Dose Date: <ul style="list-style-type: none"> • Ref Date = Missing → Study Day = Missing • Ref Date < First Dose Date → Study Day = Ref Date – First Dose Date • Ref Date ≥ First Dose Date → Study Day = Ref Date – (First Dose Date) + 1
<p>Period 1 (Up to Week 12)</p> <ul style="list-style-type: none"> • Period 1 (Up to Week 12) is defined as time from randomisation up to dosing of period 2 study medication (week 12) or date of study withdrawal or date of treatment withdrawal plus follow up, whichever is earlier. • A participant completed 12 weeks of treatment if study medication (injection) was administered at week 11 visit or later up to next study medication administration or study medication (capsule) was administered at week 11 plus 6 days or later up to next study medication administration • A participant completed week 12 if week 12 assessments were performed and study medication of the next period was administered. • A participant withdrew from the study if the withdrawal date is < date of study medication administration of period 2 (week 12)
<p>Period 2 (Post Week 12)</p> <ul style="list-style-type: none"> • Period 2 (post week 12) is defined as time from first dose of study medication of period 2 (Week 12) until date of study completion or date of study withdrawal or date of treatment withdrawal plus safety follow up whichever is earlier. • A participant withdrew from the study if the withdrawal date > date of study medication administration of period 2
<p>Study Completion</p> <ul style="list-style-type: none"> • For subjects not entering LTE study: completion of study is defined as completion of treatment plus follow up period. • For subjects entering LTE: completion of study is defined as completion of the week 52 visit.

14.6.2. Study Population

<p>Treatment Compliance</p> <ul style="list-style-type: none"> Treatment compliance will be calculated based on the formula: For GSK3196165: $\text{Treatment Compliance} = \frac{\text{Number of Actual Doses}}{\text{Planned Treatment Duration in Weeks}} * 100$ For Sarilumab: $\text{Treatment Compliance} = \frac{\text{Number of Actual Doses}}{(\text{Planned Treatment Duration in Weeks}/2)} * 100$ Treatment compliance could be greater than 100% if there are events of overdose. Cumulative compliance (since Day 1) at each visit will be calculated. Planned Treatment Duration is 24 weeks. Compliance for early treatment discontinuation participants will only be calculated up until the date of early treatment discontinuation.
<p>Date of Birth and Age</p> <ul style="list-style-type: none"> Only the year of birth will be captured, and therefore the date of birth is then derived as follows: $\text{Year of birth} = \text{YYYY} \rightarrow \text{Date of birth} = \text{30th June YYYY}$ Age in years will be calculated as integer part of (latest of (randomisation date, screening date)– date of birth). Birth date will be presented in listings as ‘YYYY’.
<p>Extent of Exposure</p> <ul style="list-style-type: none"> Number of days of exposure to study drug will be calculated based on the formula: For GSK3196165: $\text{Duration of Exposure in Days} = [(\text{Treatment stop date} - \text{treatment start date}) + 7] - [(\text{Number of missed injections}) * 7]$ For Sarilumab: $\text{Duration of Exposure in Days} = [(\text{Treatment Stop Date} - \text{Treatment Start Date}) + 14] - [(\text{Number of missed injections}) * 7]$ Participants who were randomized but did not report a treatment start date will be categorised as having zero days of exposure. The cumulative dose will be based on the formula: $\text{Cumulative Dose} = \text{Sum of Total Dose at Each Visit}$
<p>Disease History/Duration</p> <ul style="list-style-type: none"> RA duration since diagnosis in years will be calculated based on the formula: $\text{RA Duration Since Diagnosis in Years} = \frac{(\text{Date of First Dose of Study Treatment} - \text{Start date of RA diagnosis} + 1)}{365.25}$ RA duration since first symptoms in years will be calculated based on the formula: $\text{RA Duration Since First Symptoms in Years} = \frac{(\text{Date of First Dose of Study Treatment} - \text{Start date of first symptoms} + 1)}{365.25}$
<p>Stratification Stratum (Previously Failed Medication)</p> <ul style="list-style-type: none"> Stratification stratum will be derived from the randomisation numbers as follows:

Randomization Numbers	Stratum
PPD	1 bDMARD
	> 1 bDMARD
	>=1 JAK inhibitor

Corticosteroid Scaling Factor

- To assess corticosteroid use and determine average daily corticosteroid dose, all corticosteroid dosages will be converted to a prednisone equivalent in milligrams by multiplying the dose of the steroid (using the coded term from GSKDrug) by the conversion factor to get prednisone equivalent units.
- The following conversion factors will be used:

Corticosteroid	Scaling Factor
Betamethasone	8.33
Dexamethasone	6.67
Meprednisone	0.8
Methylprednisolone	0.8
Prednisolone	1
Prednisone, Prednisone Acetate	1
Triamcinolone	0.8
Predmet (NOS)	0.8
Deflazacort	1.2

Prior and Concomitant Medication**RA Concomitant medication will be split into following categories:**

- DMARDs
 - Methotrexate (all methotrexate medications combined into one category)
 - Other csDMARDs (not Methotrexate)
 - csDMARDs > 1
 - bsDMARDs/boDMARDs/tsDMARDs
- Corticosteroids (the following groups will be derived by route)
 - Oral
 - Intra-Articular
- Other RA medications

Prior RA medications will be split into following categories:

- DMARDs
 - Methotrexate (all methotrexate medications combined into one category)
 - Other csDMARDs (not Methotrexate)
 - csDMARDs >1
 - bsDMARDs/boDMARDs/tsDMARDs
 - >=1 of the above
 - =1 of the above
 - >1 of the above
 - Inadequate response to >=1 bs/boDMARD
 - Inadequate response to >=1 tsDMARD
 - Inadequate response to >1 bsDMARD/boDMARD/tsDMARD
- Oral corticosteroids
- Other RA medications

RA Concomitant medication will be derived as following:

Follow Section 14.4.1.1 for definition of “concomitant” medication.

- DMARDs:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG” using all “medication type” which includes C1SCAT=“CONVENTIONAL SYNTHETIC DMARDs”, C1SCAT=“BIOLOGICAL ORIGINATOR DMARDs”, C1SCAT=“BIOSIMILAR DMARDs”, and C1SCAT=“TARGETED SYNTHETIC DMARDs”.
- Methotrexate:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG”, using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDs” where ingredient/CMDECOD contains “METHOTREXATE”. All methotrexate medications will be combined together into one category called “Methotrexate”
- Other csDMARDs (not methotrexate):

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG”, using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDs”, but excluding methotrexate (where ingredient/CMDECOD contains “METHOTREXATE”)
- csDMARDs > 1:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” where a participant has taken more than 1 csDMARD (2 or more).

- bsDMARDs/boDMARDs/tsDMARDs:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG” using “medication type” which includes C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS”, C1SCAT=“BIOSIMILAR DMARDS” and C1SCAT=“TARGETED SYNTHETIC DMARDS”.

- Corticosteroids Oral:

Derived from “RA other medication” page in eCRF, C1CAT=“OTHER RHEUMATOID ARTHRITIS MEDICATION” using C1SCAT= “CORTICOSTEROID” and C1ROUTE=“ORAL”

- Corticosteroids IA:

Derived from “Intra-Articular Corticosteroids” page in eCRF, C1CAT=“OTHER RHEUMATOID ARTHRITIS MEDICATION” using C1SCAT=“CORTICOSTEROID” and C1ROUTE = “INTRA-ARTICULAR”

- Other RA medication:

Derived from “RA other medication” page in eCRF, C1CAT=“OTHER RHEUMATOID ARTHRITIS MEDICATION” using all “medication type” which includes C1SCAT=“Corticosteroid” all routes except C1ROUTE=“ORAL” and C1ROUTE=“INTRA-ARTICULAR”, C1SCAT=“OPIOID” and C1SCAT=“OTHER”.

Non-RA Concomitant medication will be derived as following:

Follow Section [14.4.1.1](#) for definition of “concomitant” medication.

Non RA medication is derived from “Non-RA concomitant medications” page in eCRF, C1CAT=“NON RHEUMATOID ARTHRITIS MEDICATION”.

Uncoded concomitant medication will be combined together in one category called “Uncoded”

Prior RA medication will be derived as following:

Follow Section [14.4.1.1](#) for definition of “prior” medication.

- DMARDS:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG” using all “medication type” which includes C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS”, C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS”, C1SCAT=“BIOSIMILAR DMARDS” and C1SCAT=“TARGETED SYNTHETIC DMARDS”.

- Methotrexate:

Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=“DISEASE-MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” where ingredient/CMDECOD contains “METHOTREXATE”. All methotrexate medications will be combined together into one category called “Methotrexate”

- Other csDMARDs (not methotrexate):

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" using C1SCAT="CONVENTIONAL SYNTHETIC DMARDS" where ingredient/ CMDECOD contains "METHOTREXATE".

○ csDMARDs > 1:

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" using C1SCAT="CONVENTIONAL SYNTHETIC DMARDS" where a participant has taken more than 1 csDMARD.

○ bsDMARDS/boDMARDS/tsDMARDS:

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" using C1SCAT="BIOSIMILAR DMARDS", C1SCAT="BIOLOGICAL ORIGINATOR DMARDS" and C1SCAT="TARGETED SYNTHETIC DMARDS".

- ≥ 1 of the above is derived as above for participants that have taken at least one of the bsDMARDS, boDMARDS or tsDMARDS
- =1 of the above is derived as above for participants that have taken one of the bsDMARDS, boDMARDS or tsDMARDS
- >1 of the above is derived as above for participants that have taken more than one of the bsDMARDS, boDMARDS or tsDMARDS

○ Inadequate response to ≥ 1 bs/boDMARD:

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" where a subject had at least one of the following: C1SCAT="BIOSIMILAR DMARDS" or C1SCAT="BIOLOGICAL ORIGINATOR DMARDS", with one or more of the following selected "lack of initial efficacy" or "loss of efficacy" or "adverse event", QNAM="PRSMEDEN" and QVAL contains "ADVERSE EVENT", "LACK OF INITIAL EFFICACY", or "LOSS OF EFFICACY".

○ Inadequate response to ≥ 1 tsDMARD:

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" where a subject had at least one C1SCAT="TARGETED SYNTHETIC DMARDS", with one or more of the following selected "lack of initial efficacy" or "loss of efficacy" or "adverse event", QNAM="PRSMEDEN" and QVAL contains "ADVERSE EVENT", "LACK OF INITIAL EFFICACY", or "LOSS OF EFFICACY".

○ Inadequate response to >1 bsDMARD/boDMARD/tsDMARD:

Derived from "RA Medications MTX, csDMARD and bDMARD" page in eCRF, C1CAT="DISEASE-MODIFYING ANTIRHEUMATIC DRUG" where a subject had at least two of the following: C1SCAT="BIOSIMILAR DMARDS" or C1SCAT="BIOLOGICAL ORIGINATOR DMARDS" or "C1SCAT=TARGETED SYNTHETIC DMARDS", with one or more of the following selected "lack of initial efficacy" or "loss of efficacy" or "adverse event", QNAM="PRSMEDEN" and QVAL contains "ADVERSE EVENT", "LACK OF INITIAL EFFICACY", or "LOSS OF EFFICACY".

○ Corticosteroids Oral:

Derived from "RA other medication" page in eCRF, C1CAT="OTHER RHEUMATOID ARTHRITIS MEDICATION" using C1SCAT="CORTICOSTEROID" and C1ROUTE="ORAL".

<ul style="list-style-type: none"> ○ Other RA medication: Derived from “RA other medication” page in eCRF, C1CAT=“OTHER RHEUMATOID ARTHRITIS MEDICATION” using all “medication type” which includes C1SCAT=“corticosteroid” which includes all routes except C1ROUTE=“ORAL”, C1SCAT=“OPIOID” and C1SCAT=“OTHER”. <p>The following medications will be combined into one category:</p> <ul style="list-style-type: none"> ○ All Methotrexate medications will be combined into one category called “Methotrexate” ○ Hydroxychloroquine and Hydroxychloroquine Sulfate will be combined into “Hydroxychloroquine” ○ Chloroquine, Chloroquine Phosphate and Chloroquine Sulfate will be combined into “Chloroquine” ○ Filgotinib and Filgotinib Maleate will be combined into "Filgotinib" ○ Tofacitinib and Tofacitinib Citrate will be combined into "Tofacitinib"

Concomitant COVID-19 Vaccine
<ul style="list-style-type: none"> ● COVID-19 Vaccines will be derived from the most recent list of terms provided by GSK Medical Dictionary at the time of reporting

14.6.3. Efficacy

14.6.3.1. ACR20/50/70

ACR20/50/70
Proportion of ACR20/50/70 responders
<ul style="list-style-type: none"> ● The American College of Rheumatology’s (ACR) definition for calculating improvement in RA is calculated as a 20% improvement (ACR20) in both tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR-core set measures: patient and physician global assessments, patient’s assessment of arthritis pain, disability, and an acute-phase reactant (i.e. CRP value). Similarly, ACR50 and ACR70 are calculated with the respective percent improvement. This efficacy measurement will be made at every post-baseline study assessment time point. ● The specific components of the ACR Assessments that will be used in this study are: <ul style="list-style-type: none"> ○ Tender/Painful Joint count 68 (TJC68) ○ Swollen Joint Count 66 (SJC66) ○ Patient’s Assessment of Arthritis Pain ○ Patient’s Global Assessment of Arthritis Disease Activity ○ Physician’s Global Assessment of Arthritis ○ CRP (mg/L) ○ Health Assessment Questionnaire – Disability Index (HAQ-DI) ● Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the ACR calculation. ● For all visits, if any of the component scores are missing, then those scores will be considered as not having met the criteria for improvement. Therefore, if TJC68 or SJC66 or 3 or more of the 5 remaining ACR-core set measures are missing, ACR20/ ACR50/ ACR70 will each be considered missing.

- For component scores with missing Baseline values or a Baseline value of 0, the percentage improvement can't be calculated and the component will be considered as missing for all visits. If the baseline value is missing, do not use screening visit data for imputation.

14.6.3.2. Tender/Painful and Swollen Joint Counts

Tender/Painful Joint Count (TJC) and Swollen Joint Count (SJC)
TJC28/68 and SJC28/66
<ul style="list-style-type: none"> • Four different scores will be calculated to evaluate swelling and tenderness of joints. TJC28 and SJC28 will take 28 joints into account, SJC66 and TJC68 will use 66 and 68 joints, respectively. • The assessment for swelling is the total number of joints with a present swelling and ranges from 0 to 28 for SJC28 and 0 to 66 for SJC66. • The assessment for tenderness is the total number of joints with a present tenderness and ranges from 0 to 28 for TJC28 and 0 to 68 for TJC68. • The following 28 joints will be taken into account for TJC28 and SJC28: Shoulder (2 joints), Knee (2), Elbow (2), Wrist (2), Fingers (IP, PIP, MCP: 20). • Additionally the following joints will be taken into account for SJC66/TJC68: Temporomandibular (2), Sternoclavicular (2), Acromioclavicular (2), Fingers (DIP: 8), Ankle (2), Tarsus (2), Toes (IP, PIP, MTP: 20), Hip (2, only for TJC). • Replaced or fused joints are considered non-evaluable in the swelling and tenderness assessment. • If there are missing observations for tender or swollen joints then the remaining observations will be assessed and weighted by dividing the number presented by number of non-missing and by multiplying by 28/66/68 for the joint count. • If a joint has undergone inter-articular injection of corticosteroid during the course of the study, this joint is recorded in the concomitant medication dataset. The joint will be considered to be tender and swollen for 8 weeks post IA corticosteroid injection.


14.6.3.3. Pain VAS

Patient's assessment of Arthritis Pain VAS
Pain VAS
<ul style="list-style-type: none"> • Subjects will assess the severity of their current arthritis pain using a continuous visual analog scale (VAS) with anchors "0" (CCI) and "100" (CCI).

14.6.3.4. Patient's/Physician's Global Assessment of Arthritis Disease Activity

Patient's/Physician's Global Assessment of Arthritis Disease Activity (PtGA/PhGA)
PtGA
<ul style="list-style-type: none"> • Subjects will complete a global assessment of disease activity using the patient global assessment of disease activity (PtGA) item, a continuous VAS with anchors "0" (CCI) to "100" (CCI).
PhGA
<ul style="list-style-type: none"> • Physicians will complete a global assessment of disease activity using the physician global assessment of disease activity item (PhGA), a continuous VAS with anchors "0" (CCI) to "100" (CCI).

CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.



CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.

14.6.3.6. CDAI

CDAI
CDAI Total Score
<ul style="list-style-type: none"> The Clinical Disease Activity Index (CDAI) is a composite score consisting of the sum of SJC28, TJC28, PtGA and PhGA. Since PtGA and PhGA are both collected on a VAS scale 0-100, the respective scores will be divided by 10 before computing the CDAI total score. CDAI ranges from 0 to 76 with higher values representing higher disease activity. Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the CDAI calculation. If one of the components is missing at an individual assessment point the CDAI value for that assessment will be set to missing.
CDAI Low disease activity (CDAI-LDA)
<ul style="list-style-type: none"> Low Disease Activity is achieved for a non-missing CDAI total score ≤ 10.
CDAI Remission
<ul style="list-style-type: none"> Remission is achieved for a non-missing CDAI total score ≤ 2.8.

14.6.3.7. DAS28-CRP and DAS28-ESR

DAS28-CRP
DAS28-CRP
<ul style="list-style-type: none"> The components of the DAS28-CRP arthritis assessment includes: <ul style="list-style-type: none"> Tender Joint Count 28 (TJC28) Swollen Joint Count 28 (SJC28) C-reactive protein (CRP) (in mg/L) Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=CCI to 100=CCI) The DAS28-CRP score will be calculated using the following formula: $\text{DAS28-CRP} = 0.56 \cdot \sqrt{\text{TJC28}} + 0.28 \cdot \sqrt{\text{SJC28}} + 0.36 \cdot \ln(\text{CRP} + 1) + 0.014 \cdot \text{PtGA} + 0.96$ Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the DAS28 calculation. If one of the components is missing at an individual assessment point, no imputations will be done and the DAS28 value for that assessment will be set to missing.
DAS28-CRP Low disease activity (LDA)
<ul style="list-style-type: none"> Low Disease Activity is achieved for a DAS28-CRP ≤ 3.2.

DAS28-CRP Remission
<ul style="list-style-type: none"> • Remission is achieved for a DAS28-CRP <2.6
DAS28-ESR
DAS28-ESR
<ul style="list-style-type: none"> • The components of the DAS28-ESR arthritis assessment includes: <ul style="list-style-type: none"> ○ Tender Joint Count 28 (TJC28) ○ Swollen Joint Count 28 (SJC28) ○ Erythrocyte sedimentation rate (ESR) (in mm/hr) ○ Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=CCI to 100=CCI) • The DAS28-ESR score will be calculated using the following formula: $\text{DAS28(ESR)} = 0.56 \cdot \sqrt{\text{TJC28}} + 0.28 \cdot \sqrt{\text{SJC28}} + 0.7 \cdot \ln(\text{ESR}) + 0.014 \cdot \text{PtGA}$ • Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the DAS28 calculation. • If one of the components is missing at an individual assessment point, no imputations will be done and the DAS28 value for that assessment will be set to missing. • An ESR value of 0 will be substituted with ESR=1 for the calculation of DAS28-ESR.
DAS28-ESR Low disease activity (LDA)
<ul style="list-style-type: none"> • Low Disease Activity is achieved for a DAS28-ESR ≤3.2.
DAS28-ESR Remission
<ul style="list-style-type: none"> • Remission is achieved for a DAS28-ESR <2.6

14.6.3.8. EULAR Response

EULAR Response
EULAR Good/Moderate Response
<ul style="list-style-type: none"> DAS28-CRP and DAS28-ESR scores will each be categorised using EULAR response criteria. Response at a given time point is defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to baseline. The definition of no response, moderate response and good response is captured in the following table:
<p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p>
<ul style="list-style-type: none"> If the post-baseline DAS28 value is missing, then the corresponding EULAR category will be set to missing.


14.6.3.9. ACR/EULAR Remission

ACR/EULAR Remission
Boolean-based ACR/EULAR Remission
<ul style="list-style-type: none"> Boolean-based remission is achieved if all of the following requirements are met at the same time: <ul style="list-style-type: none"> TJC68 \leq 1 SJC66 \leq 1 CRP \leq 1mg/dl PtGA \leq 10 Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the calculation. If one of the components is missing at an individual assessment point, the Boolean-based remission for that assessment will be set to missing.
Index-based ACR/EULAR Remission
<ul style="list-style-type: none"> The Simple Disease Activity Index (SDAI) is a composite score consisting of the sum of SJC28, TJC28, PtGA, PhGA, and CRP (mg/dl). Since PtGA and PhGA are both collected on a VAS scale 0-100, the respective scores will be divided by 10 before computing the SDAI total score. Index-based remission is achieved if the following requirement is met: <ul style="list-style-type: none"> SDAI \leq 3.3 Individual components collected outside of a +/- 2 day window from visit date will be considered missing for the purpose of the calculation. If one of the components is missing at an individual assessment point, the Index-based remission for that assessment will be set to missing.


14.6.3.10. SF-36

SF-36
SF-36
<ul style="list-style-type: none"> • Health-related quality of life will be assessed using the subject-completed Medical Outcomes Study Short-Form 36 (SF-36) which is a generic health survey that contains 36 questions covering eight domains of health. The SF-36 yields an eight-scale profile of functional health and well-being scores as well as physical and mental component health summary scores. The version 2, 1-week recall questionnaire will be used. Recoding, calculations, and standardisation will be done using Quality Metrics SF-36 scoring software.
SF-36 Domain Scores
<ul style="list-style-type: none"> • Individual question responses will be inputted into the Quality Metrics SF-36 scoring software to compute the eight domain scores: <ul style="list-style-type: none"> ○ Physical functioning (PF) ○ Role function – Physical aspect (RP) ○ Bodily Pain (BP) ○ General health perception (GH) ○ Mental Health (MH) ○ Role function – Emotional aspect (RE) ○ Social functioning (SF) ○ Vitality (VT) • Higher scores represent better health status.
SF-36 Physical and Mental component scores
<ul style="list-style-type: none"> • Individual question responses will be inputted into the Quality Metrics SF-36 scoring software to compute the physical and mental component scores.


CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.



CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.



CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.



Adverse Events of Special Interest (AESI)	
AEs of Special Interest (AESI)	
<ul style="list-style-type: none"> Adverse events of special interest (AESI) and other important adverse events will be derived using MEDRA and Common Terminology Criteria for Adverse Events v5.0 (NCI, 2017) and will include: 	
AESI	Programmatical Derivation
Serious infections and Serious infections excluding COVID-19 Infections	<p>Serious infections: Filter on Infections and Infestations SOC, limited to serious.</p> <p>Serious infections excluding COVID-19 infections: Filter on Infections and Infestations SOC, limited to serious and exclude the following PTs: Suspected COVID-19, "COVID-19", "COVID-19 pneumonia" or "Asymptomatic COVID-19".</p>
Opportunistic infections	Opportunistic infections will be derived, using the "Opportunistic infections" (Broad) SMQ and adjudicated by the SRT. Adjudicated opportunistic infections will be summarized.
Active TB, latent TB, and TB reactivation	<p>Derived from preferred terms of "Tuberculosis". Use HLT: 'Tuberculous Infections'.</p> <p>All tuberculosis infections will be adjudicated by SRT. The outcome of the adjudication will be Active TB, latent TB or TB reactivation which will be summarised.</p>
Neutropenia	Derived using PT of "Neutropenia" and/or "neutrophil count decreased" and/or "neutrophil percentage decreased". Only AEs/SAEs of neutropenia and/or neutrophil count decreased and/or neutrophil percentage decreased where the corresponding absolute neutrophil count (from laboratory data) are CTCAE grade 3 or 4 will be reported as AESI.
Persistent Cough	<p>Cough CTCAE \geq Grade 2 recorded for 3 consecutive weeks (\geq21 Days).</p> <p>Identified from: Cough 'Yes' entered in the pulmonary assessment eCRF with Grade determined from AE reporting with the following definition:</p>
<small>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</small>	

	<p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p>
<p>Persistent dyspnea</p>	<p>Persistent dyspnoea grade ≥ 2 for three consecutive weeks (≥ 21 days).</p> <p>Identified from: Dyspnoea rating scale on the pulmonary assessment eCRF page with the following grading:</p> <p>CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws and therefore have been excluded.</p>
<p>PAP (Pulmonary alveolar proteinosis)</p>	<p>Derived using preferred term (PT) "alveolar proteinosis". (LLT of 'pulmonary alveolar proteinosis' maps to PT of 'alveolar proteinosis'). All cases adjudicated by Pulmonary Adjudication Committee (PAC).</p> <p>The adjudicated PAP outcome will be summarized.</p>
<p>Serious hypersensitivity reactions, including anaphylaxis</p>	<p>Serious hypersensitivity reactions will be adjudicated using 'Hypersensitivity' (Broad) SMQ, 'Anaphylactic reaction' (Broad) SMQ and 'anaphylactic/anaphylactoid shock condition' (Broad) SMQ based on SAE listings.</p> <p>Final adjudication will be conducted by SRT and the adjudicated hypersensitivity will be summarized.</p>
<p>Injection site reactions</p>	<p>Derived from HLT term "injection site reactions", HLT term "administration site reaction NEC" and PT term "injection related reaction".</p>

Other Important AEs
Protocol defined cardiovascular (CV) events and adjudicated CV events
<ul style="list-style-type: none"> • CV Events CV events as reported in the database will be included in the summary table for all AEs. • Adjudicated CV Events Endpoints of interest: cardiovascular (CV) death, myocardial infarction (MI), hospitalisation for unstable angina, stroke, hospitalisation for heart failure, deep vein thrombosis (DVT) and pulmonary embolism (PE). These will be derived using PT terms listed in clinical events classification (CEC) Charter and adjudicated by Duke Clinical Research Institute (DCRI) CEC group. Adjudicated CV endpoints will be summarised. Adjudicated CV Events will also be reported as the following categories: <ul style="list-style-type: none"> ○ MACE: CV death, non-fatal MI, non-fatal stroke ○ Broad MACE: CV death, MI, hospitalisation for unstable angina, stroke, hospitalisation for heart failure, DVT and PE ○ Broad MACE excluding DVT and PE ○ VTE (DVT and/or PE) ○ DVT only ○ PE only
GI Perforation and Adjudicated GI perforation
<ul style="list-style-type: none"> • GI perforation Events GI perforation events as reported in the database will be included in the summary table for all AEs. • Adjudicated GI perforation This will be adjudicated by CEC. Data reported in EDC and the adjudicated GI Perforation will be used in the outputs.
Malignancy
<ul style="list-style-type: none"> • Malignancies will be reported as the following categories: <ul style="list-style-type: none"> ○ Solid, excluding non-melanoma skin cancer (NMSC) – derived from Non-haematological malignant tumours (SMQ) and Non-haematological tumours of unspecified malignancy (SMQ) and excluding NMSC terms identified below ○ NMSC – PTs derived from Skin neoplasms, malignant and unspecified (SMQ): <ul style="list-style-type: none"> ▪ Atypical fibroxanthoma ▪ Basal cell carcinoma ▪ Basosquamous carcinoma of skin ▪ Bowen's disease ▪ Carcinoma in situ of skin ▪ Keratoacanthoma ▪ Marjolin's ulcer ▪ Skin squamous cell carcinoma metastatic ▪ Skin squamous cell carcinoma recurrent ▪ Squamous cell carcinoma of skin ○ Hematologic – derived from Haematological malignant tumours (SMQ) and Haematological tumours of unspecified malignancy (SMQ) ○ Lymphoma – derived from Malignant Lymphomas (broad SMQ)
Herpes Infections
<ul style="list-style-type: none"> • Derived from HLT term "Herpes Viral Infections" excluding the following terms: Human herpesvirus 6 encephalitis, Human herpesvirus 6 infection, Human herpesvirus 7 infection, Human herpesvirus 8 infection, Exanthema subitum

Other Important AEs
<ul style="list-style-type: none"> They will be further categorised as Herpes Zoster, Herpes Simplex and Non-Specific using preferred terms from the most recent version of MedDRA at the time of reporting.
All Cause Mortality
<ul style="list-style-type: none"> Any SAE with a fatal outcome
Serious Pulmonary infections
<ul style="list-style-type: none"> Any SAE in HLGT "respiratory tract infections"
Serious Pulmonary infections excluding COVID-19 Infections
<ul style="list-style-type: none"> Any SAE in HLGT "respiratory tract infections" excluding the following PTs: Suspected COVID-19", "COVID-19", "COVID-19 pneumonia" or "Asymptomatic COVID-19".
Pneumonia (serious and non-serious)
<ul style="list-style-type: none"> Derived from Infective pneumonia (narrow SMQ)
Pneumonia (serious and non-serious) excluding COVID-19 Infections
<ul style="list-style-type: none"> Derived from Infective pneumonia (narrow SMQ) excluding the following PTs: Suspected COVID-19", "COVID-19", "COVID-19 pneumonia" or "Asymptomatic COVID-19".
Hepatitis B and Hepatitis B Reactivation
<ul style="list-style-type: none"> AEs and SAEs using PTs 'hepatitis B' and 'hepatitis B reactivation'
Thromboembolic events
<ul style="list-style-type: none"> AEs and SAEs using 'Embolic and thrombotic events (SMQ)
COVID-19 Infections and Adjudicated COVID-19 Infections
<ul style="list-style-type: none"> COVID-19 Infections COVID-19 infections will be derived from the following PTs: "Suspected COVID-19", "COVID-19", "COVID-19 pneumonia" or "Asymptomatic COVID-19". All events will be split into serious or non-serious based on how they are reported i.e. all COVID-19 SAEs will be categorised as serious and all COVID-19 AEs will be categorised as non-serious. Non-serious cases of COVID-19 will be split into confirmed, suspected or probable cases based on the eCRF and cases for each category will be displayed. The serious adverse events of COVID-19 will be adjudicated by PAC and only the adjudicated events summarised. Adjudicated COVID-19 Infections Each case that is adjudicated to confirmed case of COVID-19 or probable case of COVID-19 will also be assigned a grade based on World Health Organisation (WHO) original scale. All adjudicated confirmed cases of COVID-19 and all adjudicates probable cases of COVID-19 will be split into 3 categories (see the categorisation below) and cases for each category will be summarised: <ul style="list-style-type: none"> Non hospitalised includes the following WHO grades: grade 1-CCI [REDACTED] and grade 2-CCI [REDACTED]. Hospitalised includes the following WHO grades: grade 3-CCI [REDACTED]; grade 4-CCI [REDACTED]; grade 5-CCI [REDACTED]; grade 6-CCI [REDACTED] and grade 7-CCI [REDACTED]). Death
Laboratory Parameters
eGFR
<ul style="list-style-type: none"> This will be provided in the dataset by Q2

Laboratory Parameters
Laboratory Results
<p>If a laboratory value which is expected to have a numeric value for summary purposes, has a non-detectable level reported in the database, where the numeric value is missing, but typically a character value starting with '<x' or '>x' (or indicated as less than x or greater than x in the comment field) is present, the number of significant digits in the observed values will be used to determine how much to add or subtract in order to impute the corresponding numeric value.</p> <ul style="list-style-type: none">• Example 1: 2 Decimal Places= '< x ' becomes $x - 0.01$• Example 2: 1 Decimal Place= '> x' becomes $x + 0.1$• Example 3: 0 Decimal Places= '< x' becomes $x - 1$
Immunogenicity
<ul style="list-style-type: none">• Positive binding antibody assay results are to be categorised as transient positive or persistent positive accordingly to the following definitions:• For all post-baseline visits, other than final study assessment<ul style="list-style-type: none">○ Transient positive = a single positive immunogenic response at a visit, where the previous visit was negative○ Persistent positive = a positive immunogenic response at a visit, where the previous visit was also positive

14.7. Appendix 7: Reporting Standards for Missing Data

14.7.1. Premature Withdrawals

Element	Reporting Detail
General	<ul style="list-style-type: none"> • Participant study completion (i.e. as specified in the protocol) was defined as completion of all phases of the study including the follow up. • Withdrawn participants will not be replaced in the study. • All available data from participants who were withdrawn from the study will be listed and all available planned data will be included in summary tables and figures, unless otherwise specified. • Withdrawal visits will be slotted as per Appendix 3: Assessment Windows or will be summarised as withdrawal visits. • If a scheduled visit and an EW visit occur within the same visit window and are both available, the scheduled visit will be used for any summaries/analyses. The EW visit will appear in listing only. • For efficacy analyses, if an EW visit is assigned to a non-standard efficacy visit, i.e., a visit at which efficacy assessments are not scheduled per the Time and Events Table, then these EW data will be ignored in the statistical analysis, but all data will be listed.

14.7.2. Handling of Missing Data

Element	Reporting Detail
General	<ul style="list-style-type: none"> • Missing data occurs when any requested data is not provided, leading to blank fields on the collection instrument: <ul style="list-style-type: none"> ○ These data will be indicated by the use of a “blank” in subject listing displays. Unless all data for a specific visit are missing in which case the data is excluded from the table. ○ Answers such as “Not applicable” and “Not evaluable” are not considered to be missing data and should be displayed as such.
Outliers	<ul style="list-style-type: none"> • Any participants excluded from the summaries and/or statistical analyses will be documented along with the reason for exclusion in the clinical study report.
Adverse Events	<ul style="list-style-type: none"> • AEs with missing intensity will be considered as severe.

14.7.2.1. Handling of Missing and Partial Dates

Element	Reporting Detail
General	<ul style="list-style-type: none"> • Partial dates will be displayed as captured in subject listing displays.
Adverse Events	<ul style="list-style-type: none"> • Although every effort will be made to prevent and eliminate partial dates, the eCRF allows for the possibility of partial dates (i.e., only month and year) to be recorded for AE start and end dates; that is, the day of the month may be missing. In such a case, the following conventions will be applied for calculating the time to onset and the duration of the event: <ul style="list-style-type: none"> ○ <u>Missing Start Day</u>: First of the month will be used unless this is before the start date of study treatment; in this case the study treatment start date will be used and hence the event is considered On-treatment as per Appendix 4: Study Phases and Treatment Emergent Adverse Events. ○ <u>Missing Stop Day</u>: Last day of the month will be used, unless this is after the stop date of study treatment; in this case the study treatment stop date will be used. • Completely missing start or end dates will remain missing, with no imputation applied. Consequently, time to onset and duration of such events will be missing.
Concomitant Medications/ Medical History	<ul style="list-style-type: none"> • Partial dates for any concomitant medications recorded in the CRF will be imputed using the following convention: <ul style="list-style-type: none"> ○ If the partial date is a start date, a '01' will be used for the day and 'Jan' will be used for the month ○ If the partial date is a stop date, a '28/29/30/31' will be used for the day (dependent on the month and year) and 'Dec' will be used for the month. • The recorded partial date will be displayed in listings.
RA diagnosis and symptom onset	<ul style="list-style-type: none"> • Missing day, but month and year present: <ul style="list-style-type: none"> ○ Date is set to the first day of the month (e.g., XX-Sep-2010 is considered as 01-Sep-2010). • Missing day and month, but year present: <ul style="list-style-type: none"> ○ Date is set to 01 January (e.g., XX-XXX-2010 is considered as 01-Jan-2010)

14.7.2.2. Handling of Missing Efficacy Data

Unless otherwise stated, apply the missing data imputation strategies detailed in [Section 7.1.1.6](#) and [Section 7.2.1.6](#).

14.8. Appendix 8: Laboratory Parameters of Interest

14.8.1. Laboratory Value Gradings

Laboratory value gradings will be derived using the most recent version of CTCAE at the time of reporting.

14.8.2. Laboratory Values of Potential Clinical Importance

Hematology				
Laboratory Parameter	Units	Category	Clinical Concern Range	
			Low Flag (< x)	High Flag (>x)
Hematocrit	Ratio of 1	Male	0.2	0.6
		Female	0.2	0.6
		Change from baseline	↓0.075	
Hemoglobin	g/L	Male	80	180
		Female	80	180
		Change from baseline	↓20	
Lymphocytes	x10 ⁹ /L		0.75	
Neutrophil Count	x10 ⁹ /L		1.0	16
Platelet Count	x10 ⁹ /L		100	550
White Blood Cell Count (WBC)	x10 ⁹ /L		2.0	20
Eosinophils	x10 ⁹ /L			1

Clinical Chemistry				
Laboratory Parameter	Units	Category	Clinical Concern Range	
			Low Flag (< x)	High Flag (>x)
Albumin	g/L		30	55
Calcium	mmol/L		2	2.75
Creatinine	μmol/L			150
	μmol/L	Change from baseline		↑ 44.2
Glucose	mmol/L		3	11
Potassium	mmol/L		3	5.5
Sodium	mmol/L		130	160

Clinical Chemistry				
Laboratory Parameter	Units	Category	Clinical Concern Range	
			Low Flag (< x)	High Flag (>x)
GFR from Creatinine Adjusted for BSA	mL/min/1.73 m ²		60	
Cholesterol	mmol/L			6.5
Triglycerides	mmol/L			2.3
Urea	mmol/L			10.5

Liver Function			
Test Analyte	Units	Category	Clinical Concern Range
ALT/SGPT	U/L	High	≥ 2x ULN
AST/SGOT	U/L	High	≥ 2x ULN
AlkPhos	U/L	High	≥ 2x ULN
T Bilirubin	µmol/L	High	≥ 1.5xULN
Creatinine Kinase	U/L	High	≥ 2x ULN
Gamma Glutamyl Transferase	U/L	High	≥ 2x ULN
Lactate Dehydrogenase	U/L	High	≥ 2x ULN

Urinalysis	
Test Analyte	Clinical Concern Range
Bacteria	Moderate Many
Squamous Epithelial Cells	Moderate (6-20) Many (21 or greater)
Glucose	1+ OR 1/4 G/DL (%) 2+ OR 1/4 G/DL (%) 3+ OR 1/4 G/DL (%)
Protein	1+ 2+ 3+
Erythrocytes	10-15 12-25 25-50 50-100 >100
Leukocytes	10-15 12-25 25-50 50-100 >100

Urinalysis	
Test Analyte	Clinical Concern Range
Yeast Cells	Moderate Many

For the listing of Laboratory Data for Subjects with any value of Potential Clinical Important, only include the following laboratory data:

- Alanine Aminotransferase
- Albumin
- Albumin/Globulin
- Alkaline Phosphate
- Aspartate Aminotransferase
- Basophils
- Bilirubin
- C Reactive Protein
- Calcium
- Cholesterol
- Creatinine Kinase
- Creatinine
- Cyclic Citrullinated Peptide Antibody
- Direct Bilirubin
- Eosinophils
- Erythrocyte Sedimentation Rate
- Erythrocytes
- GFR from Creatinine Adjusted for BSA
- Gamma Glutamyl Transferase
- Glucose
- HDL Cholesterol, Direct
- Hematocrit
- Hemoglobin
- Hepatitis B Core Antibody Total, Qual
- Hepatitis B Virus DNA
- Hepatitis B Virus DNA, copies
- Hepatitis B Virus DNA, log
- Hepatitis B Virus Surface Antibody, Qual
- Hepatitis B Virus Surface Antigen, Qual
- Hepatitis C Antibody, Qual
- Hepatitis C Virus RNA
- Hepatitis C Virus RNA, log
- Interferon Gamma, Qualitative
- LDL Cholesterol
- Lactate Dehydrogenase
- Leukocytes
- Lymphocytes

- Monocytes
- Neutrophils
- Platelets
- Potassium
- Protein
- Prothrombin Intl. Normalized Ratio
- Reticulocytes/Erythrocytes
- Rheumatoid Factor
- Theophylline
- Triglycerides
- Urea

14.8.3. ECG Values of Potential Clinical Importance

ECG Parameter	Units	Clinical Concern Range	
		Lower	Upper
Absolute			
Absolute QTc Interval	msec		>450
Absolute PR Interval	msec	< 110	> 220
Absolute QRS Interval	msec	< 75	> 110
Change from Baseline			
Increase from Baseline QTc	msec		>30↑

14.8.4. Vital Signs Values of Potential Clinical Importance

Vital Sign Parameter	Units	Clinical Concern Range	
		Lower	Upper
Absolute			
Systolic Blood Pressure	mmHg	< 85	> 160
Diastolic Blood Pressure	mmHg	< 45	> 100
Heart Rate	bpm	< 40	> 110
Change from Baseline			
Systolic Blood Pressure	mmHg	≥ 20↓	≥ 20↑
Diastolic Blood Pressure	mmHg	≥ 10↓	≥ 10↑
Heart Rate	bpm	≥ 15↓	≥ 15↑

14.9. Appendix 9: List of Preferred Terms

14.9.1. Herpes Zoster

Adjudication by GSK SRT will identify events that are recurrent or disseminated. Herpes Zoster is considered disseminated if there is involvement of other organs other than the skin or if skin lesions (1) cross the midline of the body or (2) are in non-adjacent dermatomes or (3) are located in more than three adjacent dermatomes. Herpes zoster is considered an opportunistic infection (OI) if it is adjudicated as recurrent or disseminated. However, there may be some uncommon occurrences of a herpes zoster case that is adjudicated as an OI but is neither recurrent nor disseminated.

14.9.2. Mycobacterium Tuberculosis

Tuberculosis (TB) cases are reviewed by the GSK SRT to determine if a case is an OI. The following principles are applied: Pulmonary TB in an endemic area is not considered an OI. Pulmonary TB in a non-endemic area would be considered an OI unless the participant had close contact with a person infected with TB. Extra pulmonary TB is generally considered an OI unless the affected extra pulmonary area followed a wound or trauma.

14.10. Appendix 10: Missing Data Imputation Strategies

14.10.1. Primary Estimand Strategy

14.10.1.1. Multiple Imputation using off-treatment data within treatment arm

1. Exclude week 1 data and participants with missing baseline values.
2. Generate 1000 multiply imputed datasets using a monotone logistic imputation with augmentation (binary endpoints) or monotone regression imputation (continuous endpoints) including terms for baseline value, all previous visit values, treatment group, treatment discontinuation and treatment group-by-treatment discontinuation interaction, i.e. a model of the form

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}TD_i + \alpha_{4i}trt + \alpha_{5i}(trt * TD_i) + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$
 where y_i is the result at visit i and TD_i is the treatment discontinuation indicator at visit i .
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3.

14.10.1.2. Multiple Imputation using off-treatment data across all treatment arms

1. Exclude week 1 data and participants with missing baseline values.
2. Generate 1000 multiply imputed datasets using a monotone logistic imputation with augmentation (binary endpoints) or monotone regression imputation (continuous endpoints) including terms for baseline value, all previous visit values, treatment group and treatment discontinuation, i.e. a model of the form

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}TD_i + \alpha_{4i}trt + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$
 where y_i is the result at visit i and TD_i is the treatment discontinuation indicator at visit i .
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3.

14.10.1.3. Multiple imputation under MAR assumption

1. Exclude week 1 data and participants with missing baseline values.
2. Generate For each of the 1000 multiply imputed datasets using a monotone logistic imputation with augmentation (binary endpoints) or monotone regression imputation (continuous endpoints) including terms for baseline value, all previous visit values and treatment group, to impute any missing data post study withdrawal, i.e. a model of the form

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}trt + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$
 where y_i is the result at visit i .
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3.

14.10.2. Supplemental Estimand 1 Strategy

1. Impute all data for each visit following the intercurrent event for categorical variables to be non-response.
2. Exclude week 1 data and participants with missing baseline values.
3. In order to impute intermittent missing data, generate 1000 multiply imputed datasets using a monotone logistic imputation with augmentation (binary endpoints) or monotone regression imputation (continuous endpoints) including terms for baseline value, all previous visit values and treatment group, i.e. a model of the form

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}trt + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$

where y_i is the result at visit i .

4. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3.

14.10.3. Supplemental Estimand 2 Strategy

1. Set all data for each visit following the intercurrent event to missing.
2. Exclude week 1 data and participants with missing baseline values.
3. Generate 1000 multiply imputed datasets, using a monotone logistic imputation with augmentation (binary endpoints) or monotone regression imputation (continuous endpoints) including terms for baseline value, all previous visit values, and treatment group, i.e. a model of the form

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}trt + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$

where y_i is the result at visit i .

4. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3.

14.10.4. Intermittent Missing Data Multiple Imputation

Under the primary estimand strategy detailed in Section 14.10.1, in the absence of a treatment discontinuation flag at a particular visit, the models will all reduce to a model of the form:

$$y_i = \alpha_{1i} + \alpha_{2i}base + \alpha_{3i}trt + \beta_{i-1}y_{i-1} + \dots + \beta_1y_1$$

where y_i is the result at visit i , which will satisfy an MAR assumption for intermittent missing data.

Under the supplemental estimand 1 strategy detailed in Section 14.10.2, intermittent missing data will be imputed separately under an MAR assumption.

Under the supplemental estimand 2 strategy detailed in Section 14.10.3, all data, including intermittent missing data, is imputed under an MAR assumption.

14.11. Appendix 11: Abbreviations and Trademarks

14.11.1. Abbreviations

Abbreviation	Description
AAC	All Analysis Complete
ACR	American College of Rheumatology
ADA	Anti-Drug Antibodies
ADaM	Analysis Data Model
AE	Adverse Event
AESI	Adverse Event of Special Interest
ANCOVA	Analysis of Covariance
bDMARD	Biologic Disease-Modifying Anti-Rheumatic Drug
BMI	Body Mass Index
boDMARD	Biological Originator Disease-Modifying Antirheumatic Drug
bsDMARD	Biosimilar Disease-Modifying Antirheumatic Drug
CDAI	Clinical Disease Activity Index
CDISC	Clinical Data Interchange Standards Consortium
CI	Confidence Interval
CIRT	Cenduit Interactive Response Technology
CRP	C-Reactive Protein
csDMARD	Conventional Synthetic Disease Modifying Antirheumatic Drug
CSR	Clinical Study Report
CTCAE	Common Terminology Criteria for Adverse Events
CV	Cardiovascular
CV _b / CV _w	Coefficient of Variation (Between) / Coefficient of Variation (Within)
DAS	Disease Activity Score
DBF	Database Freeze
DBR	Database Release
DMARD	Disease-Modifying Antirheumatic Drug
DOB	Date of Birth
DP	Decimal Places
eCRF	Electronic Case Record Form
EMA	European Medicines Agency
ESR	Erythrocyte Sedimentation Rate
EULAR	European League Against Rheumatism
EW	Early Withdrawal
FACIT	Functional Assessment of Chronic Illness Therapy - Fatigue
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Clinical Results Disclosure Requirements
GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
GSK	GlaxoSmithKline
HAQ-DI	Health Assessment Questionnaire Disability Index
HDL	Headline Results
ICH	International Conference on Harmonization
IDMC	Independent Data Monitoring Committee

Abbreviation	Description
IDSL	Integrated Data Standards Library
IE	Intercurrent Event
IP	Investigational Product
ITT	Intent-To-Treat
IWRS	Interactive Web Response System
JAKi	Janus Kinase Inhibitor
LDA	Low Disease Activity
LLOQ	Lower Limit of Quantification
LS	Least Squares
MACE	Major Adverse Cardiovascular Event
MAR	Missing at Random
MCID	Minimum Clinically Important Different
MCMC	Markov Chain Monte Carlo
MCS	Mental Component Score
MedDRA	Medical Dictionary for Regulatory Activities
MI	Multiple Imputation
MMRM	Mixed Model Repeated Measures
MTX	Methotrexate
NQ	Non-quantifiable
NRS	Numerical Rating Scale
OR	Odds Ratio
PAP	Pulmonary Alveolar Proteinosis
PCI	Potential Clinical Importance
PCS	Physical Component Score
PD	Pharmacodynamic
PDMP	Protocol Deviation Management Plan
PhGA	Physician's Global Assessment of Arthritis Disease Activity
PK	Pharmacokinetic
PP	Per Protocol
PopPK	Population PK
PRO	Patient Reported Outcome
CCI	
PI	Preferred Term
PtGA	Patient's Global Assessment of Arthritis Disease Activity
QC	Quality Control
QTcF	Frederica's QT Interval Corrected for Heart Rate
QTcB	Bazett's QT Interval Corrected for Heart Rate
QW	Every Week
Q2W	Every 2 Weeks
RA	Rheumatoid Arthritis
RAP	Reporting & Analysis Plan
CCI	
RF	Rheumatoid Factor
SAC	Statistical Analysis Complete
SAE	Serious Adverse Events

Abbreviation	Description
SC	Subcutaneous
SDTM	Study Data Tabulation Model
SF-36	36-Item Short Form Survey
SJC	Swollen Joint Count
SMQ	Standardised MedDRA Query
SOC	System Organ Class
SOP	Standard Operation Procedure
SRT	Safety Review Team
TA	Therapeutic Area
TB	Mycobacterium Tuberculosis
TEAE	Treatment Emergent Adverse Event
TFL	Tables, Figures & Listings
TJC	Tender Joint Count
tsDMARD	Targeted Synthetic Disease Modifying Antirheumatic Drug
VAS	Visual Analog Scale
WOCBP	Woman of Childbearing Potential
WPMI	Within Patient Meaningful Improvement
4B-OHC	4β-hydroxycholesterol

14.11.2. Trademarks

Trademarks of the GlaxoSmithKline Group of Companies
N/A

Trademarks not owned by the GlaxoSmithKline Group of Companies
PainDETECT
PROMIS
SAS
SF-36

14.12. Appendix 12: List of Data Displays

All data displays will use the term “subject” rather than “participant” in accordance with CDSIC and GSK Statistical Display Standards.

14.12.1. Data Display Numbering

The following numbering will be applied for RAP generated displays:

Section	Tables	Figures
Study Population	1.1 to 1.30	1.1 to 1.2
Japan Study Population	1.301 to 1.307	-
Efficacy	2.1 to 2.88	2.1 to 2.68
Japan Efficacy	2.301 to 2.308	-
Safety	3.1 to 3.137	3.1 to 3.7
Japan Safety	3.301 to 3.336	-
Pharmacokinetic	4.1	-
Japan Pharmacokinetic	4.301 to 4.302	-
Pharmacodynamic and / or Biomarker	5.1 to 5.10	5.1 to 5.4
Section	Listings	
ICH Listings	1 to 14	
Other Listings	15 to 45	

14.12.2. Mock Example Shell Referencing

Non IDSL specifications will be referenced as indicated and if required example mock-up displays provided in the final version of this document.

14.12.3. Deliverables

Delivery [Priority] ^[1]	Description
HDL[1]	Headline Results Complete
SAC[2]	Statistical Analysis Complete
AAC[3]	All Analysis Complete

NOTES:

1. Indicates priority (i.e. order) in which displays will be generated for the reporting effort

Study Population Tables

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Subject Disposition					
1.1.	Randomised	Non-Standard POP_T1 (Based on ES1)	Summary of Subject Disposition for the Subject Conclusion Record	ICH E3, FDAAA, EudraCT Include Total Column	SAC[2]
1.2.	Randomised	Non-Standard POP_T1 (Based on ES1)	Summary of Subject Status and Subject Disposition for Withdrawals due to COVID-19 Pandemic	Only include: <ul style="list-style-type: none"> Related to COVID-19 Pandemic This information should be gathered from COVID-19 impact form in eCRF. Include Total Column	SAC[2]
1.3.	Randomised	Non-Standard POP_T2 (Based on SD1)	Summary of Treatment Status and Reasons for Discontinuation of Study Treatment	ICH E3 Include Total Column	SAC[2]
1.4.	Randomised	Non-Standard POP_T2 (Based on SD1)	Summary of Treatment Status and Reasons for Discontinuation of Study Treatment due to COVID-19 Pandemic	Only include: <ul style="list-style-type: none"> Related to COVID-19 Pandemic This information should be gathered from COVID-19 impact form in eCRF. Include Total Column	SAC[2]

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
1.5.	Screened	ES6	Summary of Screening Status and Reasons for Screen Failure	Journal Requirements	SAC[2]
1.6.	Enrolled	NS1	Summary of Number of Subjects by Country and Site ID by Implementation of Pandemic Measures	EudraCT/Clinical Operations Summarise by: <ul style="list-style-type: none"> • Overall • Before Implementation of Pandemic Measures • After Implementation of Pandemic Measures 	SAC[2]
Protocol Deviation					
1.7.	ITT	DV1	Summary of Important Protocol Deviations	ICH E3 Only categories are to be reported in the table.	SAC[2]
1.8.	ITT	DV1	Summary of Important Protocol Deviations Related to the COVID-19 Pandemic	Only include: <ul style="list-style-type: none"> • Important related to COVID-19 Pandemic Only categories are to be reported in the table.	SAC[2]
Population Analysed					
1.9.	Screened	SP1	Summary of Study Populations	IDSL	SAC[2]

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
1.10.	Enrolled	SP2	Summary of Protocol Deviations Leading to Exclusion from the Per Protocol Population(s)	IDSL Include total column. Only categories are to be reported in the table.	SAC[2]
Demographic and Baseline Characteristics					
1.11.	ITT	DM1	Summary of Demographic Characteristics	ICH E3, FDAAA, EudraCT Add BMI to the output.	HDL[1]
1.12.	Enrolled	DM11	Summary of Age Ranges	EudraCT	SAC[2]
1.13.	ITT	DM6	Summary of Race and Racial Combinations	ICH E3, FDA, FDAAA, EudraCT	SAC[2]
1.14.	ITT	Non-Standard POP_T3	Summary of Baseline Efficacy Parameters	Include all efficacy endpoints	HDL[1]
1.15.	ITT	Non-Standard POP_T4	Summary of Rheumatoid Arthritis Disease History		HDL[1]
1.16.	ITT	Non-Standard POP_T5	Summary of History of Tobacco Use and Family History of Cardiovascular Risk Factors	Display by Overall, Age <50 and Age>=50	SAC[2]
Prior and Concomitant Medications					
1.17.	ITT	AE1	Summary of Medical Conditions	ICH E3 Include Preferred Terms.	SAC[2]

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
1.18.	ITT	Non-Standard POP_T6	Summary of RA Concomitant Medications	Include Total Column.	SAC[2]
1.19.	ITT	CM1	Summary of All Concomitant Medications	ICH E3 Include Total Column.	SAC[2]
1.20.	ITT	Non-Standard POP_T7	Summary of RA Prior Medications	Include Total Column.	SAC[2]
1.21.	ITT	CM1	Summary of All Prior Medications	Include Total Column.	SAC[2]
1.22.	ITT	Non-Standard POP_T8	Summary of RA Medications taken at Baseline (Day 1)	Include Total Column.	SAC[2]
1.23.	ITT	Non-Standard POP_T9	Summary of Concomitant COVID-19 Vaccines	Include Total Column.	SAC[2]
Exposure and Treatment Compliance					
1.24.	Safety	Non-Standard POP_T10	Summary of Exposure to Study Treatment	ICH E3 Include Total Column.	SAC[2]
1.25.	Safety	Non-Standard POP_T11	Summary of Overall Compliance Based on Exposure	Include Total Column.	SAC[2]

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
COVID-19					
1.26.	ITT	PAN4	Summary of COVID-19 Visit Impacts		SAC[2]
1.27.	ITT	DM1	Summary of Demographic Characteristics by Pre and Post Pandemic Measures	Summarise by: <ul style="list-style-type: none"> • Before Implementation of Pandemic Measures • After Implementation of Pandemic Measures 	SAC[2]
CCI					
Tables for Disclosure					
1.29.	Randomised	Non-Standard POP_T1	Summary of Subject Disposition for the Subject Conclusion Record (by Randomised Treatment Arm)	Display by randomised treatment arm (i.e. all 6 treatment arms)	AAC[3]
1.30.	ITT	DM1	Summary of Demographic Characteristics (by Randomised Treatment Arm)	Display by randomised treatment arm (i.e. all 6 treatment arms)	AAC[3]
Japan Subgroup					
1.301	Japanese Randomised	Non-Standard POP_T1 (Based on ES1)	Summary of Subject Disposition for the Subject Conclusion Record for Japanese Subjects	Include Total Column.	AAC[3]

Study Population Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
1.302	Japanese ITT	DM1	Summary of Demographic Characteristics for Japanese Subjects		AAC[3]
1.303	Japanese ITT	Non-Standard POP_T3	Summary of Baseline Efficacy Parameters for Japanese Subjects	Include Total Column.	AAC[3]
1.304	Japanese ITT	Non-Standard POP_T4	Summary of Rheumatoid Arthritis Disease History for Japanese Subjects	Include Total Column.	AAC[3]
1.305	Japanese ITT	Non-Standard POP_T8	Summary of RA Medications taken at Baseline (Day 1) for Japanese Subjects	Include Total Column.	AAC[3]
1.306	Japanese Safety	Non-Standard POP_T10	Summary of Exposure to Study Treatment for Japanese Subjects	Include Total Column.	AAC[3]
1.307	Japanese Safety	Non-Standard POP_T11	Summary of Overall Compliance Based on Exposure for Japanese Subjects	Include Total Column.	AAC[3]

Study Population Figures

Study Population Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Subject Disposition					
1.1.	Randomised	PAN6	Plot of Recruitment over time by Country Relative to COVID-19 Pandemic Measures		SAC[2]
COVID-19					
1.2.	ITT	PAN8	Plot of Visits Impacted by COVID-19 Pandemic		SAC[2]

Efficacy Tables

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
ACR20					
2.1.	ITT	Non-Standard EFF_T1	Summary and Analysis of ACR20 Response at Each Assessment Visit (Primary Estimand)		HDL[1]
2.2.	ITT	Non-Standard EFF_T1	Summary and Analysis of ACR20 Response at Each Assessment Visit (Supplemental Estimand 1)		SAC[2]
2.3.	ITT	Non-Standard EFF_T1	Summary and Analysis of ACR20 Response at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]
2.4.	ITT	Non-Standard EFF_T2	Summary of Observed ACR20 Response at Each Assessment Visit		SAC[2]
HAQ-DI					
2.5.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in HAQ-DI Score at Each Assessment Visit (Primary Estimand)		HDL[1]
2.6.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in HAQ-DI Score and in Functional Areas of the HAQ-DI Score at Each Assessment Visit		SAC[2]
CDAI Total Score					
2.7.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in CDAI Total score at Each Assessment Visit (Primary Estimand)		HDL[1]
2.8.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in CDAI Total score at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.9.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in CDAI Total Score at Each Assessment Visit		SAC[2]
CCI					
Arthritis Pain VAS					
2.12.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Arthritis Pain VAS Score at Each Assessment Visit (Primary Estimand)		HDL[1]
2.13.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Arthritis Pain VAS Score at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]
2.14.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Arthritis Pain VAS Score at Each Assessment Visit		SAC[2]
CDAI-LDA					
2.15.	ITT	Non-Standard EFF_T1	Summary and Analysis of CDAI-LDA Response (CDAI≤10) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.16.	ITT	Non-Standard EFF_T2	Summary of Observed CDAI-LDA Response (CDAI≤10) at Each Assessment Visit		SAC[2]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
ACR50/70					
2.17.	ITT	Non-Standard EFF_T1	Summary and Analysis of ACR50 Response at Each Assessment Visit (Primary Estimand)		SAC[2]
2.18.	ITT	Non-Standard EFF_T1	Summary and Analysis of ACR70 Response at Each Assessment Visit (Primary Estimand)		SAC[2]
2.19.	ITT	Non-Standard EFF_T2	Summary of Observed ACR50/70 Response at Each Assessment Visit	Page by ACR50 and ACR70	SAC[2]
CDAI Remission					
2.20.	ITT	Non-Standard EFF_T1	Summary and Analysis of CDAI Remission Response (CDAI \leq 2.8) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.21.	ITT	Non-Standard EFF_T2	Summary of Observed CDAI Remission (CDAI \leq 2.8) at Each Assessment Visit		SAC[2]
DAS28-CRP LDA					
2.22.	ITT	Non-Standard EFF_T1	Summary and Analysis of DAS28-CRP LDA Response (DAS28-CRP \leq 3.2) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.23.	ITT	Non-Standard EFF_T2	Summary of Observed DAS28-CRP LDA Response (DAS28-CRP \leq 3.2) at Each Assessment Visit		SAC[2]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
DAS28-CRP Remission					
2.24.	ITT	Non-Standard EFF_T1	Summary and Analysis of DAS28-CRP Remission Response (DAS28-CRP<2.6) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.25.	ITT	Non-Standard EFF_T2	Summary of Observed DAS28-CRP Remission Response (DAS28-CRP<2.6) at Each Assessment Visit		SAC[2]
DAS28-ESR LDA					
2.26.	ITT	Non-Standard EFF_T1	Summary and Analysis of DAS28-ESR LDA Response (DAS28-ESR≤3.2) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.27.	ITT	Non-Standard EFF_T2	Summary of Observed DAS28-ESR LDA Response (DAS28-ESR≤3.2) at Each Assessment Visit		SAC[2]
DAS28-ESR Remission					
2.28.	ITT	Non-Standard EFF_T1	Summary and Analysis of DAS28-ESR Remission Response (DAS28-ESR<2.6) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.29.	ITT	Non-Standard EFF_T2	Summary of Observed DAS28-ESR Remission Response (DAS28-ESR<2.6) at Each Assessment Visit		SAC[2]
Good/Moderate EULAR Response					
2.30.	ITT	Non-Standard EFF_T1	Summary and Analysis of Good/Moderate EULAR Response (based on DAS28-CRP) at Each Assessment Visit (Primary Estimand)		SAC[2]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.31.	ITT	Non-Standard EFF_T2	Summary of Observed Good/Moderate EULAR Response (based on DAS28-CRP) at Each Assessment Visit		SAC[2]
ACR/EULAR Remission Boolean-based and Index-based					
2.32.	ITT	Non-Standard EFF_T2	Summary of Observed Index-based ACR/EULAR Remission Response at Each Assessment Visit		SAC[2]
2.33.	ITT	Non-Standard EFF_T2	Summary of Observed Boolean-based ACR/EULAR Remission Response at Each Assessment Visit		SAC[2]
Tender Joint Counts					
2.34.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in TJC28 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.35.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in TJC68 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.36.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in TJC28 and TJC68 at Each Assessment Visit		SAC[2]
Swollen Joint Counts					
2.37.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in SJC28 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.38.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in SJC66 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.39.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in SJC28 and SJC66 at Each Assessment Visit		SAC[2]


Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
CRP/ESR					
2.40.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in CRP (mg/L) at Each Assessment Visit (Primary Estimand)		SAC[2]
2.41.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in CRP (mg/L) and ESR (mm/h) at Each Assessment Visit		SAC[2]
2.42.	ITT	Non-Standard EFF_T5	Summary of Ratio to Baseline in CRP (mg/L) and ESR (mm/h) at Each Assessment Visit (Log Transformed)		SAC[2]
Patient's Global Assessment					
2.43.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Patient's Global Assessment of Arthritis at Each Assessment Visit (Primary Estimand)		SAC[2]
2.44.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Patient's Global Assessment of Arthritis at Each Assessment Visit		SAC[2]
Physician's Global Assessment					
2.45.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Physician's Global Assessment of Arthritis at Each Assessment Visit (Primary Estimand)		SAC[2]
2.46.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Physician's Global Assessment of Arthritis at Each Assessment Visit		SAC[2]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
DAS28-CRP					
2.47.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in DAS28-CRP at Each Assessment Visit (Primary Estimand)		SAC[2]
2.48.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in DAS28-CRP at Each Assessment Visit		SAC[2]
DAS28-ESR					
2.49.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in DAS28-ESR at Each Assessment Visit (Primary Estimand)		SAC[2]
2.50.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in DAS28-ESR at Each Assessment Visit		SAC[2]
SF-36 (Physical, Mental and Individual Components)					
2.51.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Physical Score of SF-36 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.52.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Physical Score of SF-36 at Each Assessment Visit		SAC[2]
2.53.	ITT	Non-Standard EFF_T3	Analysis of Change from Baseline in Mental Score of SF-36 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.54.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Mental Score of SF-36 at Each Assessment Visit		SAC[2]
2.55.	ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Domain Scores of SF-36 at Each Assessment Visit		SAC[2]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]



Efficacy: Tables						
No.	Population	IDSL / Example Shell	Title		Programming Notes	Deliverable [Priority]




CCI

Efficacy: Tables						
No.	Population	IDSL / Example Shell	Title		Programming Notes	Deliverable [Priority]



Efficacy: Tables						
No.	Population	IDSL / Example Shell	Title		Programming Notes	Deliverable [Priority]



Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
CCI					
Sensitivity Analyses					
2.88.	Per Protocol	Non-Standard EFF_T1	Summary and Analysis of ACR20 Response at Each Assessment Visit (Primary Estimand) (Per Protocol Population)		AAC[3]
Japan Subgroup					
2.301	Japanese ITT	Non-Standard EFF_T2	Summary of Observed ACR20 Response at Each Assessment Visit for Japanese Subjects	Display raw proportions	AAC[3]
2.302	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in HAQ-DI Score and in Functional Areas of the HAQ-DI Score at Each Assessment Visit for Japanese Subjects		AAC[3]
2.303	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in CDAI Total Score at Each Assessment Visit for Japanese Subjects		AAC[3]

Efficacy: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.304	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in FACIT-Fatigue at Each Assessment Visit for Japanese Subjects		AAC[3]
2.305	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in Arthritis Pain VAS Score at Each Assessment Visit for Japanese Subjects		AAC[3]
2.306	Japanese ITT	Non-Standard EFF_T2	Summary of Observed ACR50/70 Response at Each Assessment Visit for Japanese Subjects		AAC[3]
2.307	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in DAS28-CRP at Each Assessment Visit for Japanese Subjects		AAC[3]
2.308	Japanese ITT	Non-Standard EFF_T4	Summary of Observed Change from Baseline in DAS28-ESR at Each Assessment Visit for Japanese Subjects		AAC[3]

Efficacy Figures

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
ACR20					
2.1.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR20 Response at Each Assessment Visit (Primary Estimand)		HDL[1]
2.2.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR20 Response at Each Assessment Visit (Supplemental Estimand 1)		SAC[2]
2.3.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR20 Response at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]
HAQ-DI					
2.4.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in HAQ-DI Score at Each Assessment Visit (Primary Estimand)		HDL[1]
CDAI Total Score					
2.5.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in CDAI Total Score at Each Assessment Visit (Primary Estimand)		HDL[1]
2.6.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in CDAI Total Score at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
CCI					
Arthritis Pain VAS					
2.8.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Arthritis Pain VAS at Each Assessment Visit (Primary Estimand)		HDL[1]
2.9.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Arthritis Pain VAS at Each Assessment Visit (Supplemental Estimand 2)		AAC[3]
CDAI-LDA					
2.10.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving CDAI-LDA (CDAI≤10) at Each Assessment Visit (Primary Estimand)		SAC[2]
ACR50/70					
2.11.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR50 Response at Each Assessment Visit (Primary Estimand)		SAC[2]
2.12.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR70 Response at Each Assessment Visit (Primary Estimand)		SAC[2]
CDAI Remission					
2.13.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving CDAI Remission (CDAI≤2.8) at Each Assessment Visit (Primary Estimand)		SAC[2]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
DAS28-CRP LDA					
2.14.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving DAS28-CRP LDA (DAS28-CRP \leq 3.2) at Each Assessment Visit (Primary Estimand)		SAC[2]
DAS28-CRP Remission					
2.15.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving DAS28-CRP Remission (DAS28-CRP $<$ 2.6) at Each Assessment Visit (Primary Estimand)		SAC[2]
DAS28-ESR LDA					
2.16.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving DAS28-ESR LDA (DAS28-ESR \leq 3.2) at Each Assessment Visit (Primary Estimand)		SAC[2]
DAS28-ESR Remission					
2.17.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving DAS28-ESR Remission (DAS28-ESR $<$ 2.6) at Each Assessment Visit (Primary Estimand)		SAC[2]
Good/Moderate EULAR Response					
2.18.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving Good/Moderate EULAR Response (based on DAS28-CRP) at Each Assessment Visit (Primary Estimand)		SAC[2]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Tender Joint Counts					
2.19.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in TJC28 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.20.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in TJC68 at Each Assessment Visit (Primary Estimand)		SAC[2]
Swollen Joint Counts					
2.21.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in SJC28 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.22.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in SJC66 at Each Assessment Visit (Primary Estimand)		SAC[2]
CRP					
2.23.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in CRP (mg/L) at Each Assessment Visit (Primary Estimand)		SAC[2]
Patient's Global Assessment					
2.24.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Patient's Global Assessment at Each Assessment Visit (Primary Estimand)		SAC[2]
Physician's Global Assessment					
2.25.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Physician's Global Assessment at Each Assessment Visit (Primary Estimand)		SAC[2]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
DAS28-CRP					
2.26.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in DAS28-CRP at Each Assessment Visit (Primary Estimand)		SAC[2]
DAS28-ESR					
2.27.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in DAS28-ESR at Each Assessment Visit (Primary Estimand)		SAC[2]
SF-36 (Physical, Mental and Individual Components)					
2.28.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Physical Score of SF-36 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.29.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means Change from Baseline in Mental Score of SF-36 at Each Assessment Visit (Primary Estimand)		SAC[2]
2.30.	ITT	Non-Standard EFF_F3	Spydergram of Individual Domain Scores of SF-36 at Each Assessment Visit		SAC[2]
Subgroup: ACR20					
2.31.	ITT	Non-Standard EFF_F4	Forest Plot of Demographic Subgroup Results for ACR20 – Comparison to Placebo at Week 12		SAC[2]
2.32.	ITT	Non-Standard EFF_F4	Forest Plot of Demographic Subgroup Results for ACR20 – Comparison to Sarilumab at Week 24		SAC[2]


Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.33.	ITT	Non-Standard EFF_F4	Forest Plot of Disease Characteristic Subgroup Results for ACR20 – Comparison to Placebo at Week 12		SAC[2]
2.34.	ITT	Non-Standard EFF_F4	Forest Plot of Disease Characteristic Subgroup Results for ACR20 – Comparison to Sarilumab at Week 24		SAC[2]
Subgroup: HAQ-DI					
2.35.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for HAQ-DI – Comparison to Placebo at Week 12		SAC[2]
2.36.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for HAQ-DI – Comparison to Sarilumab at Week 24		SAC[2]
2.37.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for HAQ-DI – Comparison to Placebo at Week 12		SAC[2]
2.38.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for HAQ-DI – Comparison to Sarilumab at Week 24		SAC[2]
Subgroup: CDAI Total					
2.39.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for CDAI Total Score – Comparison to Placebo at Week 12		SAC[2]
2.40.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for CDAI Total Score – Comparison to Sarilumab at Week 24		SAC[2]
2.41.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for CDAI Total Score – Comparison to Placebo at Week 12		SAC[2]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.42.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for CDAI Total Score – Comparison to Sarilumab at Week 24		SAC[2]
Subgroup: Arthritis Pain VAS					
2.43.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for Arthritis Pain VAS – Comparison to Placebo at Week 12		SAC[2]
2.44.	ITT	Non-Standard EFF_F5	Forest Plot of Demographic Subgroup Results for Arthritis Pain VAS – Comparison to Sarilumab at Week 24		SAC[2]
2.45.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for Arthritis Pain VAS – Comparison to Placebo at Week 12		SAC[2]
2.46.	ITT	Non-Standard EFF_F5	Forest Plot of Disease Characteristic Subgroup Results for Arthritis Pain VAS – Comparison to Sarilumab at Week 24		SAC[2]
Additional Figures Splitting out Pooled Placebo Post Week 12					
2.47.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR20 Response at Each Assessment Visit (Primary Estimand) Splitting out Pooled Placebo Post Week 12	Display pooled placebo arm split out after week 12	AAC[3]
2.48.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in HAQ-DI Score at Each Assessment Visit (Primary Estimand) Splitting out Pooled Placebo Post Week 12	Display pooled placebo arm split out after week 12	AAC[3]

Efficacy: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
2.49.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in CDAI Total Score at Each Assessment Visit (Primary Estimand) Splitting out Pooled Placebo Post Week 12	Display pooled placebo arm split out after week 12	AAC[3]
2.50.	ITT	Non-Standard EFF_F2	Plot of Least Squares Means of Change from Baseline in Arthritis Pain VAS at Each Assessment Visit (Primary Estimand) Splitting out Pooled Placebo Post Week 12	Display pooled placebo arm split out after week 12	AAC[3]
2.51.	ITT	Non-Standard EFF_F1	Proportion of Subjects Achieving ACR50 Response at Each Assessment Visit (Primary Estimand) Splitting out Pooled Placebo Post Week 12	Display pooled placebo arm split out after week 12	AAC[3]


CCI

Efficacy: Figures						
No.	Population	IDSL / Example Shell	Title		Programming Notes	Deliverable [Priority]



CCI

Efficacy: Figures						
No.	Population	IDSL / Example Shell	Title		Programming Notes	Deliverable [Priority]



Safety Tables

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Adverse Events (AEs)					
3.1.	Safety	AE13 (modified)	Overall Summary of Adverse Events (Period 1)		SAC[2]
3.2.	Safety - Subjects who Entered Period 2	AE13 (modified)	Overall Summary of Adverse Events (Period 2)		SAC[2]
3.3.	Safety	AE13 (modified)	Overall Summary of Adverse Events (Period 1+2)		SAC[2]
3.4.	Safety	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 1)	ICH E3	SAC[2]
3.5.	Safety - Subjects who Entered Period 2	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 2)	ICH E3	SAC[2]
3.6.	Safety	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 1+2)	ICH E3	SAC[2]
3.7.	Safety	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 1)	ICH E3	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.8.	Safety - Subjects who Entered Period 2	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 2)	ICH E3	SAC[2]
3.9.	Safety	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 1+2)	ICH E3	SAC[2]
3.10.	Safety	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 1)	ICH E3	HDL[1]
3.11.	Safety - Subjects who Entered Period 2	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 2)	ICH E3	SAC[2]
3.12.	Safety	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 1+2)	ICH E3	HDL[1]
3.13.	Safety	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment by System Organ Class and Preferred Term (Period 1)	IDSL	SAC[2]
3.14.	Safety - Subjects who Entered Period 2	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment by System Organ Class and Preferred Term (Period 2)	IDSL	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.15.	Safety	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment by System Organ Class and Preferred Term (Period 1+2)	IDSL	SAC[2]
3.16.	Safety	AE3	Summary of Common ($\geq 5\%$) Adverse Events by Overall Frequency (Period 1)	ICH E3	SAC[2]
3.17.	Safety - Subjects who Entered Period 2	AE3	Summary of Common ($\geq 5\%$) Adverse Events by Overall Frequency (Period 2)	ICH E3	SAC[2]
3.18.	Safety	AE3	Summary of Common ($\geq 5\%$) Adverse Events by Overall Frequency (Period 1+2)	ICH E3	SAC[2]
3.19.	Safety	AE15	Summary of Common ($\geq 5\%$) Non-Serious Adverse Events by System Organ Class and Preferred Term (Number of Subject and Occurrences) (Period 1)	FDAAA, EudraCT	SAC[2]
3.20.	Safety - Subjects who Entered Period 2	AE15	Summary of Common ($\geq 5\%$) Non-Serious Adverse Events by System Organ Class and Preferred Term (Number of Subject and Occurrences) (Period 2)	FDAAA, EudraCT	SAC[2]
3.21.	Safety	AE15	Summary of Common ($\geq 5\%$) Non-Serious Adverse Events by System Organ Class and Preferred Term (Number of Subject and Occurrences) (Period 1+2)	FDAAA, EudraCT	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.22.	Safety	AE16	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Number of Subjects and Occurrences) (Period 1)	FDAAA, EudraCT	SAC[2]
3.23.	Safety - Subjects who Entered Period 2	AE16	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Number of Subjects and Occurrences) (Period 2)	FDAAA, EudraCT	SAC[2]
3.24.	Safety	AE16	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Number of Subjects and Occurrences) (Period 1+2)	FDAAA, EudraCT	SAC[2]
3.25.	Safety	AE5A	Summary of All Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 1)	ICH E3	SAC[2]
3.26.	Safety - Subjects who Entered Period 2	AE5A	Summary of All Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 2)	ICH E3	SAC[2]
3.27.	Safety	AE5A	Summary of All Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 1+2)	ICH E3	SAC[2]
3.28.	Safety	AE5A	Summary of All Drug-Related Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 1)	ICH E3	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.29.	Safety - Subjects who Entered Period 2	AE5A	Summary of All Drug-Related Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 2)	ICH E3	SAC[2]
3.30.	Safety	AE5A	Summary of All Drug-Related Adverse Events by Maximum Intensity by System Organ Class and Preferred Term (Period 1+2)	ICH E3	SAC[2]
3.31.	Safety	AE3	Summary of Non-Serious Drug-Related Adverse Events by Overall Frequency (Period 1)	PLS Requirements	SAC[2]
3.32.	Safety - Subjects who Entered Period 2	AE3	Summary of Non-Serious Drug-Related Adverse Events by Overall Frequency (Period 2)	PLS Requirements	SAC[2]
3.33.	Safety	AE3	Summary of Non-Serious Drug-Related Adverse Events by Overall Frequency (Period 1+2)	PLS Requirements	SAC[2]
3.34.	Safety	AE20	Summary of Serious Fatal and Non-Fatal Drug-Related Adverse Events by Overall Frequency (Period 1)	PLS Requirements	SAC[2]
3.35.	Safety - Subjects who Entered Period 2	AE20	Summary of Serious Fatal and Non-Fatal Drug-Related Adverse Events by Overall Frequency (Period 2)	PLS Requirements	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.36.	Safety	AE20	Summary of Serious Fatal and Non-Fatal Drug-Related Adverse Events by Overall Frequency (Period 1+2)	PLS Requirements	SAC[2]
3.37.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for All Adverse Events (Period 1)		SAC[2]
3.38.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for All Adverse Events (Period 2)		SAC[2]
3.39.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for All Adverse Events (Period 1+2)		SAC[2]
Adverse Events of Special Interest (AESI) and Other Important AEs					
3.40.	Safety	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 1)		HDL[1]
3.41.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 2)		SAC[2]
3.42.	Safety	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 1+2)		HDL[1]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.43.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Adverse Events of Special Interest (Period 1)		SAC[2]
3.44.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Adverse Events of Special Interest (Period 2)		SAC[2]
3.45.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Adverse Events of Special Interest (Period 1+2)		SAC[2]
3.46.	Safety	Non-Standard SAFE_T3	Summary of Other Important Adverse Events (Period 1)		SAC[2]
3.47.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T3	Summary of Other Important Adverse Events (Period 2)		SAC[2]
3.48.	Safety	Non-Standard SAFE_T3	Summary of Other Important Adverse Events (Period 1+2)		SAC[2]
3.49.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Other Important Adverse Events (Period 1)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.50.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Other Important Adverse Events (Period 2)		SAC[2]
3.51.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Other Important Adverse Events (Period 1+2)		SAC[2]
3.52.	Safety	Non-Standard SAFE_T4	Summary of Adjudicated Cardiovascular Event Categories (Period 1)		SAC[2]
3.53.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T4	Summary of Adjudicated Cardiovascular Event Categories (Period 2)		SAC[2]
3.54.	Safety	Non-Standard SAFE_T4	Summary of Adjudicated Cardiovascular Event Categories (Period 1+2)		SAC[2]
3.55.	Safety	ESI1 (modified)	Summary of Characteristics of Injection Site Reactions (Period 1)		SAC[2]
3.56.	Safety - Subjects who Entered Period 2	ESI1 (modified)	Summary of Characteristics of Injection Site Reactions (Period 2)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.57.	Safety	ESI1 (modified)	Summary of Characteristics of Injection Site Reactions (Period 1+2)		SAC[2]
3.58.	Safety	Non-Standard SAFE_T5	Summary of Injection Site Reactions (Period 1)		SAC[2]
3.59.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T5	Summary of Injection Site Reactions (Period 2)		SAC[2]
3.60.	Safety	Non-Standard SAFE_T5	Summary of Injection Site Reactions (Period 1+2)		SAC[2]
3.61.	Safety	Non-Standard SAFE_T6	Summary of Serious or Adjudicated Opportunistic Infections (Period 1)	Display only the rows with counts for Type of Infection and Origin of Infection.	SAC[2]
3.62.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T6	Summary of Serious or Adjudicated Opportunistic Infections (Period 2)	Display only the rows with counts for Type of Infection and Origin of Infection.	SAC[2]
3.63.	Safety	Non-Standard SAFE_T6	Summary of Serious or Adjudicated Opportunistic Infections (Period 1+2)	Display only the rows with counts for Type of Infection and Origin of Infection.	SAC[2]
3.64.	Safety	Non-Standard SAFE_T7	Summary of Adjudicated Serious Hypersensitivity Reactions (Period 1)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.65.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T7	Summary of Adjudicated Serious Hypersensitivity Reactions (Period 2)		SAC[2]
3.66.	Safety	Non-Standard SAFE_T7	Summary of Adjudicated Serious Hypersensitivity Reactions (Period 1+2)		SAC[2]
Pulmonary Findings					
3.67.	Safety	Non-Standard SAFE_T8	Summary of Pulmonary Findings (Period 1)		SAC[2]
3.68.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T8	Summary of Pulmonary Findings (Period 2)		SAC[2]
3.69.	Safety	Non-Standard SAFE_T8	Summary of Pulmonary Findings (Period 1+2)		SAC[2]
3.70.	Safety	Non-Standard SAFE_T9	Summary of Pulse Oximetry Results (Period 1)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.71.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T9	Summary of Pulse Oximetry Results (Period 2)		SAC[2]
3.72.	Safety	Non-Standard SAFE_T9	Summary of Pulse Oximetry Results (Period 1+2)		SAC[2]
Laboratory: Chemistry, Hematology & Fasting Lipids					
3.73.	Safety	LB1	Summary of Chemistry Changes from Baseline (Period 1)	ICH E3 Exclude CRP	SAC[2]
3.74.	Safety - Subjects who Entered Period 2	LB1	Summary of Chemistry Changes from Baseline (Period 2)	ICH E3 Exclude CRP	SAC[2]
3.75.	Safety	LB1	Summary of Chemistry Changes from Baseline (Period 1+2)	ICH E3 Exclude CRP	SAC[2]
3.76.	Safety	LB16A (modified)	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1)	ICH E3	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.77.	Safety - Subjects who Entered Period 2	LB16A (modified)	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 2)	ICH E3	SAC[2]
3.78.	Safety	LB16A (modified)	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1+2)	ICH E3	SAC[2]
3.79.	Safety	LB1	Summary of Hematology Changes from Baseline (Period 1)	ICH E3 Exclude ESR	SAC[2]
3.80.	Safety - Subjects who Entered Period 2	LB1	Summary of Hematology Changes from Baseline (Period 2)	ICH E3 Exclude ESR	SAC[2]
3.81.	Safety	LB1	Summary of Hematology Changes from Baseline (Period 1+2)	ICH E3 Exclude ESR	SAC[2]
3.82.	Safety	LB16A (modified)	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1)	ICH E3	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.83.	Safety - Subjects who Entered Period 2	LB16A (modified)	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 2)	ICH E3	SAC[2]
3.84.	Safety	LB16A (modified)	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1+2)	ICH E3	SAC[2]
3.85.	Safety	LB1	Summary of Fasting Lipids Changes from Baseline (Period 1)		SAC[2]
3.86.	Safety - Subjects who Entered Period 2	LB1	Summary of Fasting Lipids Changes from Baseline (Period 2)		SAC[2]
3.87.	Safety	LB1	Summary of Fasting Lipids Changes from Baseline (Period 1+2)		SAC[2]
3.88.	Safety	LB18	Summary of Laboratory Parameters of Interest CTCAE Worst Grade Shift from Baseline Grade (Period 1)		SAC[2]
3.89.	Safety – Subjects who Entered Period 2	LB18	Summary of Laboratory Parameters of Interest CTCAE Worst Grade Shift from Baseline Grade (Period 2)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.90.	Safety	LB18	Summary of Laboratory Parameters of Interest CTCAE Worst Grade Shift from Baseline Grade (Period 1+2)		SAC[2]
3.91.	Safety	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 1)	ICH E3	SAC[2]
3.92.	Safety – Subjects who Entered Period 2	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 2)	ICH E3	SAC[2]
3.93.	Safety	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 1+2)	ICH E3	SAC[2]
Laboratory: Hepatobiliary (Liver)					
3.94.	Safety	LIVER1	Summary of Liver Monitoring/Stopping Event Reporting (Period 1)	IDSL	SAC[2]
3.95.	Safety - Subjects who Entered Period 2	LIVER1	Summary of Liver Monitoring/Stopping Event Reporting (Period 2)	IDSL	SAC[2]
3.96.	Safety	LIVER1	Summary of Liver Monitoring/Stopping Event Reporting (Period 1+2)	IDSL	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.97.	Safety	LIVER10	Summary of Hepatobiliary Laboratory Abnormalities (Period 1)	IDSL	SAC[2]
3.98.	Safety - Subjects who Entered Period 2	LIVER10	Summary of Hepatobiliary Laboratory Abnormalities (Period 2)	IDSL	SAC[2]
3.99.	Safety	LIVER10	Summary of Hepatobiliary Laboratory Abnormalities (Period 1+2)	IDSL	SAC[2]
ECG					
3.100.	Safety	EG1	Summary of ECG Findings	IDSL	SAC[2]
3.101.	Safety	EG2	Summary of Change from Baseline in ECG Values by Visit (Period 1)	IDSL	SAC[2]
3.102.	Safety - Subjects who Entered Period 2	EG2	Summary of Change from Baseline in ECG Values by Visit (Period 2)	IDSL	SAC[2]
3.103.	Safety	EG2	Summary of Change from Baseline in ECG Values by Visit (Period 1+2)	IDSL	SAC[2]
3.104.	Safety	EG10	Summary of Maximum QTc Values Post-Baseline Relative to Baseline by Category (Period 1)	IDSL	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.105.	Safety – Subjects who Entered Period 2	EG10	Summary of Maximum QTc Values Post-Baseline Relative to Baseline by Category (Period 2)	IDSL	SAC[2]
3.106.	Safety	EG10	Summary of Maximum QTc Values Post-Baseline Relative to Baseline by Category (Period 1+2)	IDSL	SAC[2]
3.107.	Safety	EG11	Summary of Maximum Increase in QTc Values Post-Baseline Relative to Baseline by Category (Period 1)	IDSL	SAC[2]
3.108.	Safety – Subjects who Entered Period 2	EG11	Summary of Maximum Increase in QTc Values Post-Baseline Relative to Baseline by Category (Period 2)	IDSL	SAC[2]
3.109.	Safety	EG11	Summary of Maximum Increase in QTc Values Post-Baseline Relative to Baseline by Category (Period 1+2)	IDSL	SAC[2]
Vital Signs					
3.110.	Safety	VS1	Summary of Change from Baseline in Vital Signs (Period 1)	ICH E3	SAC[2]
3.111.	Safety - Subjects who Entered Period 2	VS1	Summary of Change from Baseline in Vital Signs (Period 2)	ICH E3	SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.112.	Safety	VS1	Summary of Change from Baseline in Vital Signs (Period 1+2)	ICH E3	SAC[2]
3.113.	Safety	VS3	Summary of Worst Case Vital Signs Results Relative to Normal Range Post-Baseline Relative to Baseline (Period 1)	IDSL	SAC[2]
3.114.	Safety – Subjects who Entered Period 2	VS3	Summary of Worst Case Vital Signs Results Relative to Normal Range Post-Baseline Relative to Baseline (Period 2)	IDSL	SAC[2]
3.115.	Safety	VS3	Summary of Worst Case Vital Signs Results Relative to Normal Range Post-Baseline Relative to Baseline (Period 1+2)	IDSL	SAC[2]
Safety Biomarkers (Immunogenicity)					
3.116.	Safety	Non-Standard SAFE_T10	Summary of Anti-GSK3196165 Antibodies (ADA)		AAC[3]
3.117.	Safety	Non-Standard SAFE_T11	Summary of Binding Antibody at Each Assessment Visit		AAC[3]
3.118.	Safety	Non-Standard SAFE_T12	Summary of Neutralising Antibody at Each Assessment Visit		AAC[3]

CONFIDENTIAL

202018

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
COVID-19					
3.119.	Safety	PAN1	Summary of COVID-19 Assessments for Subjects with COVID-19 Adverse Events (Period 1)		SAC[2]
3.120.	Safety - Subjects who Entered Period 2	PAN1	Summary of COVID-19 Assessments for Subjects with COVID-19 Adverse Events (Period 2)		SAC[2]
3.121.	Safety	PAN1	Summary of COVID-19 Assessments for Subjects with COVID-19 Adverse Events (Period 1+2)		SAC[2]
3.122.	Safety	PAN2	Summary of COVID-19 Additional Assessments for Subjects with COVID-19 Adverse Events (Period 1)		SAC[2]
3.123.	Safety - Subjects who Entered Period 2	PAN2	Summary of COVID-19 Additional Assessments for Subjects with COVID-19 Adverse Events (Period 2)		SAC[2]
3.124.	Safety	PAN2	Summary of COVID-19 Additional Assessments for Subjects with COVID-19 Adverse Events (Period 1+2)		SAC[2]
3.125.	Safety	PAN3	Summary of COVID-19 Symptoms for Subjects with COVID-19 Adverse Events (Period 1)	Remove "no" and "unknown" rows	SAC[2]

CONFIDENTIAL

202018

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.126.	Safety - Subjects who Entered Period 2	PAN3	Summary of COVID-19 Symptoms for Subjects with COVID-19 Adverse Events (Period 2)	Remove "no" and "unknown" rows	SAC[2]
3.127.	Safety	PAN3	Summary of COVID-19 Symptoms for Subjects with COVID-19 Adverse Events (Period 1+2)	Remove "no" and "unknown" rows	SAC[2]
3.128.	Safety	Non-Standard SAFE_T13	Summary of Adjudicated Serious Cases of COVID-19 Infections (Period 1)		SAC[2]
3.129.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T13	Summary of Adjudicated Serious Cases of COVID-19 Infections (Period 2)		SAC[2]
3.130.	Safety	Non-Standard SAFE_T13	Summary of Adjudicated Serious Cases of COVID-19 Infections (Period 1+2)		SAC[2]
3.131.	Safety	Non-Standard SAFE_T15	Summary of COVID-19 Infections (Period 1)		SAC[2]
3.132.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T15	Summary of COVID-19 Infections (Period 2)		SAC[2]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.133.	Safety	Non-Standard SAFE_T15	Summary of COVID-19 Infections (Period 1+2)		SAC[2]
Additional Adverse Events					
3.134.	Safety	Non-Standard SAFE_T14	Summary of Common ($\geq 2\%$) Adverse Events by Time from Randomisation		AAC[3]
Exposure Adjusted SAEs					
3.135.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Serious Adverse Events (Period 1)		SAC[2]
3.136.	Safety - Subjects who Entered Period 2	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Serious Adverse Events (Period 2)		SAC[2]
3.137.	Safety	Non-Standard SAFE_T1	Summary of Exposure Adjusted Incidence Rates per 100 Person Years for Serious Adverse Events (Period 1+2)		SAC[2]
Japan subgroup					
3.301.	Japanese Safety	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 1) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.302.	Japanese Safety – Subjects who Entered Period 2	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 2) for Japanese Subjects		AAC[3]
3.303.	Japanese Safety	AE1	Summary of All Adverse Events by System Organ Class and Preferred Term (Period 1+2) for Japanese Subjects		AAC[3]
3.304.	Japanese Safety	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 1) for Japanese Subjects		AAC[3]
3.305.	Japanese Safety – Subjects who Entered Period 2	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 2) for Japanese Subjects		AAC[3]
3.306.	Japanese Safety	AE1	Summary of All Drug-Related Adverse Events by System Organ Class and Preferred Term (Period 1+2) for Japanese Subjects		AAC[3]
3.307.	Japanese Safety	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 1) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.308.	Japanese Safety – Subjects who Entered Period 2	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 2) for Japanese Subjects		AAC[3]
3.309.	Japanese Safety	AE1	Summary of Serious Adverse Events by System Organ Class and Preferred Term (Period 1+2) for Japanese Subjects		AAC[3]
3.310.	Japanese Safety	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from Study by System Organ Class and Preferred Term (Period 1) for Japanese Subjects		AAC[3]
3.311.	Japanese Safety – Subjects who Entered Period 2	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from Study by System Organ Class and Preferred Term (Period 2) for Japanese Subjects		AAC[3]
3.312.	Japanese Safety	AE1	Summary of Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from Study by System Organ Class and Preferred Term (Period 1+2) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.313.	Japanese Safety	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 1) for Japanese Subjects		AAC[3]
3.314.	Japanese Safety – Subjects who Entered Period 2	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 2) for Japanese Subjects		AAC[3]
3.315.	Japanese Safety	Non-Standard SAFE_T2	Summary of Adverse Events of Special Interest (AESI) (Period 1+2) for Japanese Subjects		AAC[3]
3.316.	Japanese Safety	LB1	Summary of Chemistry Changes from Baseline (Period 1) for Japanese Subjects		AAC[3]
3.317.	Japanese Safety - Subjects who Entered Period 2	LB1	Summary of Chemistry Changes from Baseline (Period 2) for Japanese Subjects		AAC[3]
3.318.	Japanese Safety	LB1	Summary of Chemistry Changes from Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.319.	Japanese Safety	LB16	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.320.	Japanese Safety - Subjects who Entered Period 2	LB16	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 2) for Japanese Subjects		AAC[3]
3.321.	Japanese Safety	LB16	Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.322.	Japanese Safety	LB1	Summary of Hematology Changes from Baseline (Period 1) for Japanese Subjects		AAC[3]
3.323.	Japanese Safety - Subjects who Entered Period 2	LB1	Summary of Hematology Changes from Baseline (Period 2) for Japanese Subjects		AAC[3]
3.324.	Japanese Safety	LB1	Summary of Hematology Changes from Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.325.	Japanese Safety	LB16	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.326.	Japanese Safety - Subjects who Entered Period 2	LB16	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 2) for Japanese Subjects		AAC[3]
3.327.	Japanese Safety	LB16	Summary of Worst Case Hematology Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.328.	Japanese Safety	LB1	Summary of Fasting Lipids Changes from Baseline (Period 1) for Japanese Subjects		AAC[3]
3.329.	Japanese Safety - Subjects who Entered Period 2	LB1	Summary of Fasting Lipids Changes from Baseline (Period 2) for Japanese Subjects		AAC[3]
3.330.	Japanese Safety	LB1	Summary of Fasting Lipids Changes from Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.331.	Japanese Safety	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 1) for Japanese Subjects		AAC[3]

Safety: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
3.332.	Japanese Safety - Subjects who Entered Period 2	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 2) for Japanese Subjects		AAC[3]
3.333.	Japanese Safety	UR1	Summary of Worst Case Urinalysis Results (Discrete or Character Values) Post-Baseline Relative to Baseline (Period 1+2) for Japanese Subjects		AAC[3]
3.334.	Japanese Safety	VS1	Summary of Change from Baseline in Vital Signs (Period 1) for Japanese Subjects		AAC[3]
3.335.	Japanese Safety - Subjects who Entered Period 2	VS1	Summary of Change from Baseline in Vital Signs (Period 2) for Japanese Subjects		AAC[3]
3.336.	Japanese Safety	VS1	Summary of Change from Baseline in Vital Signs (Period 1+2) for Japanese Subjects		AAC[3]

Safety Figures

Safety: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Adverse Events					
3.1.	Safety	AE10	Plot of Relative Risks for Common ($\geq 5\%$) Adverse Events		SAC[2]
3.2.	Safety	AE10	Plot of Relative Risks for Adverse Events of Special Interest		SAC[2]
Laboratory: Chemistry, Hematology & Fasting Lipids					
3.3.	Safety	LB9	Distribution of Laboratory Parameters of Interest by Time and Treatment with Maximum over Time		SAC[2]
Laboratory: Hepatobiliary (Liver)					
3.4.	Safety	LIVER14	Scatter Plot of Maximum vs Baseline for ALT		SAC[2]
3.5.	Safety	LIVER9	Scatter Plot of Maximum Total Bilirubin vs Maximum ALT		SAC[2]
Adverse Events (Treatment Policy Handling Strategy)					
3.6.	Safety	AE10	Plot of Relative Risks for Common ($\geq 5\%$) Adverse Events (Treatment Policy Handling Strategy)		AAC[3]
3.7.	Safety	AE10	Plot of Relative Risks for Adverse Events of Special Interest (Treatment Policy Handling Strategy)		AAC[3]

Pharmacokinetic Tables

Pharmacokinetic: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
PK Concentration					
4.1.	PK	PK01	Summary of GSK3196165 Serum Concentrations (ng/mL) by Visit		SAC[2]
Japan Subgroup					
4.301.	Japanese PK	PK01	Summary of GSK3196165 Serum Concentrations (ng/mL) by Visit for Japanese Subjects		AAC[3]
4.302.	Non-Japanese PK	PK01	Summary of GSK3196165 Serum Concentrations (ng/mL) by Visit for Non-Japanese Subjects		AAC[3]

Biomarker Tables

Biomarker: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Exploratory: Pharmacodynamic Biomarkers					
5.1	Safety	Non-Standard BIOM_T1	Summary of Observed Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit		AAC[3]
5.2	Safety	Non-Standard BIOM_T1	Summary of Observed Percentage Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit		AAC[3]
5.3	Safety	Non-Standard BIOM_T2	Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Placebo Comparison)		AAC[3]
5.4	Safety	Non-Standard BIOM_T2	Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Sarilumab Comparison)		AAC[3]
5.5	Safety	Non-Standard BIOM_T3	Repeated Measures Analysis of Ratio to Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Placebo Comparison) (Log Transformed)		AAC[3]
5.6	Safety	Non-Standard BIOM_T3	Repeated Measures Analysis of Ratio to Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Sarilumab Comparison) (Log Transformed)		AAC[3]

Biomarker: Tables					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
CCI					
Exploratory: Safety Biomarkers					
5.9	Safety	Non-Standard BIOM_T1	Summary of Observed Result of GM-CSF Autoantibody (ug/L) at Baseline		AAC[3]
CCI					

Biomarker Figures

Biomarker: Figures					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Exploratory: Pharmacodynamic Biomarkers					
5.1	Safety	Non-Standard EFF_F2	Plot of Observed Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit		AAC[3]
5.2	Safety	Non-Standard EFF_F2	Plot of Observed Percentage Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit		AAC[3]
5.3	Safety	Non-Standard EFF_F2	Plot of Least Squares Means from Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Placebo Comparison)		AAC[3]
5.4	Safety	Non-Standard EFF_F2	Plot of Least Squares Means from Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Sarilumab Comparison)		AAC[3]
5.5	Safety	Non-Standard EFF_F2	Plot of Least Squares Means from Repeated Measures Analysis of Ratio to Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Placebo Comparison) (Log Transformed)		AAC[3]
5.6	Safety	Non-Standard EFF_F2	Plot of Least Squares Means from Repeated Measures Analysis of Ratio to Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit (Sarilumab Comparison) (Log Transformed)		AAC[3]

ICH Listings

ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Subject Disposition					
1.	Randomised	ES2	Listing of Reasons for Study Withdrawal	ICH E3	SAC[2]
2.	Randomised	SD2	Listing of Reasons for Study Treatment Discontinuation	ICH E3	SAC[2]
3.	ITT	BL1	Listing of Subjects for Whom the Treatment Blind was Broken	ICH E3	SAC[2]
Protocol Deviations					
4.	ITT	DV2	Listing of Important Protocol Deviations	ICH E3	SAC[2]
5.	ITT	IE3	Listing of Subjects with Inclusion/Exclusion Criteria Deviations	ICH E3	SAC[2]
Populations Analysed					
6.	Enrolled	SP3	Listing of Subjects Excluded from Per Protocol Population	ICH E3	SAC[2]
Demographic and Baseline Characteristics					
7.	ITT	DM2	Listing of Demographic Characteristics	ICH E3 Include BMI in output.	SAC[2]
8.	ITT	DM9	Listing of Race	ICH E3	SAC[2]
Exposure and Treatment Compliance					
9.	Safety	EX3	Listing of Exposure Data	ICH E3	SAC[2]

ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Adverse Events					
10.	Safety	AE8	Listing of All Adverse Events	ICH E3	SAC[2]
11.	Safety	AE14	Listing of Reasons for Considering as a Serious Adverse Event	ICH E3	SAC[2]
12.	Safety	DD3	Death Subject Profile	ICH E3	SAC[2]
All Laboratory					
13.	Safety	LB5A	Listing of All Laboratory Data for Subjects with Any Value of Potential Clinical Importance	ICH E3	SAC[2]
14.	Safety	UR2	Listing of Urinalysis Data for Subjects with Any Value of Potential Clinical Importance	ICH E3	SAC[2]

Non-ICH Listings

Non-ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Subject Disposition					
15.	Screened	ES7	Listing of Reasons for Screen Failure	BIMO Requirements	SAC[2]
Protocol Deviations					
16.	ITT	DV2	Listing of Non-Important COVID-19 related Protocol Deviations	COVID Requirements	SAC[2]
Prior and Concomitant Medications					
17.	ITT	CM3	Listing of Prior and Concomitant Medications	BIMO Requirements Include "medication taken for pain"	SAC[2]
18.	ITT	CM3	Listing of Intra-Articular Corticosteroids	Add columns for: <ul style="list-style-type: none"> • "medication taken for pain" • "Location of dose administration" • "Laterality" 	SAC[2]
Adverse Events					
19.	Safety	AE7	Listing of Subject Numbers for Individual Adverse Events	Non-ICH Required	SAC[2]
20.	Safety	AE8XO	Listing of Non-Fatal Serious Adverse Events	Non-ICH Required Include "Action Taken with Background Therapy"	SAC[2]
21.	Safety	AE8XO	Listing of Adverse Events Leading to Permanent Discontinuation of Study Treatment or Withdrawal from Study	Non-ICH Required Include "Action Taken with Background Therapy"	SAC[2]

Non-ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
22.	Safety	AE8XO	Listing of Other Significant Adverse Events	Non-ICH Required Include "Action Taken with Background Therapy"	SAC[2]
23.	Safety	AE8XO	Listing of Adverse Events of Special Interest (AESI)	Include "Action Taken with Background Therapy"	SAC[2]
24.	Safety	AE2	Listing of Relationship Between Adverse Event System Organ Classes, Preferred Terms, and Verbatim Text	BIMO Requirements	SAC[2]
25.	Safety	Non-Standard SAFE_L1	Listing of Neutrophils and Associated Infections	Select the following subgroup and add under the title: "Subset of Subjects who experienced grade 3 or 4 Neutropenia"	SAC[2]
26.	Safety	Non-Standard SAFE_L1	Listing of Lymphocytes and Associated Infections	Select the following subgroup and add under the title: "Subset of Subjects who experienced grade 3 or 4 Lymphopenia"	SAC[2]
Hepatobiliary (Liver)					
27.	Safety	LIVER15	Listing of Liver Event Stopping Profile	Non-ICH Required	SAC[2]
All Laboratory					
28.	Safety	LB5A	Listing of All Local Laboratory Data	COVID Requirements	SAC[2]
ECG					
29.	Safety	EG5	Listing of All ECG Findings for Subjects with an Abnormal ECG Finding	BIMO Requirements	SAC[2]
30.	Safety	EG3	Listing of All ECG Values for Subjects with Any Value of Potential Clinical Importance	BIMO Requirements	SAC[2]

Non-ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
Vital Signs					
31.	Safety	VS4	Listing of All Vital Signs for Subjects with any Value of Potential Clinical Importance	BIMO Requirements	SAC[2]
32.	Safety	PREG1	Listing of Subjects Who Became Pregnant During the Study	Non-ICH Required	SAC[2]
PK Concentrations					
33.	Safety	PK07	Listing of GSK3196165 Serum Concentrations	Non-ICH Required Include "Time Since Last Dose (days)"	SAC[2]
COVID-19					
34.	ITT	PAN7	Listing of All Subjects with Visits and Assessments Impacted by COVID-19 Pandemic	COVID Requirements	SAC[2]
35.	Safety	PAN12	Listing of COVID-19 Assessments and Symptom Assessments for Subjects with COVID-19 Adverse Events	COVID Requirements Include "Serious Event"	SAC[2]
36.	Screened	PAN5	Listing of Start Dates of COVID-19 Pandemic Measures by Country	COVID Requirements	SAC[2]
Cardiovascular Event Listings (Conditionally required)					
37.	Safety	ARR1	Arrhythmia Subject Profile	Non-ICH Required	AAC[3]
38.	Safety	CHF1	Congestive Heart Failure Subject Profile	Non-ICH Required	AAC[3]
39.	Safety	CVATIA1	Cerebrovascular Events/Stroke Subject Profile	Non-ICH Required	AAC[3]
40.	Safety	DVT1	Deep venous Thrombosis/ Pulmonary Embolism Subject Profile	Non-ICH Required	AAC[3]

Non-ICH: Listings					
No.	Population	IDSL / Example Shell	Title	Programming Notes	Deliverable [Priority]
41.	Safety	MI1	Myocardial Infarction /Unstable Angina Subject Profile	Non-ICH Required	AAC[3]
42.	Safety	PATE1	Peripheral Arterial Thrombosis Embolism Subject Profile	Non-ICH Required	AAC[3]
43.	Safety	PUL1	Pulmonary Hypertension Subject Profile	Non-ICH Required	AAC[3]
44.	Safety	REV1	Revascularization Subject Profile	Non-ICH Required	AAC[3]
45.	Safety	VAL1	Valvulopathy Subject Profile	Non-ICH Required	AAC[3]

14.13. Appendix 13: Example Mock Shells for Data Displays

Example: POP_T1
 Protocol: 202018
 Population: Safety

Page 1 of n

Table 1.1
 Summary of Subject Status and Subject Disposition for the Study Conclusion Record

	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)	Treatment 5 (N=xx)	Treatment 6 (N=xx)
Subject Status						
Completed	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Completed Safety Follow up	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Entered Long Term Extension	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Withdrawn	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Withdrawn in Period 1 [1]	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Withdrawn in Period 2 [2]	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Primary Reason [3] for Study Withdrawal in Period 1 [1]						
ADVERSE EVENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LACK OF EFFICACY	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL DEVIATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL-SPECIFIED WITHDRAWAL	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
CRITERION MET						
STUDY TERMINATED BY SPONSOR	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LOST TO FOLLOW-UP	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PHYSICIAN DECISION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INFORMED CONSENT WITHDRAWN	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INVESTIGATOR SITE CLOSED	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Example: POP_T1 (cntd.)
 Protocol: 202018
 Population: Safety

Table 1.1
 Summary of Subject Status and Subject Disposition for the Study Conclusion Record

	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)	Treatment 5 (N=xx)	Treatment 6 (N=xx)
Primary Reason [3] for Study						
Withdrawal in Period 2 [2]						
ADVERSE EVENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LACK OF EFFICACY	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL DEVIATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL-SPECIFIED WITHDRAWAL CRITERION MET	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
STUDY TERMINATED BY SPONSOR	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LOST TO FOLLOW-UP	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PHYSICIAN DECISION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INFORMED CONSENT WITHDRAWN	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INVESTIGATOR SITE CLOSED	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Outcome of Adverse Events Which Led to Study Withdrawal in Period 1 [1]						
NON-FATAL	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
FATAL	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Outcome of Adverse Events Which Led to Study Withdrawal in Period 2 [2]						
NON-FATAL	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
FATAL	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

[1] Period 1 - up to 12 weeks, defined as time from randomisation and first dose of treatment up to dosing of Period 2 treatment (Week 12) or date of study withdrawal or date of treatment withdrawal plus safety follow up whichever is earlier.
 [2] Period 2 - post week 12, defined as time from first dose of treatment of period 2 (week 12) until date of study completion or date of study withdrawal or date of treatment withdrawal plus safety follow up whichever is earlier.
 [3] Subjects may have only one primary reason.

CONFIDENTIAL

202018

Example: POP_T2
 Protocol: 202018
 Population: Safety

Page 1 of n

Table 1.x
 Summary of Treatment Status and Reasons for Discontinuation of Study Treatment

	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)	Treatment 5 (N=xx)	Treatment 6 (N=xx)
Treatment Status						
Prematurely Discontinued Treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Prematurely Discontinued Treatment in Period 1 [1]	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Prematurely Discontinued Treatment in Period 2 [2]	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Primary Reason [3] for Treatment Discontinuation in Period 1 [1]						
ADVERSE EVENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LACK OF EFFICACY	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL DEVIATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL-SPECIFIED WITHDRAWAL CRITERION MET	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
STUDY TERMINATED BY SPONSOR	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LOST TO FOLLOW-UP	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PHYSICIAN DECISION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
WITHDRAWAL BY SUBJECT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
SPONSOR TERMINATED STUDY TREATMENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INVESTIGATOR SITE CLOSED	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Example: POP_T2 (cntd.)
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Treatment Status and Reasons for Discontinuation of Study Treatment

	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)	Treatment 5 (N=xx)	Treatment 6 (N=xx)
Primary Reason [3] for Treatment Discontinuation in Period 2 [2]						
ADVERSE EVENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LACK OF EFFICACY	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL DEVIATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PROTOCOL-SPECIFIED WITHDRAWAL CRITERION MET	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
STUDY TERMINATED BY SPONSOR	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
LOST TO FOLLOW-UP	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PHYSICIAN DECISION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
WITHDRAWAL BY SUBJECT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
SPONSOR TERMINATED STUDY TREATMENT	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
INVESTIGATOR SITE CLOSED	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

[1] Treatment Discontinuation in Period 1- defined as time from first dose of treatment up to date of treatment withdrawal prior to week 12 dosing.

[2] Treatment Discontinuation in Period 2- defined as time from first dose of treatment period 2 (week 12) until date of treatment withdrawal post week 12.

[3] Subjects may have only one primary reason for treatment discontinuation.

Example: POP_T3
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Baseline Efficacy Parameters

	Statistic	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)
Swollen Joint Count 28	n	xx	xx	xx	xx
	Mean	xx.x	xx.x	xx.x	xx.x
	SD	xx.xx	xx.xx	xx.xx	xx.xx
	Median	xx.x	xx.x	xx.x	xx.x
	Minimum	xx	xx	xx	xx
	Maximum	xx	xx	xx	xx
Swollen Joint Count 66	n	xx	xx	xx	xx
	Mean	xx.x	xx.x	xx.x	xx.x
	SD	xx.xx	xx.xx	xx.xx	xx.xx
	Median	xx.x	xx.x	xx.x	xx.x
	Minimum	xx	xx	xx	xx
	Maximum	xx	xx	xx	xx
Tender Joint Count 28	n	xx	xx	xx	xx
...
Tender Joint Count 68	n	xx	xx	xx	xx
...
...	n	xx	xx	xx	xx

Example: POP_T4
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Table 1.x
 Summary of Rheumatoid Arthritis Disease History

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Time since RA diagnosis (years)						
n	xx	xx	xx	xx	xx	xx
Mean	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
SD	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
Median	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
Min.	xxx	xxx	xxx	xxx	xxx	xxx
Max.	xxx	xxx	xxx	xxx	xxx	xxx
Time since RA diagnosis						
n	xx	xx	xx	xx	xx	xx
<= 2 years	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>2-5 years	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>5-10 years	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>10 years	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Missing	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
RA functional class						
n	xx	xx	xx	xx	xx	xx
I	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
II	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
III	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Time since start of RA symptoms (years)						
n	xx	xx	xx	xx	xx	xx
Mean	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
SD	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
Median	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
Min.	xxx	xxx	xxx	xxx	xxx	xxx
Max.	xxx	xxx	xxx	xxx	xxx	xxx

Note: Time since RA diagnosis and start of RA symptoms is calculated up to date of first study medication administration.
 [1] Stratum information is obtained from IWRS.

Example: POP_T4 (continued)

Table 1.x
Summary of Rheumatoid Arthritis Disease History

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Stratum (Previously failed medication) [1]						
n	xx	xx	xx	xx	xx	xx
1 bDMARD	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>1 bDMARD	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>=1 JAK inhibitor	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Baseline Anti-CCP Status						
n	xx	xx	xx	xx	xx	xx
Positive	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Negative	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Missing	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Baseline RF Status						
n	xx	xx	xx	xx	xx	xx
Positive	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Negative	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Missing	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Baseline Anti-CCP and RF Status						
n	xx	xx	xx	xx	xx	xx
At Least one Positive	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Both Negative	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: Time since RA diagnosis and start of RA symptoms is calculated up to date of first study medication administration.
[1] Stratum information is obtained from IWRS.

Example: POP_T5
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of Cardiovascular Risk Factors

Age group: xxxxxx	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
History of Tobacco Use						
n	xx	xx	xx	xx	xx	xx
Never smoked	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Current Smoker	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Former Smoker	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Unknown	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
If former smoker: Time between last smoking and assessment date (years)						
n	xx	xx	xx	xx	xx	xx
Mean	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
SD	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
Median	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
Min.	xxx	xxx	xxx	xxx	xxx	xxx
Max.	xxx	xxx	xxx	xxx	xxx	xxx
Family history of cardiovascular risk factors [1]						
n	xx	xx	xx	xx	xx	xx
Yes	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Unknown	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Angina Pectoris						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: [1] Family history of premature coronary artery disease in women <65 years or men < 55 years in first degree relatives only.

Example: POP_T5 (continued)
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of Cardiovascular Risk Factors

Age group: xxxxxx	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Diabetes mellitus						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Hyperlipidemia						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Hypertension						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Myocardial Infarction						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Stroke						
n	xx	xx	xx	xx	xx	xx
Current	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Past	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
No Medical History	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: [1] Family history of premature coronary artery disease in women < 65 years or men < 55 years in first degree relatives only.

Example: POP_T6
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of RA Concomitant Medications

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
ANY MEDICATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
DMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Methotrexate	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Other csDMARDs (not methotrexate)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
csDMARDs >1	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
bsDMARDs/boDMARDs/tsDMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Corticosteroids	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Oral	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Intra-Articular	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Other RA medications	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: Concomitant medication is defined as any medication taken after the first dose of study treatment, regardless of whether it was started prior to the first dose of study treatment or not.

Note: For subjects that discontinued treatment, medications taken after the date of treatment discontinuation up to the end of safety follow up are also presented in this table.

Example: POP_T7
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of RA Prior Medications

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx
ANY MEDICATION	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
DMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Methotrexate	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Other csDMARDs (not methotrexate)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
csDMARDs >1	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
bsDMARDs/boDMARDs/tsDMARDs				
>=1 of bs/bo/tsDMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
=1 of bs/bo/tsDMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>1 of bs/bo/tsDMARDs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Inadequate response to >=1 bs/boDMARD	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Inadequate response to >=1 tsDMARD	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Inadequate response to >1 bs/bo/tsDMARD	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Oral corticosteroids	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Other RA medications	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: Prior medication is defined as any medication that started before first dose of study treatment.

Example: POP_T8
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of RA Medications taken at Baseline (Day 1)

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Methotrexate	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Other csDMARDs (not methotrexate)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
csDMARDs >1	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Methotrexate dose at baseline						
n	xx	xx	xx	xx	xx	xx
No Methotrexate	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
<10mg/week	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>=10mg/week	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Corticosteroids [1]	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Corticosteroid dose at baseline (mg/day) [1]						
n	xx	xx	xx	xx	xx	xx
Mean	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
SD	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
Median	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x	xxx.x
Min.	xxx	xxx	xxx	xxx	xxx	xxx
Max.	xxx	xxx	xxx	xxx	xxx	xxx

[1] Only includes subjects who have taken oral corticosteroids for at least 4 weeks prior to baseline

CONFIDENTIAL

202018

Example: POP_T9
Protocol: 202018
Population: Intent-to-Treat

Page 1 of n

Table 1.x
Summary of Concomitant COVID-19 Vaccines

	Treatment 1	Treatment 2	Treatment 3	Treatment 4	Treatment 5	Treatment 6
	N=xx	N=xx	N=xx	N=xx	N=xx	N=xx
Any Medication	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
PFIZER BIONTECH COVID-19 VACCINE	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
MODERNA COVID-19 VACCINE	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Example: POP_T10
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Exposure to Study Treatment

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Duration of drug exposure [injections] (days)						
Period 1						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 1+2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx

Example: POP_T10 (cntd.)
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Exposure to Study Treatment

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Number of injections						
Period 1						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 1+2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx

Example: POP_T10 (cntd.)
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Exposure to Study Treatment

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Number of injections						
Period 1+2						
1 - 12	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
13 - 24	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
25 - 40	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
> 40	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Number of missed injections						
Period 1						
0 missed injections	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Period 2						
0 missed injections	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Period 1+2						
0 missed injections	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>1 missed injection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

CONFIDENTIAL

202018

Example: POP_T11
 Protocol: 202018
 Population: Safety

Page 1 of n

Table 1.x
 Summary of Overall Compliance Based on Exposure

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Percent Overall Compliance [injections]						
Period 1						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx
Period 1+2						
n	xx	xx	xx	xx	xx	xx
Mean	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
SD	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Median	xx.x	xx.x	xx.x	xx.x	xx.x	xx.x
Min.	xx	xx	xx	xx	xx	xx
Max.	xx	xx	xx	xx	xx	xx

Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100.
 Planned Treatment Duration is 24 weeks, adjusted for early treatment discontinuation subjects.

Example: POP_T11 (cntd.)
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Overall Compliance Based on Exposure

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Overall Compliance Categories [injections]						
Period 1						
<80%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
80-105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Period 2						
<80%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
80-105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Period 1+2						
<80%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
80-105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
>105%	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100.
 Planned Treatment Duration is 24 weeks, adjusted for early treatment discontinuation subjects.

Example: POP_T12
 Protocol: 202018
 Population: Intent-to-Treat

Table 1.x
 Summary of Neuropathic Pain Component as Identified by the Pain DETECT Questionnaire

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx	Total N=xx
Screening Result							
n	xx	xx	xx	xx	xx	xx	xx
Neuropathic	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Nociceptive	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Unclear	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Example: EFF_T1
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Summary and Analysis of the Proportion of Subjects Achieving [ACR20/CDAI-LDA/...] at Each Assessment Visit

Visit: Week X

Statistic	Pooled PBO (N=xx)	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg Q2W (N=xx)	PBO to OTI 90mg QW (N=xx)	PBO to OTI 150mg QW (N=xx)	PBO to SARI 200mg Q2W (N=xx)
%Responders	xx.x	xx.x	xx.x	xx.x			
SE %Responders	xx.xx	xx.xx	xx.xx	xx.xx			
Difference vs. Pooled PBO (%)		xx.x	xx.x	xx.x			
95% CI (%)		(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)			
Difference vs. SARI (%)	xx.x	xx.x	xx.x				
95% CI (%)	(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)				
Odds Ratio vs. Pooled PBO		xx.x	xx.x	xx.x			
95% CI (%)		(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)			
p-value		0.xxxx	0.xxxx	0.xxxx			
Odds Ratio vs. SARI	xx.x	xx.x	xx.x	xx.x			
95% CI (%)	(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)			
p-value	0.xxxx	0.xxxx	0.xxxx	0.xxxx			

Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 1/supplemental estimand 2].

Note: Positive differences and Odds Ratios >1 indicate an improvement of treatment over placebo or sarilumab.

Note: 95% confidence intervals for the difference to placebo and sarilumab are constructed using asymptotic Wald confidence limits without correction.

Note: Odds Ratios and corresponding 95% confidence intervals for odds ratios are generated from the logistic regression model adjusted for [Baseline Value], Treatment Group and Previously Failed Medication Category.

Note: Placebo switch treatment arms will only be displayed after Week 12.

Example: EFF_T2
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Summary of Observed [ACR20] Response at Each Assessment Visit

Parameter: XXX [optional]

	Pooled PBO (N=xx)	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg Q2W (N=xx)	PBO to OTI 90mg QW (N=xx)	PBO to OTI 150mg QW (N=xx)	PBO to SARI 200mg Q2W (N=xx)
Week 1							
N	xx	xx	xx	xx			
n (%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)			
Week 2							
N	xx	xx	xx	xx			
n (%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)			
Week 3							
N	xx	xx	xx	xx			
n (%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)			
...							
Week 13							
N		xx	xx	xx	xx	xx	xx
n (%)		xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
...							

Note: N is the number of subjects with non-missing data at that visit

Example: EFF_T3
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Analysis of Change from Baseline in [HAQ-DI/CDAI Total/...] at Each Assessment Visit [(Primary Estimand)]

Visit: Week 1

Statistic	Pooled PBO (N=xx)	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg 2QW (N=xx)	PBO to OTI 90mg QW (N=xx)	PBO to OTI 150mg QW (N=xx)	PBO to SARI 200mg Q2W (N=xx)
LS Mean Change	xx.x	xx.x	xx.x	xx.x			
Standard Error	xx.xx	xx.xx	xx.xx	xx.xx			
LS Mean Difference from Pooled PBO		xx.x	xx.x	xx.x			
95% CI (%)		(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)			
p-value		0.xxxx	0.xxxx	0.xxxx			
LS Mean Difference from SARI	xx.x	xx.x	xx.x				
95% CI (%)	(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)				
p-value	0.xxxx	0.xxxx	0.xxxx				

Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 1/supplemental estimand 2]

Note: All estimates are obtained from an ANCOVA analysis adjusted for Baseline Value, Treatment Group and Previously Failed Medication Category.

Note: Placebo switch treatment arms will only be displayed after Week 12.

Example: EFF_T4
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Summary of Observed [Result/Change from Baseline] in [HAQ-DI/CDAI Total/...] at Each Assessment Visit

Parameter: XXXX [optional]

Treatment	Visit	n	Mean	SD	95% CI	Median	Min.	Max.
Pooled PBO (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 1	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx

OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 1	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx

	Week 13	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 16	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
...	
...
PBO to OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 13	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 16	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx

...	

Example: EFF_T5
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Summary of Ratio to Baseline in [CRP] at Each Assessment Visit (Log Transformed)

Parameter: XXXX

Treatment	Visit	n	Geometric Mean	%CVb	95% CI	Median	Min.	Max.
Pooled PBO (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 1	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
			xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx

OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 1	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
			xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	
	Week 13	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
xx.x			xx.xx	(xx.x,xx.x)	xx.x	xx	xx	
Week 16	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx	
		xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx	
	
PBO to OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 13	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
			xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	Week 16	xx	xx.x	xx.xx	(xx.x,xx.x)	xx.x	xx	xx
	

Example: EFF_T6
Protocol: 202018 Confidential
Population: Intent-To-Treat

Table 2.x
Summary of Observed [ACR20] Response Within 4/8/12/16/24 Weeks Post Baseline

Achieved Response	Pooled PBO (N=xx)	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg Q2W (N=xx)
Within 4 weeks n(%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Within 8 weeks n(%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Within 12 weeks n(%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Within 16 weeks n(%)		xx (xx%)	xx (xx%)	xx (xx%)
Within 24 weeks n(%)		xx (xx%)	xx (xx%)	xx (xx%)

Example: EFF_T7
Protocol: 202018 Confidential
Population: Intent-To-Treat

Table 2.x
Summary of Observed Maintained [ACR20] Response for 12 Weeks After the First Occurrence

Maintained Response	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg Q2W (N=xx)
For 12 weeks n(%)	xx (xx%)	xx (xx%)	xx (xx%)

Note: If a subject has at most two non-consecutive visits with missing response data within the 12 week window after first occurrence of response and the subject was in response for all other visits, then the subject will be considered to have maintenance of response.

Example: EFF_T8
 Protocol: 202018 Confidential
 Population: Intent-To-Treat

Table 2.x
 Analysis of Time to Onset of [ACR20] Response

	OTI 90mg QW (N=xx)	OTI 150mg QW (N=xx)	SARI 200mg Q2W (N=xx)
Number of Subjects			
n	xx	xx	xx
Endpoint (ACR20)	xx (xx%)	xx (xx%)	xx (xx%)
Censored	xx (xx%)	xx (xx%)	xx (xx%)
Early Study Withdrawal	xx (xx%)	xx (xx%)	xx (xx%)
Study Completion	xx (xx%)	xx (xx%)	xx (xx%)
Estimate for Time to ACR20 (Weeks) [1]			
1 st Quartile	xx.x	xx.x	xx.x
Median	xx.x	xx.x	xx.x
3 rd Quartile	xx.x	xx.x	xx.x
Adjusted Hazard Ratio [2]			
Estimate	x.xx	x.xx	x.xx
95% CI	(x.xx, x.xx)	(x.xx, x.xx)	(x.xx, x.xx)
p-value	0.xxx	0.xxx	0.xxx
Estimate for Time to ACR20 (Weeks) [3]			
1 st Quartile	xx.x	xx.x	xx.x
Median	xx.x	xx.x	xx.x
3 rd Quartile	xx.x	xx.x	xx.x


[1] Statistics will be missing when the number of events is too low to estimate the values from the survival function.

[2] A hazard ratio <1 indicates a lower risk with this treatment compared with Sarilumab. Hazard Ratio is adjusted for Baseline TJC68, Baseline SJC66 and Previously Failed Medication Category.

[3] Among subjects achieving response.

Example: EFF_F1
Protocol: 202018 Confidential
Population: Intent-to-Treat

Figure 2.x
Proportion of Subjects Achieving [ACR20/50/70 Response] at Each Assessment Visit [(Primary Estimand)]




Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 1/supplemental estimand 2]

Example: EFF_F2
Protocol: 202018 Confidential
Population: Intent-to-Treat

Figure 2.x

Plot of Least Squares Means of Change from Baseline in [HAQ-DI/CDAI Total Score/...] at Each Assessment Visit [(Primary Estimand)]



Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 1/supplemental estimand 2]
Note: All estimates are obtained from an ANCOVA analysis adjusted for Baseline Value, Treatment Group and Previously Failed Medication Category.


Example: EFF_F3

Protocol: 202018 Confidential
Population: Intent-to-Treat

Page 1 of n

Figure 2.x
Spydergram of Individual Domain Scores of SF-36 at Each Assessment Visit

Visit: Week 12




Note: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Function, RE=Role Emotional, MH=Mental Health.

Example: EFF_F4
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Figure 2.x
 Forest Plot of [Demographic] Subgroup Results for [ACR20] - Comparison to [Placebo at Week 12]

Treatment: OTI 90mg QW




Note: All estimates are produced following multiple imputation specified for the primary estimand.
 Note: Odds Ratios and corresponding 95% confidence intervals for odds ratios are generated from the logistic regression model adjusted for Baseline TJC68, Baseline SJC66, Treatment Group and Previously Failed Medication Category.

Example: EFF_F5
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Figure 2.x
 Forest Plot of [Demographic] Subgroup Results for [HAQ-DI] - Comparison to [Placebo at Week 12]

Treatment: OTI 90mg QW




Note: All estimates are produced following multiple imputation specified for the primary estimand.
 Note: All estimates are for the least squared means obtained from the ANCOVA analysis adjusted for Baseline Value, Treatment Group and Previously Failed Medication.

Example: EFF_F6
Protocol: 202018 Confidential
Population: Intent-to-Treat

Figure 2.x

Proportion of Subjects Achieving Maintained [ACR50 Response] for At Least 12 Weeks After the First Occurrence



Note: If a subject has at most two non-consecutive visits with missing response data within the 12 week window after first occurrence of response and the subject was in response for all other visits, then the subject will be considered to have maintenance of response.

Example: BIOM_T1
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Table 5.x

Summary of Observed [Result/Change from Baseline] in [Pharmacodynamic Biomarkers/...] at Each Assessment Visit

Parameter: XXXX

Treatment	Visit	n	Mean	SD	Median	(Q1, Q3)	Min	Max
Pooled PBO (N=xx)	Baseline	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
	Week 1	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx

OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
	Week 1	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx

	Week 13	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
	Week 16	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
...	
...
PBO to OTI 90mg QW (N=xx)	Baseline	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
	Week 13	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx
	Week 16	xx	xx.x	xx.xx	xx.x	(xx.x, xx.x)	xx	xx

...

Note: Values reported below lower limit of quantification were replaced by one-half the limit of quantification.

Example: BIOM_T2
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Table 5.x
 Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit
 ([Placebo/Sarilumab] Comparison)

Biomarker: [Chemokine (C-C Motif) Ligand 17]
 Visit: Week 1

Statistic	Pooled PBO N=xx	OTI 90mg QW N=xx	OTI 150mg QW N=xx	SARI 200mg Q2W N=xx
n [1]	xx	xx	xx	xx
LS Mean Change	xx.x	xx.x	xx.x	xx.x
Standard Error	xx.xx	xx.xx	xx.xx	xx.xx
LS Mean Difference from Pooled PBO		xx.x	xx.x	xx.x
95% CI (%)		(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)
p-value		0.xxxxx	0.xxxxx	0.xxxxx

[1] Number of subjects with analysable data at the given timepoint.
 Note: All estimates are obtained from an MMRM analysis adjusted for Baseline Value, Treatment Group, Previously Failed Medication Category, Visit and Treatment Group by Visit.

Example: BIOM_T3
 Protocol: 202018 Confidential
 Population: Intent-to-Treat

Table 5.x
 Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit
 ([Placebo/Sarilumab] Comparison) (Log Transformed)

Biomarker: [Chemokine (C-C Motif) Ligand 17]
 Visit: Week 1

Statistic	Pooled PBO N=xx	OTI 90mg QW N=xx	OTI 150mg QW N=xx	SARI 200mg Q2W N=xx
n [1]	xx	xx	xx	xx
LS Geometric Mean	xx.x	xx.x	xx.x	xx.x
%CVb	xx.xx	xx.xx	xx.xx	xx.xx
Ratio to Pooled PBO		xx.x	xx.x	xx.x
95% CI (%)		(xx.x, xx.x)	(xx.x, xx.x)	(xx.x, xx.x)
p-value		0.xxxx	0.xxxx	0.xxxx

[1] Number of subjects with analysable data at the given timepoint.

Note: All estimates are obtained from an MMRM analysis adjusted for Baseline Value, Treatment Group, Previously Failed Medication Category, Visit and Treatment Group by Visit.

Example: AE13 (modified)
 Protocol: 202018
 Population: Safety

Table 3.x
 Overall Summary of Adverse Events (Period X)

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx
Any AE	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs related to study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to discontinuation of study treatment only	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to discontinuation of background therapy only	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to discontinuation of both study treatment and background therapy	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to dose interruption/delay of study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to dose interruption/delay of background therapy	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
AEs leading to dose reduction of background therapy	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Any SAE	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
SAEs related to study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Fatal SAEs	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Fatal SAEs related to study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Any SAE excluding COVID-19 Infections	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
SAEs excluding COVID-19 Infections related to study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Fatal SAEs excluding COVID-19 Infections	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Fatal SAEs excluding COVID-19 Infections related to study treatment	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

Example: SAFE_T1
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Exposure Adjusted Incidence Rates per 100 years for All Adverse Events (Period X)

System Organ Class Preferred Term	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx
Total Treatment Exposure (person-years)	xx.xx	xx.xx	xx.xx	xx.xx
Any Adverse Event	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Infections and Infestations				
Any Adverse Event	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Nasopharyngitis	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Upper Respiratory Tract Infection	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Bronchitis	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Pharyngitis	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Rhinitis	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Oral Herpes	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]
Viral Infection	xx.x [xx]	xx.x [xx]	xx.x [xx]	xx.x [xx]

Note: The rate and number of events "Rate [#]" are reported in this table. # = Number of events.
 Note: Rate is event rate per 100 person-years, calculated as the number of events multiplied by 100, divided by the total treatment exposure in years.

Example: SAFE_T2
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Adverse Events of Special Interest (AESI) (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]	Treatment 5 N=xx n (%) [#]	Treatment 6 N=xx n (%) [#]
Any AESI	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Serious infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Serious infections excluding COVID-19 Infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Active TB	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Latent TB	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
TB reactivation	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Neutropenia	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Persistent cough	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Persistent dyspnoea	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pulmonary alveolar proteinosis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Serious Hypersensitivity reactions	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Injection site reaction	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Note: Persistent cough or persistent dyspnoea defined as a cough (CTACE Grade >= 2) or a dyspnoea (dyspnoea scale Grade >= 2) for three consecutive weeks (>=21 days).

Note: Neutropenia is defined as AEs/SAEs of neutropenia where the corresponding absolute neutrophil counts are grade 3 or 4 (<1.0 X 10⁹/L).

Note: Opportunistic infections, Active TB, Latent TB, TB reactivation events, serious hypersensitivity reactions and pulmonary alveolar proteinosis have been adjudicated and only adjudicated events displayed in the summary table.

Example: SAFE_T3
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Other Important Adverse Events (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Any Other Important AEs	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Adjudicated GI Perforation	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Adjudicated CV Events	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
CV Death	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Myocardial Infarction	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hospitalisation for Unstable Angina	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Stroke	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hospitalisation for Heart Failure	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Deep Vein Thrombosis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pulmonary Embolism	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Any Malignancy	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Solid, Excluding Non-melanoma Skin Cancer	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Non-melanoma Skin Cancer	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hematologic	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Lymphoma	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Note: Some Pneumonia SAEs may also be captured in category of Serious Pulmonary Infection.

Example: SAFE_T3 (continued)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Other Important Adverse Events (Period X)

	Treatment 1	Treatment 2	Treatment 3	Treatment 4
	N=xx n (%) [#]	N=xx n (%) [#]	N=xx n (%) [#]	N=xx n (%) [#]
Any Herpes Infection	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Herpes Zoster	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Herpes Simplex	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Non-Specific Herpes Infection	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
All-Cause Mortality	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Serious Pulmonary Infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Serious Pulmonary Infections excluding COVID-19 Infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pneumonia (Serious and Non-Serious)	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pneumonia (Serious and Non-Serious) excluding COVID-19 Infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hepatitis B and Hepatitis B Reactivation	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Thromboembolic Events	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.
 Note: Some Pneumonia SAEs may also be captured in category of Serious Pulmonary Infection.

Example: SAFE_T4
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Adjudicated Cardiovascular Event Categories (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Any Adjudicated CV Event	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
MACE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Broad MACE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Broad MACE, Excluding DVT and PE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
VTE (DVT and/or PE)	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
DVT only	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
PE only	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Example ES11 (modified)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Characteristics of Injection Site Reaction

Period: Period X

	Treatment 1 (N=100)	Treatment 2 (N=100)	Treatment 3 (N=100)
Number of Subjects with the Event	50 (50%)	40 (40%)	40 (40%)
Number of Events	60	65	55
Event Characteristics (% based on all subjects) [1]			
Serious	10/100 (10%)	16/100 (16%)	8/100 (8%)
Study treatment related	25/100 (25%)	10/100 (10%)	20/100 (20%)
Led to study withdrawal	5/100 (5%)	4/100 (4%)	2/100 (2%)
Event Characteristics (% based on subjects with the Event) [1]			
Serious	10/50 (20%)	16/40 (40%)	8/40 (20%)
Study treatment related	25/50 (50%)	10/40 (25%)	20/40 (50%)
Led to study withdrawal	5/50 (10%)	4/40 (10%)	2/40 (5%)

Note: [1] Subjects may be included in more than one category for 'Event Characteristics'.

Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > Recovering/Resolving > Recovered/Resolved

Note: [3] Subjects are counted once under each action that was taken.

Note: [4] Background therapy is any csDMARD.

Example ES11 (modified)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Characteristics of Injection Site Reaction

Study: Period X

	Treatment 1 (N=100)	Treatment 2 (N=100)	Treatment 3 (N=100)
Number of occurrences (% based on all subjects)			
One	30/100 (30%)	20/100 (20%)	8/100 (8%)
Two	15/100 (15%)	10/100 (10%)	30/100 (30%)
Three or more	5/100 (5%)	10/100 (10%)	2/100 (2%)
Number of occurrences (% based on subjects with the Event)			
One	30/50 (60%)	20/40 (50%)	8/40 (20%)
Two	15/50 (30%)	10/40 (25%)	30/40 (75%)
Three or more	5/50 (10%)	10/40 (25%)	2/40 (5%)
Outcome (% based on all subjects) [2]			
Recovered/Resolved	20/100 (20%)	10/100 (10%)	8/100 (8%)
Recovering/Resolving	10/100 (10%)	20/100 (20%)	30/100 (30%)
Not Recovered/Not Resolved	10/100 (10%)	5/100 (5%)	0/100
Recovered/Resolved with sequelae	5/100 (5%)	0/100	0/100
Fatal	5/100 (5%)	5/100 (5%)	2/100 (2%)
Outcome (% based on subjects with the Event) [2]			
Recovered/Resolved	20/50 (40%)	10/40 (25%)	8/40 (20%)
Recovering/Resolving	10/50 (20%)	20/40 (50%)	30/40 (75%)
Not Recovered/Not Resolved	10/50 (20%)	5/40 (13%)	0/40
Recovered/Resolved with sequelae	5/50 (10%)	0/40	0/40
Fatal	5/50 (10%)	5/40 (13%)	2/40 (5%)

Note: [1] Subjects may be included in more than one category for 'Event Characteristics'.

Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > Recovering/Resolving > Recovered/Resolved

Note: [3] Subjects are counted once under each action that was taken.

Note: [4] Background therapy is any csDMARD.

Example ESI1 (modified)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Characteristics of Injection Site Reaction

Period: Period X

	Treatment 1 (N=100)	Treatment 2 (N=100)	Treatment 3 (N=100)
Maximum Intensity (% based on all subjects)			
Mild	30/100 (30%)	20/100 (20%)	8/100 (8%)
Moderate	15/100 (15%)	10/100 (10%)	30/100 (30%)
Severe	5/100 (5%)	10/100 (10%)	2/100 (2%)
Maximum Intensity (% based on subjects with the Event)			
Mild	30/50 (60%)	20/40 (50%)	8/40 (20%)
Moderate	15/50 (30%)	10/40 (25%)	30/40 (75%)
Severe	5/50 (10%)	10/40 (25%)	2/40 (5%)

Note: [1] Subjects may be included in more than one category for 'Event Characteristics'.

Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > Recovering/Resolving > Recovered/Resolved

Note: [3] Subjects are counted once under each action that was taken.

Note: [4] Background therapy is any csDMARD.

Example ESI1 (modified)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Characteristics of Injection Site Reaction

Period: Period X

	Treatment 1 (N=100)	Treatment 2 (N=100)	Treatment 3 (N=100)
Action Taken (% based on all subjects) [3]			
Study treatment withdrawn	20/100 (20%)	10/100 (10%)	8/100 (8%)
Dose not changed	5/100 (5%)	0/100	0/100
Dose interrupted/delayed	0/100	5/100 (5%)	2/100 (2%)
Not applicable	5/100 (10%)	0/100	0/100
Action Taken (% based on subjects with the Event) [3]			
Study treatment withdrawn	20/50 (40%)	10/40 (25%)	8/40 (20%)
Dose not changed	5/50 (10%)	0/40	0/40
Dose interrupted/delayed	0/50	5/40 (13%)	2/40 (5%)
Not applicable	5/50 (10%)	0/40	0/40
Action Taken with Background Therapy(% based on all subjects) [3] [4]			
Drug withdrawn	20/100 (20%)	10/100 (10%)	8/100 (8%)
Dose reduced	10/100 (10%)	20/100 (20%)	30/100 (30%)
Dose not changed	5/100 (5%)	0/100	0/100
Dose interrupted/delayed	0/100	5/100 (5%)	2/100 (2%)
Not applicable	5/100 (10%)	0/100	0/100
Action Taken (% based on subjects with the Event) [3]			
Background Therapy [4] withdrawn	20/50 (40%)	10/40 (25%)	8/40 (20%)
Dose reduced	10/50 (20%)	20/40 (50%)	30/40 (75%)
Dose not changed	5/50 (10%)	0/40	0/40
Dose interrupted/delayed	0/50	5/40 (13%)	2/40 (5%)
Not applicable	5/50 (10%)	0/40	0/40

Note: [1] Subjects may be included in more than one category for 'Event Characteristics'.

Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > Recovering/Resolving > Recovered/Resolved

Note: [3] Subjects are counted once under each action that was taken.

Note: [4] Background therapy is any csDMARD.

Example: SAFE_T5
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Injection Site Reaction (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Any injection site reactions	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
<= 1 Day post injection	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
> 1 Day post injection \$	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as a non-serious AE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as an SAE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Type of Reactions				
Itching/Pruritus	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Redness/Erythema	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pain	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bruising	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Swelling/Edema	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Warm to Touch	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences. (\$) until 1 day before next injection.

Example: SAFE_T6
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Serious or Adjudicated Opportunistic Infections (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Any serious or opportunistic infections	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as a non-serious AE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as an SAE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Type of Infection				
Bacterial - Gram Positive	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bacterial - Gram Negative	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bacterial - Atypical	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bacterial - Unknown	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bacterial - Other	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - Zoster/shingles	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - Simplex, orogenital	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - EBV	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - HCV	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - HBV	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - HBV Reactivation	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - Unknown	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Viral - Other	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Note: \$ until 1 day before next injection.

Note: Adjudication of serious hypersensitivity reactions was done internally.

Example: SAFE_T6 (continued)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Serious or Adjudicated Opportunistic Infections (Period X)

Type of Infection	Treatment 1	Treatment 2	Treatment 3	Treatment 4
	N=xx n (%) [#]	N=xx n (%) [#]	N=xx n (%) [#]	N=xx n (%) [#]
Opportunistic - Esophageal candidiasis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - CMV viremia	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - CMV invasive	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Pneumocystis Jiroveci	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Cryptococcus	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Disseminated herpes zoster	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - BK virus encephalitis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Fungal	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Protozoal/helminthic	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Latent tuberculosis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Active tuberculosis	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Atypical mycobacterial	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Aspergillus	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Fungal non aspergillus	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Fungal non cryptococcal	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Unknown	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Opportunistic - Other	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Note: \$ until 1 day before next injection.

Note: Adjudication of serious hypersensitivity reactions was done internally.

Example: SAFE_T6 (continued)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Serious or Adjudicated Opportunistic Infections (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Origin of Infection				
Community	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hospital	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
ICU	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Unknown	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Parenteral antibiotics or antimicrobial medication administered	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Culture/swab taken	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Diagnostic imaging or other diagnostic tests performed	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Had grade 3 neutropenia or worse at the time of infection	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences.

Note: \$ until 1 day before next injection.

Note: Adjudication of serious hypersensitivity reactions was done internally.

Example: SAFE_T7
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Adjudicated Serious Hypersensitivity Reactions (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Any serious hypersensitivity reactions	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
<= 1 Day post injection	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
> 1 Day post injection \$	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as a non-serious AE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Reported as an SAE	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Type of Systemic Reactions				
Headache	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Pruritus	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Urticaria	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Rash	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Angioedema	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Fatigue	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Myalgia	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Arthralgia	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Bronchospasm	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hypotension requiring vasopressors	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Hypotension not requiring vasopressors	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Dizziness	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Syncope	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Crampy abdominal pain	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Respiratory failure requiring intubation	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
ICU Management required	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Other	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences. (\$) until 1 day before next injection.

Example: SAFE_T7 (continued)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Adjudicated Serious Hypersensitivity Reactions (Period X)

	Treatment 1 N=xx n (%) [#]	Treatment 2 N=xx n (%) [#]	Treatment 3 N=xx n (%) [#]	Treatment 4 N=xx n (%) [#]
Met anaphylaxis criteria				
Criterion 1	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Criterion 2	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]
Criterion 3	x (x) [x]	x (x) [x]	x (x) [x]	x (x) [x]

Note: n=number of subjects with at least one event. #=number of individual occurrences. (\$) until 1 day before next injection.

Example: SAFE_T8
 Protocol: 202018
 Population: Safety

Page 1 of n

Table 3.x
 Summary of Pulmonary Findings (Period X)

Subjects with at least one event of	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx
Cough	xx (xx)	xx (xx)	xx (xx)	xx (xx)
Abnormal lung auscultation	xx (xx)	xx (xx)	xx (xx)	xx (xx)
Dyspnoea	xx (xx)	xx (xx)	xx (xx)	xx (xx)

Note: Cough includes subjects who reported cough of any grade.

Note: Abnormal lung auscultation includes subjects with any abnormality recorded.

Note: Dyspnoea includes subjects who reported dyspnoea of any grade.

Example: SAFE_T9
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Pulse Oximetry Results (Period X)

Visit	Treatment 1	Treatment 2	Treatment 3	Treatment 4
Blood Oxygen	N=xx	N=xx	N=xx	N=xx
Baseline				
n	xx	xx	xx	xx
<80%	xx (xx)	xx (xx)	xx (xx)	xx (xx)
80% to <90%	xx (xx)	xx (xx)	xx (xx)	xx (xx)
>=90%	xx (xx)	xx (xx)	xx (xx)	xx (xx)
Worst Post-Baseline Result				
n	xx	xx	xx	xx
<80%	xx (xx)	xx (xx)	xx (xx)	xx (xx)
80% to 90%	xx (xx)	xx (xx)	xx (xx)	xx (xx)
>=90%	xx (xx)	xx (xx)	xx (xx)	xx (xx)

Example: LB16A (modified)
 Protocol: 202018
 Population: Safety

Table 3.76

Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline (Period 1)

Test (units): Alanine Aminotransferase (IU/L)
 Term: Alanine aminotransferase increased

Treatment	Planned Time	Change Categories [2]		
Pooled PBO (N=78)	Baseline	n	xx	
			Grade 1 xx (xx%)	
			Grade 2 xx (xx%)	
			Grade 3 xx (xx%)	
			Grade 4 xx (xx%)	
		Maximum Grade Shift Post Baseline	n	xx
			Worsen to Grade 1 xx (xx%)	
			Worsen to Grade 2 xx (xx%)	
			Worsen to Grade 3 xx (xx%)	
			Worsen to Grade 4 xx (xx%)	
		Worsen to Grades 1 to 4 xx (xx%)		
		Worsen to Grades 2 to 4 xx (xx%)		
		Worsen to Grades 3 to 4 xx (xx%)		
OTI 90mg QW (N=157)	Baseline	n	xx	
			Grade 1 xx (xx%)	
			Grade 2 xx (xx%)	
			Grade 3 xx (xx%)	
			Grade 4 xx (xx%)	

Note: A worsening is defined as a worsening in grade relative to baseline grade. Subjects with missing baseline values are assumed to have baseline value of grade 0.

[1] Grades were derived based on numeric criteria as defined in CTCAEv5.0 and did not take into consideration of clinical signs or symptoms, concomitant medication usage which is needed for the final grade associated with the adverse event.

[2] n = number of subjects with values at the specified planned time.

Example: SAFE_T10
 Protocol: 202018
 Population: Safety

Page 1 of n

Table 3.x
 Summary of Anti-GSK3196165 Antibodies (ADA)

	Treatment 1	Treatment 2	Treatment 3
	N=xx	N=xx	N=xx
Baseline ADA results			
n	xx	xx	xx
Negative ADA	xx (xx)	xx (xx)	xx (xx)
Confirmed positive ADA	xx (xx)	xx (xx)	xx (xx)
At least one confirmed positive ADA that subsequently tested positive for Neutralising Antibodies	xx (xx)	xx (xx)	xx (xx)
At least one confirmed positive ADA that subsequently tested negative for Neutralising Antibodies	xx (xx)	xx (xx)	xx (xx)

Note: A subject is considered to have a positive ADA result if they have a positive screening assay, a positive confirmation assay and a titre value. A baseline ADA result is the closest ADA sample prior to the subject receiving the first dose of GSK3196165. Only confirmed ADA positive samples were tested in the Neutralizing Antibody assay.

Example: SAFE_T10 (continued)
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Anti-GSK3196165 Antibodies (ADA)

	Treatment 1	Treatment 2	Treatment 3
	N=xx	N=xx	N=xx
Post-baseline ADA results			
n	xx	xx	xx
At least one confirmed positive ADA result	xx (xx)	xx (xx)	xx (xx)
All negative ADA results	xx (xx)	xx (xx)	xx (xx)
Confirmed positive ADA result that are positive for Neutralising Antibodies	xx (xx)	xx (xx)	xx (xx)
Confirmed positive ADA result that are negative for Neutralising Antibodies	xx (xx)	xx (xx)	xx (xx)

Note: A subject is considered to have a positive ADA result if they have a positive screening assay, a positive confirmation assay and a titre value. A baseline ADA result is the closest ADA sample prior to the subject receiving the first dose of GSK3196165. Only confirmed ADA positive samples were tested in the Neutralizing Antibody assay.

Example: SAFE_T11
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Binding Antibody at Each Assessment Visit

Visit	Assay Result		Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx
Baseline	n		xx	xx	xx
	Negative		xx (xx%)	xx (xx%)	xx (xx%)
	Positive		xx (xx%)	xx (xx%)	xx (xx%)
	Titre Value	Median	xx.x	xx.x	xx.x
		Min.	xx	xx	xx
		Max.	xx	xx	xx
Week 2	n		xx	xx	xx
	Negative		xx (xx%)	xx (xx%)	xx (xx%)
	Positive		xx (xx%)	xx (xx%)	xx (xx%)
	Titre Value	Median	xx.x	xx.x	xx.x
		Min.	xx	xx	xx
		Max.	xx	xx	xx
...					
ANY TIME POST BASELINE	n		xx	xx	xx
	Negative		xx (xx%)	xx (xx%)	xx (xx%)
	Positive		xx (xx%)	xx (xx%)	xx (xx%)
	Persistent positive		xx (xx%)	xx (xx%)	xx (xx%)
	Transient positive		xx (xx%)	xx (xx%)	xx (xx%)
	Titre Value	Median	xx.x	xx.x	xx.x
		Min.	xx	xx	xx
		Max.	xx	xx	xx

Note: The values shown at the anytime post baseline visit are based on each subject's highest post baseline titre.

Note: Any Time Post Baseline would be positive for a subject who had negative and positive baseline results.

Note: Transient positive is defined as a single positive immunogenic response where the previous visit is negative, that does not occur at the final study assessment and persistent positive is defined as a positive immunogenic response where the previous visit is positive of the final study assessment is positive.

Note: The titre value includes the method sample dilution of 1/10.

Example: SAFE_T12
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Neutralising Antibody at Each Assessment Visit

Visit	Assay Result	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx
Baseline	n	xx	xx	xx
	Negative	xx (xx%)	xx (xx%)	xx (xx%)
	Positive	xx (xx%)	xx (xx%)	xx (xx%)
Week 2	n	xx	xx	xx
	Negative	xx (xx%)	xx (xx%)	xx (xx%)
	Positive	xx (xx%)	xx (xx%)	xx (xx%)
...				
ANY TIME POST BASELINE	n	xx	xx	xx
	Negative	xx (xx%)	xx (xx%)	xx (xx%)
	Positive	xx (xx%)	xx (xx%)	xx (xx%)

Note: NAb assay result is only presented for subjects with a positive ADA assay.

Note: Any Time Post Baseline would be positive for a subject who had negative and positive baseline results.

Example: SAFE_T13
 Protocol: 202018
 Population: Safety

Table 3.x
 Summary of Adjudicated Serious Cases of COVID-19 Infections (Period X)

	Treatment 1 N=xx n (%)	Treatment 2 N=xx n (%)	Treatment 3 N=xx n (%)	Treatment 4 N=xx n (%)
Confirmed Cases of COVID-19	x (x)	x (x)	x (x)	x (x)
Non Hospitalised (WHO grade 1 and 2)	x (x)	x (x)	x (x)	x (x)
Hospitalised (WHO grade 3, 4 and 5)	x (x)	x (x)	x (x)	x (x)
Hospitalised (WHO grade 6 and 7)	x (x)	x (x)	x (x)	x (x)
Death	x (x)	x (x)	x (x)	x (x)
Probable Cases of COVID-19	x (x)	x (x)	x (x)	x (x)
Non Hospitalised (WHO grade 1 and 2)	x (x)	x (x)	x (x)	x (x)
Hospitalised (WHO grade 3, 4 and 5)	x (x)	x (x)	x (x)	x (x)
Hospitalised (WHO grade 6 and 7)	x (x)	x (x)	x (x)	x (x)
Death	x (x)	x (x)	x (x)	x (x)

Note: WHO original scale - non hospitalised (grade 1-2) ; grade 2-3 ; grade 3-4 ; grade 4-5 ; grade 5-6 ; grade 6-7 ; grade 7-8

Example: SAFE_T14
 Protocol: 202018
 Population: Safety

Table 1.x
 Summary of Common (>=2%) Adverse Events by Time from Randomisation

Time From Randomisation : [<=12 weeks / >12 weeks and <=24 weeks / >24 weeks and <=36 weeks / >36 weeks and <=52 weeks]

	Treatment 1 N=xx	Treatment 2 N=xx	Treatment 3 N=xx	Treatment 4 N=xx	Treatment 5 N=xx	Treatment 6 N=xx
Any Adverse Event	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
XXXXXX	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

CONFIDENTIAL

202018

Example: SAFE_T15
Protocol: 202018
Population: Safety

Page 1 of x

Table 3.x
Summary of COVID-19 Infections (Period X)

	Treatment 1 (N=xx)	Treatment 2 (N=xx)	Treatment 3 (N=xx)	Treatment 4 (N=xx)
Any COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Any Non-Serious COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Confirmed COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Suspected COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Probable COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Any Serious COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Confirmed COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Suspected COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)
Probable COVID-19 Infection	xx (xx%)	xx (xx%)	xx (xx%)	xx (xx%)

CONFIDENTIAL

202018

Example: SAFE_L1
 Protocol: 202018
 Population: Safety

Page 1 of n

Listing x
 Listing of Neutrophils and Associated Infections
 Subset of Subjects who experienced grade 3 or 4 Neutropenia

Site=xxx; Subject=xxxxxx.xxxxxx; Arm=xxxxxxxxxxxx;
 Sex=x; Age(YEARS)=xx; Race Details=xxxxxxxx; Weight(kg)=xx.xx

Treatment/ Period	Visit	Analysis Visit	Date	Study Day	Neutrophils (unit)		Associated Infections	
					Result	Out of Normal	Toxicity Grade	Preferred Term/ VERBATIM TEXT
Placebo/ 1	SCREENING	SCREENING	xxxx-xx-xx	x	x.xx			
	BASELINE	BASELINE	xxxx-xx-xx	xx	x.xx	xxx	x	
	WEEK 1	WEEK 1	xxxx-xx-xx	xx	x.xx	xxx	x	
	WEEK 2	WEEK 2	xxxx-xx-xx	xx	x.xx			
	UNSCHEDULED	WEEK 2	xxxx-xx-xx	xx	x.xx	xxx	x	
	WEEK 4	WEEK 4	xxxx-xx-xx	xx	x.xx			

Note: Lower Limit of Normal: xx, Upper Limit of Normal: xx

Signature Page for 202018 TMF-14433701 v1.0

Reason for signing: Approved	Name: PPD Role: Approver Date of signature: 04-Feb-2022 13:29:10 GMT+0000
------------------------------	---------------------------------------------------------------------------------

Reason for signing: Approved	Name: PPD Role: Approver Date of signature: 04-Feb-2022 14:05:17 GMT+0000
------------------------------	---------------------------------------------------------------------------------

Signature Page for TMF-14433701 v1.0